Publications

Guardamagna, M., S. E. Lochrin, J. W. Smithy, M. Postow, C. Gaudy-Marqueste, N. Malissen, S. Monestier, R. J. Sullivan, J. A. Czapla, A. R. Lawless, I. P. da Silva, G. V. Long, A. M. Menzies, F. Dimitriou, R. Dummer, C. Marchi, A. Chaurand, S. Dalle, P. A. Ascierto, M. Paone, B. A. Facchini, G. Warrier, E. J. Lipson, M. Erdmann, C. Berking, B. Archambaud, S. Roy, E. Routier, C. Boutros, P. Jamme, D. Belkadi-Sadou, N. Simon-Tillaux, and C. Robert. International real-world study of combination immunotherapy sequences in metastatic melanoma. J Immunother Cancer 13, no. 11 (2025). https://dx.doi.org/10.1136/jitc-2025-012225.

Yang, F., S. Y. Lim, I. P. da Silva, L. Yu, J. W. Conway, A. M. Menzies, G. V. Long, J. Y. Yang, and H. Rizos. Circulating IFN gamma-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma. Cancer Cell Int 25, no. 1 (2025): 424. https://dx.doi.org/10.1186/s12935-025-04067-4.

Wu, L., J. M. Wentworth, C. Liddle, N. Fewings, M. Carlino, D. A. Brown, R. Clifton-Bligh, G. V. Long, R. A. Scolyer, N. Norris, S. C. Sasson, V. H. Tsang, A. M. Menzies, and J. E. Gunton. Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans. J Clin Invest (2025). https://dx.doi.org/10.1172/JCI192938.

da Silva, I. P., L. Zimmer, J. Y. Blay, M. Maio, J. Larkin, M. O. Grimm, S. Puri, M. O. Butler, S. Patel, P. K. Thakkar, G. V. Long, and I. Melero. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open 10, no. 11 (2025): 105833. https://dx.doi.org/10.1016/j.esmoop.2025.105833.

Rawson, R. V., N. G. Maher, A. M. Menzies, S. N. Lo, N. M. Ardakani, L. A. Jackett, I. A. Vergara, T. E. Pennington, K. F. Shannon, S. Ch'ng, M. Gonzalez, E. M. Burton, M. W. Lucas, I. L. M. Reijers, E. A. Rozeman, D. E. Gyorki, S. Sandhu, M. S. Carlino, J. Howle, M. Khattak, A. Van der Westhuizen, M. C. Andrews, V. Atkinson, A. C. J. van Akkooi, A. J. Spillane, R. P. M. Saw, B. A. van de Wiel, C. U. Blank, G. V. Long, M. T. Tetzlaff, and R. A. Scolyer. Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma. Ann Oncol (2025). https://dx.doi.org/10.1016/j.annonc.2025.10.1237.

Gouveia, B. M., T. Wong, P. M. Ferguson, A. Glanz, G. Ho, C. Sinz, H. Collgros, L. K. Martin, R. Schwartz, M. A. Sharouni, C. Ramirez, M. P. Senna Santos, B. Gallo, R. A. Scolyer, A. E. Cust, S. N. Lo, and P. Guitera. In vivo cutaneous confocal microscopy for diagnosing the lentigo maligna spectrum: A multicentre prospective study and proposal of a lentigo maligna spectrum score. J Am Acad Dermatol (2025). https://dx.doi.org/10.1016/j.jaad.2025.10.087.

Hong, A. M., T. Wang, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, and G. V. Long. Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM). BMC Cancer 25, no. 1 (2025): 1615. https://dx.doi.org/10.1186/s12885-025-15066-z.

Wiggins, J. M., Q. Zhang, Y. Zhang, F. Vand-Rajabpour, D. Hanniford, L. He, Y. Lu, J. M. Kenney, K. D. Sadeghi, D. Argibay, I. Orlow, K. J. Busam, C. Lezcano, T. K. Lee, L. Luo, I. P. Gorlov, C. Amos, M. S. Ernstoff, V. E. Seshan, A. E. Cust, J. Wilmott, R. A. Scolyer, G. J. Mann, A. Reiner, C. E. Kostrzewa, E. Nagore, P. Funchain, J. Ko, S. N. Edmiston, K. Conway, P. B. Googe, D. W. Ollila, J. E. Lee, J. R. Rees, C. L. Thompson, M. Gerstenblith, M. Bosenberg, B. E. Gould Rothberg, I. Osman, Y. Saenger, A. Z. Reynolds, T. Boyce, S. Holmen, S. Yan, E. Brunsgaard, P. Bogner, P. F. Kuan, N. E. Thomas, C. B. Begg, R. Shen, M. Berwick, Y. Shao, D. Polsky, and E. Hernando. Tumor microRNA signatures associate with stage II/III melanoma patient outcomes. Clin Cancer Res (2025). https://dx.doi.org/10.1158/1078-0432.Ccr-24-3785.

Long, G. V., C. Garnett-Benson, S. Dolfi, P. A. Ascierto, J. Guo, A. A. Tarhini, S. Chandra, E. Munoz-Couselo, M. Del Vecchio, A. C. de Melo, M. Callahan, H. Gogas, R. Dummer, D. Schadendorf, P. Koelblinger, G. Quereux, I. Thomas, J. X. Yu, A. Fisher, B. Wang, P. Djidel, A. Chouzy, M. Semaan, B. Chen, A. M. Y. Cheong, and H. A. Tawbi. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: The randomized phase 3 RELATIVITY-098 trial. Nat Med (2025). https://dx.doi.org/10.1038/s41591-025-04032-8.

Varey, A. H., S. N. Lo, R. A. Scolyer, and J. F. Thompson. Predicting sentinel node positivity in melanoma patients: Personalized tools outperform National Comprehensive Cancer Network and American Joint Committee on Cancer-based criteria. J Am Coll Surg 241, no. 5 (2025): 929–30. https://dx.doi.org/10.1097/xcs.0000000000001471.

Vergara, I. A., S. N. Lo, I. Li, J. W. Conway, X. Fu, A. M. Menzies, M. S. Carlino, R. A. Scolyer, G. V. Long, and I. P. da Silva. Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients. Immunooncol Technol (2025): 101078. https://dx.doi.org/10.1016/j.iotech.2025.101078.

Novis, E., M. Rautalin, R. N. Amaria, P. A. Ascierto, C. U. Blank, M. B. Faries, D. J. Grunhagen, D. E. Gyorki, A. J. Hayes, A. M. J. Kuijpers, G. V. Long, J. M. V. Mammen, A. M. Menzies, M. I. Ross, P. Rutkowski, H. A. Tawbi, M. T. Tetzlaff, J. S. Zager, J. A. Wargo, T. J. Hieken, A. C. J. van Akkooi, and the International Neoadjuvant Melanoma Consortium. International survey on evidence for index lymph node surgery after neoadjuvant systemic therapy for stage III melanoma. Ann Surg Oncol (2025). https://dx.doi.org/10.1245/s10434-025-18475-3.

Salam, R. A., K. L. A. Dunlop, T. N. Gide, J. Wilmott, A. Smith, and A. E. Cust. Factors associated with implementation of biomarker testing and strategies to improve its clinical uptake in cancer care: Systematic review using theoretical domains framework. JCO Precis Oncol 9 (2025): e2500063. https://dx.doi.org/10.1200/po-25-00063.

Borgers, J. S. W., D. B. Johnson, E. Livingstone, D. Schadendorf, E. I. Buchbinder, L. E. Haydu, L. Gohil, W. A. Robinson, I. Mehmi, O. Hamid, M. Ferreira, A. K. S. Salama, F. Dimitriou, M. S. Carlino, G. V. Long, P. A. Ascierto, E. Simeone, Y. G. Najjar, G. A. P. Hospers, J. Choi, S. Chandra, J. D. Wayne, C. I. R. Garcia, W. Xu, C. Lebbe, L. Da-Meda, V. Atkinson, M. McKean, A. Forschner, E. A. Asare, A. Daletzakis, J. S. Taylor, F. Amant, K. K. Tsai, Z. Eroglu, J. B. A. G. Haanen, and I. C. Glitza de Oliva. Advanced stage melanoma during pregnancy: Recommendations from a retrospective, multicentre, registry-based study. EClinicalMedicine 89 (2025): 103501. https://dx.doi.org/10.1016/j.eclinm.2025.103501.

Ribas, A., M. M. Milhem, C. J. Hoimes, A. Amin, C. D. Lao, R. M. Conry, J. P. Hunt, G. A. Daniels, M. Almubarak, M. Shaheen, T. Medina, M. Barve, S. Bishnoi, E. Abdi, M. J. Chisamore, C. Guiducci, J. Gomez-Romo, A. Candia, E. Gamelin, R. L. Coffman, R. S. Janssen, and G. V. Long. Phase 2, open-label, multicenter study of nelitolimod in combination with pembrolizumab in anti-PD-1 treatment-naive advanced melanoma. Clin Cancer Res 31, no. 19 (2025): 4070–78. https://dx.doi.org/10.1158/1078-0432.CCR-25-0987.

Versluis, J. M., H. Shehwana, R. Elens, A. M. Menzies, I. L. M. Reijers, P. Dimitriadis, N. G. Maher, A. M. M. van der Veldt, E. Kapiteijn, A. Broeks, R. A. Scolyer, B. A. van de Wiel, A. C. J. van Akkooi, T. N. Schumacher, G. V. Long, and C. U. Blank. Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma. Commun Med (Lond) 5, no. 1 (2025): 407. https://dx.doi.org/10.1038/s43856-025-01118-9.

Suann, B., C. Gao, T. Muecke, H. Gim, J. Kovoor, C. Bacchi, W. O. Chan, S. Koneru, P. Kovoor, G. V. Long, J. Thomas, S. Zaman, R. L. Jeffree, and S. Bacchi. Structured curriculum vitae scoring: A possible means to improve female representation in specialty selection? , Intern Med J 55, no. 10 (2025): 1777–78. https://dx.doi.org/10.1111/imj.70213.

Long, G. V., N. Nair, D. Marbach, R. A. Scolyer, S. Wilson, D. Cotting, N. Staedler, R. N. Amaria, P. A. Ascierto, A. A. Tarhini, C. Robert, O. Hamid, C. Gaudy-Marqueste, C. Lebbe, E. Munoz-Couselo, A. M. Menzies, C. Pages, G. Curigliano, M. Mandala, N. Jessop, U. Bader, M. Perdicchio, V. Teichgraber, M. Muecke, C. Markert, and C. Blank. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: The randomized phase 1b/2 Morpheus-Melanoma trial. Nat Med (2025). https://dx.doi.org/10.1038/s41591-025-03967-2.

Boutros, A., A. M. Taylor, I. Li, N. A. Adegoke, T. Wong, A. H. R. Varey, K. F. Shannon, S. Ch'ng, R. P. M. Saw, T. Pennington, J. Stretch, A. Spillane, A. C. J. van Akkooi, R. A. Scolyer, I. P. da Silva, M. S. Carlino, G. V. Long, S. N. Lo, and A. M. Menzies. A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma. Eur J Cancer 229 (2025): 115782. https://dx.doi.org/10.1016/j.ejca.2025.115782.

Regan, M. M., P. Ascierto, E. J. Lipson, J. Palaia, A. Moshyk, A. Selvan, C. D. Lao, M. Atkins, D. F. McDermott, R. Potluri, S. Ranjan, S. Bilthare, G. V. Long, F. Stephen Hodi, H. Tawbi, and D. Schadendorf. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. J Immunother Cancer 13, no. 9 (2025). https://dx.doi.org/10.1136/jitc-2025-012747.

Cai, Z., E. L. Boys, Z. Noor, A. T. Aref, D. Xavier, N. Lucas, S. G. Williams, J. M. S. Koh, R. C. Poulos, Y. Wu, M. Dausmann, K. L. MacKenzie, A. Aguilar-Mahecha, C. Armengol, M. M. Barranco, M. Basik, E. D. Bowman, R. Clifton-Bligh, E. A. Connolly, W. A. Cooper, B. Dalal, A. DeFazio, M. Filipits, P. J. Flynn, J. D. Graham, J. George, A. J. Gill, M. Gnant, R. Habib, C. C. Harris, K. Harvey, L. G. Horvath, C. Jackson, M. R. J. Kohonen-Corish, E. Lim, J. J. Liu, G. V. Long, R. V. Lord, G. J. Mann, G. W. McCaughan, L. Morgan, L. Murphy, S. Nagabushan, A. Nagrial, J. Navines, B. J. Panizza, J. S. Samra, R. A. Scolyer, J. Souglakos, A. Swarbrick, D. Thomas, R. L. Balleine, P. G. Hains, P. J. Robinson, Q. Zhong, and R. R. Reddel. Federated deep learning enables cancer subtyping by proteomics. Cancer Discov 15, no. 9 (2025): 1803–18. https://dx.doi.org/10.1158/2159-8290.CD-24-1488.

Lipson, E. J., S. Dolfi, H. Tang, H. A. Tawbi, F. Medina-Soto, E. Castillo Gutierrez, P. Rutkowski, H. Gogas, E. Murillo, P. A. Ascierto, K. Desai, M. Maio, K. Demers, A. Mazzei, S. Keidel, K. Miller-Moslin, J. X. Yu, F. S. Hodi, D. Schadendorf, G. V. Long, and C. Garnett-Benson. Unraveling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047. Clin Cancer Res 31, no. 17 (2025): 3702–14. https://dx.doi.org/10.1158/1078-0432.CCR-24-2499.

Vergara, I. A., N. G. Maher, A. J. Potter, E. C. Paver, J. W. Conway, S. N. Lo, A. J. Colebatch, G. V. Long, J. S. Wilmott, and R. A. Scolyer. Discovery and validation of an ancillary genomic test of malignancy for primary melanocytic tumors. Clin Cancer Res 31, no. 17 (2025): 3742–53. https://dx.doi.org/10.1158/1078-0432.CCR-24-1902.

Clarke, E. L., D. Magee, J. Newton-Bishop, W. Merchant, R. Insall, N. G. Maher, R. A. Scolyer, G. Farnworth, A. Ali, S. O'Shea, and D. Treanor. The development and evaluation of a convolutional neural network for cutaneous melanoma detection in whole slide images. Arch Pathol Lab Med 149, no. 9 (2025): 831–37. https://dx.doi.org/10.5858/arpa.2024-0094-OA.

Johnson, R., M. Gonzalez, M. Rosano, S. Coburn, K. Linke, G. V. Long, G. McArthur, A. Menzies, T. Pennington, M. Lyle, L. Gent, K. White, and M. Krishnasamy. Development of a mapping framework to define specialist clinical practice nursing roles within melanoma treatment settings. Cancer Nursing 48, no. 5S (2025): S50–S50. <Go to ISI>://WOS:001560745600122.

Arance, A., M. A. Berciano-Guerrero, J. Guo, M. S. Carlino, P. A. Ascierto, M. Burotto, L. Mortier, P. Queirolo, V. Chiarion-Sileni, J. Schachter, X. Zhang, J. Martin-Liberal, M. Del Vecchio, C. E. Okpara, C. Dutcus, J. Zhang, S. J. Diede, T. Neff, and G. V. Long. Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Ann Oncol (2025). https://dx.doi.org/10.1016/j.annonc.2025.08.008.

Menzer, C., S. Dugas-Breit, M. Dugas, C. U. Blank, E. J. Groen, I. Reijers, M. Schlaak, J. Eckardt, K. P. M. Suijkerbuijk, L. Zimmer, D. B. Johnson, C. Franklin, F. Meiss, B. Schilling, F. Meier, R. Gutzmer, K. M. Thoms, T. Haalck, M. Muller, A. Kopp-Schneider, M. S. Carlino, G. V. Long, A. M. Menzies, A. A. M. van der Veldt, J. W. B. de Groot, T. Eigentler, M. Stevense-den Boer, C. Pfohler, K. Herbschleb, and J. C. Hassel. Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database. Eur J Cancer 228 (2025): 115703. https://dx.doi.org/10.1016/j.ejca.2025.115703.

Hong, A. M., S. N. Lo, G. B. Fogarty, J. Stretch, W. Wang, P. Fernandez-Penas, R. C. W. Martin, M. Foote, H. P. Soyer, J. Ruben, V. Mar, L. Rocha, C. Festa-Neto, C. Wratten, S. Hogarth, H. Collgros, A. Glanz, B. M. Gouveia, R. A. Scolyer, M. T. King, and P. Guitera. Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial. J Am Acad Dermatol 93, no. 5 (2025): 1251–60. https://dx.doi.org/10.1016/j.jaad.2025.07.028.

Boutros, A., A. Idan, S. Sleiman, F. Bacha, T. Zhang, V. Jayadev, A. M. Menzies, G. V. Long, and D. J. Handelsman. Testicular function after immune-checkpoint inhibitors treatment. Clin Endocrinol (Oxf) 103, no. 5 (2025): 721–28. https://dx.doi.org/10.1111/cen.70001.

Long, G. V., H. Tang, K. Desai, S. Wang, M. Del Vecchio, J. Larkin, C. Ritchings, S. P. Huang, J. Baden, D. Balli, H. Chang, G. Fusaro, D. Tenney, S. Dolfi, and J. Weber. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. J Immunother Cancer 13, no. 7 (2025). https://dx.doi.org/10.1136/jitc-2025-012034.

Aung, T. N., M. Liu, D. Su, S. Shafi, C. Boyaci, S. Steen, N. Tsiknakis, J. M. Vidal, N. Maher, G. Micevic, S. X. Tan, M. D. Vesely, S. Nourmohammadi, Y. Bai, D. Djureinovic, P. F. Wong, K. Bates, N. N. N. Chan, N. Gavirelatou, M. He, S. Burela, R. Barna, M. Bosic, K. Bräutigam, I. Illabochaca, Z. Chenhao, J. Gama, B. Kreis, R. Mohacsi, N. Pillar, J. Pinto, C. Poulios, M. A. Toli, E. Tzoras, Y. Bracero, F. Bosisio, G. Cserni, A. Dema, F. Fortarezza, M. S. Gonzalez, I. Gullo, F. J. Queipo Gutiérrez, E. Hacihasanoglu, V. Jovic, B. Lazar, M. Olinca, C. Neppl, R. C. Oliveira, F. Pezzuto, D. Gomes Pinto, V. Plotar, O. Pop, T. Rau, K. Skok, W. Sun, E. D. Serbes, W. Solass, O. Stanowska, M. Szasz, K. Szymonski, F. Thimm, D. Vignati, A. Vigdorovits, V. Prieto, T. Sinnberg, J. Wilmott, S. Cowper, J. Warrell, Y. Saenger, J. Hartman, J. Plummer, I. Osman, D. L. Rimm, and B. Acs. Pathologist-read vs AI-driven assessment of tumor-infiltrating lymphocytes in melanoma. JAMA Netw Open 8, no. 7 (2025): e2518906. https://dx.doi.org/10.1001/jamanetworkopen.2025.18906.

Puhr, R., E. G. Ryan, D. L. Couturier, A. C. J. van Akkooi, I. P. da Silva, S. Heritier, and S. N. Lo. Transforming clinical trials in skin cancer research: Exploring the potential of flexible and innovative designs. J Invest Dermatol 145, no. 7 (2025): 1569–79. https://dx.doi.org/10.1016/j.jid.2025.03.032.

Wijnen, S. C. M. A., P. Dimitriadis, I. L. M. Reijers, A. M. Menzies, G. V. Long, L. F. A. Wessels, and C. U. Blank. Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures. Cancer Immunol Immunother 74, no. 8 (2025): 253. https://dx.doi.org/10.1007/s00262-025-04094-0.

Braden, J., J. W. Conway, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. Do BRAF-targeted therapies have a role in the era of immunotherapy? , ESMO Open 10, no. 7 (2025): 105314. https://dx.doi.org/10.1016/j.esmoop.2025.105314.

Wong, T., S. Ch'ng, P. Ferguson, L. Martin, A. M. Menzies, I. P. da Silva, G. V. Long, R. A. Scolyer, A. C. J. van Akkooi, and S. N. Lo. Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysis. Crit Rev Oncol Hematol 214 (2025): 104816. https://dx.doi.org/10.1016/j.critrevonc.2025.104816.

Chan, W. Y., A. Stewart, R. J. Diefenbach, E. S. Gray, J. H. Lee, R. A. Scolyer, G. V. Long, and H. Rizos. Pre-amplification of cell-free DNA: Balancing amplification errors with enhanced sensitivity. Biomolecules 15, no. 6 (2025). https://dx.doi.org/10.3390/biom15060883.

Mandala, M., T. Amaral, P. Rutkowski, M. C. Sergi, M. L. Rasch, N. Benannoune, P. Serra, M. G. Vitale, D. Giannarelli, A. M. Arance, E. M. Couselo, B. Neyns, I. Dirven, M. Tucci, M. Guida, F. Spagnolo, E. Rossi, P. Queirolo, P. Quaglino, R. Depenni, J. Placzke, A. M. D. Giacomo, M. Del Vecchio, A. Indini, I. P. da Silva, A. M. Menzies, A. Hong, P. Lorigan, G. V. Long, C. Robert, and P. A. Ascierto. Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study. Eur J Cancer 225 (2025): 115567. https://dx.doi.org/10.1016/j.ejca.2025.115567.

Thompson, J. F., R. F. Uren, K. London, D. Chung, R. P. Saw, A. J. Spillane, J. R. Stretch, K. F. Shannon, J. Howle, O. E. Nieweg, S. Ch'ng, T. E. Pennington, A. J. Potter, R. A. Scolyer, and G. J. Williams. Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patients. Eur J Surg Oncol 51, no. 9 (2025): 110225. https://dx.doi.org/10.1016/j.ejso.2025.110225.

Wu, L., V. Tsang, R. Clifton-Bligh, M. S. Carlino, T. Tse, Y. Huang, M. Oatley, N. W. Cheung, G. V. Long, A. M. Menzies, and J. Gunton. Hyperglycemia in patients treated with immune checkpoint inhibitors: Key clinical challenges and multidisciplinary consensus recommendations. J Immunother Cancer 13, no. 6 (2025). https://dx.doi.org/10.1136/jitc-2024-011271.

Lipson, E. J., F. Stephen Hodi, H. Tawbi, D. Schadendorf, P. A. Ascierto, L. Matamala, E. C. Gutierrez, P. Rutkowski, H. J. Gogas, C. D. Lao, J. J. Menezes, S. Dalle, A. Arance, C. Gaudy-Marqueste, B. Chen, W. Jackson, S. Mukherjee, S. Dolfi, and G. V. Long. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer 225 (2025): 115547. https://dx.doi.org/10.1016/j.ejca.2025.115547.

Fletcher, K., M. Machaalani, R. El Hajj Chehade, A. H. Nassar, R. Nawfal, M. Manos, A. M. Menzies, F. Aboubakar-Nana, J. C. Hassel, D. J. Pinato, A. Johnson, A. C. Olsson-Brown, M. S. Carlino, A. Malgeri, A. Cortellini, A. Singh, K. Parikh, S. Y. Kim, A. R. Naqash, G. V. Long, P. Challa, T. K. Choueiri, E. Sharon, S. Shah, and D. B. Johnson. Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open 8, no. 6 (2025): e2513727. https://dx.doi.org/10.1001/jamanetworkopen.2025.13727.

Lo, S. N., C. Gjorup, A. H. Chakera, L. R. Hölmich, M. Moncrieff, A. MacKenzie Ross, O. Cassell, J. Ma, M. B. Weitemeyer, R. Olofsson Bagge, S. Klausen, V. F. Calsavara, J. P. Duprat Neto, E. Bertolli, S. Ch'ng, R. P. M. Saw, K. F. Shannon, A. J. Spillane, O. E. Nieweg, J. R. Stretch, G. J. Mann, J. L. C. Geh, L. E. Haydu, R. C. W. Martin, C. Sharon, G. C. Karakousis, M. Kashani-Sabet, G. Adigbli, M. A. El Sharouni, J. E. Gershenwald, R. A. Scolyer, J. F. Thompson, and A. H. R. Varey. Global applicability of a risk prediction tool for sentinel node positivity in patients with primary cutaneous melanoma. JAMA Dermatol 161, no. 6 (2025): 589–96. https://dx.doi.org/10.1001/jamadermatol.2025.0318.

Menzies, A. M., G. V. Long, A. Kohn, H. Tawbi, J. Webe, K. Flaherty, G. A. McArthur, P. A. Ascierto, Y. Pfluger, K. Lewis, K. K. Tsai, O. Hamid, H. Prenen, L. Fein, E. Wang, C. Guenzel, F. Zhang, J. F. Kleh, A. di Pietro, and M. A. Davies. A plain language summary of POLARIS: A study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. Future Oncol 21, no. 14 (2025): 1703–11. https://dx.doi.org/10.1080/14796694.2025.2495540.

Fletcher, K. A., R. S. Goodman, A. Lawless, R. Woodford, F. Fa'ak, A. Tipirneni, J. R. Patrinely, H. L. Yeoh, S. Rapisuwon, A. Haydon, I. Osman, J. M. Mehnert, G. V. Long, R. J. Sullivan, M. S. Carlino, A. M. Menzies, A. K. Dewan, and D. B. Johnson. Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors. JAMA Dermatol 161, no. 5 (2025): 555–57. https://dx.doi.org/10.1001/jamadermatol.2025.0025.

Novis, E., J. Tan, D. Vignati, T. Wong, R. V. Rawson, J. R. Stretch, S. N. Lo, T. E. Pennington, S. Ch'ng, K. F. Shannon, A. J. Spillane, O. E. Nieweg, J. F. Thompson, M. Rtshiladze, R. A. Scolyer, and R. P. M. Saw. Cartilage resection in the surgical management of ear melanoma. Ann Surg Oncol 32, no. 7 (2025): 5306–14. https://dx.doi.org/10.1245/s10434-025-17294-w.

Syeda, M. M., G. V. Long, J. Garrett, V. Atkinson, M. Santinami, D. Schadendorf, A. Hauschild, M. Millward, M. Mandala, V. Chiarion-Sileni, M. Smylie, G. M. Manikhas, R. Dummer, J. M. Wiggins, S. Ali, S. B. Adnaik, M. Tan, M. Dajee, and D. Polsky. Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): A biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol 26, no. 5 (2025): 641–53. https://dx.doi.org/10.1016/S1470-2045(25)00139-1.

Braden, J., A. Potter, R. V. Rawson, N. A. Adegoke, S. N. Lo, J. W. Conway, A. M. Menzies, M. S. Carlino, G. Au-Yeung, R. P. M. Saw, A. J. Spillane, K. F. Shannon, T. E. Pennington, S. Ch'ng, D. E. Gyorki, J. R. Howle, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. Longitudinal analysis reveals dynamic changes in histopathologic features in responders to neoadjuvant treatment in a stage III BRAF-mutant melanoma cohort. Mod Pathol 38, no. 8 (2025): 100776. https://dx.doi.org/10.1016/j.modpat.2025.100776.

Grover, P., S. N. Lo, I. Li, A. M. J. Kuijpers, F. Kreidieh, A. Williamson, T. Amaral, F. Dimitriou, J. Placzke, K. Olino, M. G. Vitale, P. Saiag, R. Gutzmer, C. Allayous, R. Olofsson Bagge, J. Mattsson, N. Asher, T. J. Carter, T. M. Meniawy, A. R. Lawless, J. A. Czapla, L. Warburton, C. Gaudy-Marqueste, J. J. Grob, R. G. Collins, E. Zhang, J. I. Kessels, B. Neyns, I. Mehmi, O. Hamid, M. Julve, A. J. S. Furness, K. A. Margolin, S. Lev-Ari, J. M. Ressler, W. Haque, M. A. Khattak, A. Wicky, R. Roberts-Thomson, A. Arance, G. Warrier, M. D. Schollenberger, P. Parente, E. Chatziioannou, E. J. Lipson, O. Michielin, J. S. Weber, C. Hoeller, J. Larkin, M. B. Atkins, R. Essner, D. B. Johnson, R. J. Sullivan, P. Nathan, J. Schachter, C. Lebbe, P. A. Ascierto, H. Kluger, P. Rutkowski, R. Dummer, C. Garbe, P. C. Lorigan, E. Burton, H. A. Tawbi, J. Haanen, M. S. Carlino, A. M. Menzies, and G. V. Long. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Ann Oncol 36, no. 7 (2025): 807–18. https://dx.doi.org/10.1016/j.annonc.2025.03.021.

Duncan, L. M., D. E. Elder, M. W. Piepkorn, S. R. Knezevich, W. A. M. Blokx, M. Bosenberg, K. J. Busam, R. Carr, M. G. Cook, P. Gerami, J. Ko, G. Landman, A. J. Lazar, L. Lowe, D. Mihic-Probst, B. Schmidt, C. R. Shea, R. A. Scolyer, X. Xu, J. G. Elmore, and R. L. Barnhill. Shifts in cutaneous melanocytic tumor diagnostic terminology: Melanocytoma, mpath-dx v2.0 and the WHO skin5. J Cutan Pathol (2025). https://dx.doi.org/10.1111/cup.14788.

Jackett, L. A., C. Mitchell, C. Snell, C. Hewitt, S. Yellenki, H. Snow, D. Speakman, C. Angel, C. Khoo, J. M. Pang, S. N. Lo, R. A. Scolyer, S. Fox, and D. Gyorki. Molecular analysis of cutaneous sarcomatoid neoplasms frequently identifies melanoma driver variants. Am J Surg Pathol 49, no. 7 (2025): 650–57. https://dx.doi.org/10.1097/pas.0000000000002390.

Stekelenburg, I., A. E. Laeijendecker, R. C. van Doorn, A. Doeksen, W. A. M. Blokx, Y. M. Schrage, A. C. J. van Akkooi, R. A. Scolyer, E. L. Postma, and M. A. E. Sharouni. Reconsidering the surgical approach in cutaneous melanoma: Does wide local excision after a complete diagnostic excision reduce the risk of recurrence? , Eur J Cancer 220 (2025): 115366. https://dx.doi.org/10.1016/j.ejca.2025.115366.

Bührer, E., N. Glassee, M. Kicinski, O. J. Kennedy, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, S. Gandini, S. Valpione, S. Suciu, C. Robert, A. M. M. Eggermont, P. Lorigan, and M. Mandala. Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. EJC Skin Cancer 3, no. 100727 (2025): 100727. https://dx.doi.org/10.1016/j.ejcskn.2025.100727.

Lai, B., H. P. Soyer, L. Zhu, P. M. Ferguson, B. O'Brien, T. Dodds, R. A. Scolyer, G. Ferrara, and K. J. L. Bell. The impact of providing clinical images and dermoscopy reports on the diagnosis of melanocytic skin lesions. J Eur Acad Dermatol Venereol 39, no. 7 (2025): e634–e37. https://dx.doi.org/10.1111/jdv.20655.

Zhou, L., M. Barros, E. Hsiao, Z. Eroglu, S. Sandhu, I. Samoylenko, S. N. Lo, M. S. Carlino, G. Au-Yeung, M. Gonzalez, A. J. Spillane, T. E. Pennington, K. F. Shannon, R. Kapoor, E. M. Burton, H. A. Tawbi, R. N. Amaria, C. U. Blank, J. P. Duprat, R. Brito de Paula, D. E. Gyorki, R. P. M. Saw, S. Ch'Ng, R. V. Rawson, R. A. Scolyer, I. P. da Silva, A. C. J. van Akkooi, G. V. Long, and A. M. Menzies. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J Immunother Cancer 13, no. 3 (2025). https://dx.doi.org/10.1136/jitc-2025-011483.

Luke, J. J., P. A. Ascierto, M. A. Khattak, P. Rutkowski, M. Del Vecchio, F. Spagnolo, J. Mackiewicz, L. C. Merino, V. Chiarion-Sileni, J. M. Kirkwood, C. Robert, D. Schadendorf, F. de Galitiis, M. S. Carlino, R. Dummer, P. Mohr, A. Odeleye-Ajakaye, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, and G. V. Long. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer 220 (2025): 115381. https://dx.doi.org/10.1016/j.ejca.2025.115381.

Kirkwood, J. M., P. Mohr, C. Hoeller, J. J. Grob, M. Del Vecchio, J. Lord-Bessen, S. Srinivasan, A. Nassar, F. Campigotto, H. Fairbanks, F. Taylor, R. Lawrance, G. V. Long, and J. Weber. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. Eur J Cancer 220 (2025): 115371. https://dx.doi.org/10.1016/j.ejca.2025.115371.

Weber, J., W. Haque, S. N. Markovic, A. K. S. Salama, I. Mehmi, R. J. Sullivan, Y. G. Najjar, A. C. J. van Akkooi, A. M. Menzies, G. V. Long, A. M. Taylor, J. Haanen, L. P. Zijlker, K. L. Davis, S. Karanth, D. Norton, and L. Connolly. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist 30, no. 3 (2025). https://dx.doi.org/10.1093/oncolo/oyae289.

Guan, A., and C. Quek. Single-cell multi-omics: Insights into therapeutic innovations to advance treatment in cancer. Int J Mol Sci 26, no. 6 (2025). https://dx.doi.org/10.3390/ijms26062447.

Nassar, A. H., S. Abou Alaiwi, T. El Zarif, R. Denu, W. Macaron, N. Abdel-Wahab, D. Freeman, A. Vasbinder, S. Hayeck, E. Anderson, R. S. Goodman, D. B. Johnson, S. Grynberg, R. Shapira, J. M. Kwan, R. Woodford, G. V. Long, T. Haykal, S. Dent, Y. Kojima, K. Yonemor, A. Tandon, A. Trevino, N. Akhter, E. H. Yang, G. Hui, A. Drakaki, E. El-Am, E. Kozaily, A. Al-Hader, E. Bou Farhat, P. Babu, A. Mittra, M. Li, N. Jones, J. Baena, M. Juarez Herrera, S. Foderaro, F. A. Nana, C. Kim, P. Sackstein, K. Parikh, A. P. Desai, C. Smith, A. Cortellini, D. J. Pinato, J. Korolewicz, N. Lopetegui-Lia, P. Funchain, A. Choudhary, A. Asnani, V. Navani, D. Meyers, I. Stukalin, J. A. Ocejo Gallegos, J. Trent, S. Nusrat, C. Malvar, R. R. McKay, T. G. Neilan, T. K. Choueiri, and A. R. Naqash. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: A multicenter international retrospective study. J Immunother Cancer 13, no. 3 (2025). https://dx.doi.org/10.1136/jitc-2024-009364.

Long, G. V., E. Shklovskaya, L. Satgunaseelan, Y. Mao, I. P. da Silva, K. A. Perry, R. J. Diefenbach, T. N. Gide, B. Shivalingam, M. E. Buckland, M. Gonzalez, N. Caixeiro, I. A. Vergara, X. Bai, R. V. Rawson, E. Hsiao, U. Palendira, T. G. Phan, A. M. Menzies, M. S. Carlino, C. Quek, S. M. Grimmond, J. H. A. Vissers, D. Yeo, J. E. J. Rasko, M. Khasraw, B. Neyns, D. A. Reardon, D. M. Ashley, H. Wheeler, M. Back, R. A. Scolyer, J. Drummond, J. S. Wilmott, and H. Rizos. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med 31, no. 5 (2025): 1557–66. https://dx.doi.org/10.1038/s41591-025-03512-1.

Long, G. V., V. Atkinson, S. N. Lo, A. D. Guminski, S. K. Sandhu, M. P. Brown, M. Gonzalez, G. A. McArthur, and A. M. Menzies. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol 26, no. 3 (2025): 320–30. https://dx.doi.org/10.1016/S1470-2045(24)00735-6.

Sheriff, S., M. Saba, R. Patel, G. Fisher, T. Schroeder, G. Arnolda, D. Luo, L. Warburton, E. Gray, G. V. Long, J. Braithwaite, H. Rizos, and L. A. Ellis. A scoping review of factors influencing the implementation of liquid biopsy for cancer care. J Exp Clin Cancer Res 44, no. 1 (2025): 50. https://dx.doi.org/10.1186/s13046-025-03322-w.

Kennedy, O. J., N. Glassee, M. Kicinski, E. Bührer, S. Valpione, S. Gandini, S. Suciu, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, C. Robert, A. M. M. Eggermont, P. Lorigan, and M. Mandala. Prognostic and predictive importance of body mass index and type 2 diabetes in the European organisation for research and treatment of cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. EJC Skin Cancer 3, no. 100284 (2025): 100284. https://dx.doi.org/10.1016/j.ejcskn.2025.100284.

Newell, F., I. P. da Silva, P. A. Johansson, A. M. Menzies, J. S. Wilmott, V. Addala, M. S. Carlino, H. Rizos, K. Nones, J. J. Edwards, V. Lakis, S. H. Kazakoff, P. Mukhopadhyay, P. M. Ferguson, C. Leonard, L. T. Koufariotis, S. Wood, C. U. Blank, J. F. Thompson, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. V. Pearson, G. J. Mann, N. K. Hayward, R. A. Scolyer, N. Waddell, and G. V. Long. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 43, no. 3 (2025): 563. https://dx.doi.org/10.1016/j.ccell.2025.01.011.

Lo, S. N., G. J. Williams, A. E. Cust, D. W. Ollila, A. H. R. Varey, S. Ch'ng, R. A. Scolyer, and J. F. Thompson. Risk of death due to melanoma and other causes in patients with thin cutaneous melanomas. JAMA Dermatol 161, no. 2 (2025): 167–74. https://dx.doi.org/10.1001/jamadermatol.2024.4900.

Munoz-Couselo, E., A. Soria Rivas, S. Sandhu, G. V. Long, M. F. Sanmamed, A. Spreafico, E. Buchbinder, M. Sznol, H. Prenen, A. Fedenko, M. Milhem, A. M. Arance Fernandez, J. J. Grob, L. Demidov, C. Robert, C. Habigt, S. Evers, N. Sleiman, D. Dejardin, C. Ardeshir, N. Martin, C. Boetsch, J. Charo, V. Teichgraber, A. Kraxner, N. Keshelava, and O. Bechter. Phase Ib study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. Cancer Res Commun 5, no. 2 (2025): 358–68. https://dx.doi.org/10.1158/2767-9764.CRC-24-0601.

Yoon, C. H., M. I. Ross, B. R. Gastman, J. J. Luke, P. A. Ascierto, G. V. Long, P. Rutkowski, M. Khattak, M. Del Vecchio, L. de la Cruz Merino, J. Mackiewicz, V. Chiarion-Sileni, D. Schadendorf, M. S. Carlino, Y. Zhao, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, J. E. Gershenwald, and V. K. Sondak. Adjuvant pembrolizumab in stage II melanoma: Outcomes by primary tumor location in the randomized, double-blind, phase III KEYNOTE-716 trial. Ann Surg Oncol 32, no. 4 (2025): 2756–64. https://dx.doi.org/10.1245/s10434-024-16642-6.

Mo, J., A. Zaremba, A. J. Inderjeeth, P. El Zeinaty, A. Li, A. Wicky, N. Della Marta, C. G. Marqueste, A. S. Bohne, M. Matias, N. McNamee, L. Festino, C. Chen, S. Ch'ng, A. C. J. van Akkooi, L. D. Meda, J. J. Park, P. A. Ascierto, A. Hauschild, J. H. Lee, J. J. Grob, J. Mangana, A. Guminski, O. Michielin, W. Xu, C. Lebbe, S. Sandhu, L. Zimmer, A. M. Menzies, S. N. Lo, G. V. Long, M. S. Carlino, and I. P. da Silva. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel cell carcinoma. Eur J Cancer 217 (2025): 115254. https://dx.doi.org/10.1016/j.ejca.2025.115254.

Quek, C. Harnessing molecular insights for translational impact: Highlights from the special issue titled "New Insights in Translational Bioinformatics". Int J Mol Sci 26, no. 2 (2025). https://dx.doi.org/10.3390/ijms26020579.

Dummer, R., C. Robert, R. A. Scolyer, J. M. Taube, M. T. Tetzlaff, A. M. Menzies, A. Hill, J. J. Grob, D. C. Portnoy, C. Lebbe, M. A. Khattak, J. Cohen, G. Bar-Sela, I. Mehmi, R. Shapira-Frommer, N. Meyer, A. L. Webber, Y. Ren, M. Fukunaga-Kalabis, C. Krepler, and G. V. Long. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: A phase 1/2 trial. Nat Med 31, no. 1 (2025): 144–51. https://dx.doi.org/10.1038/s41591-024-03411-x.

Hauschild, A., C. Garbe, P. A. Ascierto, L. Demidov, B. Dreno, R. Dummer, A. Eggermont, A. M. Forsea, C. Gebhardt, J. E. Gershenwald, O. Hamid, C. Hoeller, L. Kandolf, R. Kaufmann, J. M. Kirkwood, C. Lebbe, G. V. Long, J. Malvehy, S. Martin-Algarra, G. McArthur, B. Neyns, E. Richtig, C. Robert, D. Schadendorf, R. A. Scolyer, V. K. Sondak, A. Wainstein, M. Weichenthal, P. Nuti, and the Melanoma World Society Study Group. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: An international survey. Lancet Oncol 26, no. 1 (2025): 12–14. https://dx.doi.org/10.1016/S1470-2045(24)00627-2.

Lo, S. N., G. J. Williams, A. E. Cust, A. H. R. Varey, S. Ch'ng, R. A. Scolyer, and J. F. Thompson. Long-term survival across Breslow thickness categories: Findings from a population-based study of 210,042 Australian melanoma patients. J Natl Cancer Inst 117, no. 1 (2025): 152–56. https://dx.doi.org/10.1093/jnci/djae198.

Sturm, R. A., D. J. Smit, D. L. Duffy, C. McLean, R. A. Scolyer, G. A. McArthur, A. T. Papenfuss, M. S. Stark, H. P. Soyer, and V. J. Mar. Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma. Br J Dermatol 192, no. 1 (2024): 55–62. https://dx.doi.org/10.1093/bjd/ljae336.

Wu, Z., B. Nickel, F. Boroumand, D. Elder, P. M. Ferguson, R. A. Scolyer, B. O'Brien, R. Barnhill, A. S. Adamson, A. C. J. van Akkooi, J. Emery, L. Parker, D. Low, C. Low, E. Davies, S. Liu, S. Lewis, B. Spongberg-Ross, and K. J. Bell. Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: Protocol for an online randomised study. BMJ Open 14, no. 12 (2024): e089558. https://dx.doi.org/10.1136/bmjopen-2024-089558.

Tawbi, H. A., F. S. Hodi, E. J. Lipson, D. Schadendorf, P. A. Ascierto, L. Matamala, E. Castillo Gutierrez, P. Rutkowski, H. Gogas, C. D. Lao, J. Janoski De Menezes, S. Dalle, A. M. Arance, J. J. Grob, B. Ratto, S. Rodriguez, A. Mazzei, S. Dolfi, and G. V. Long. Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047. J Clin Oncol 43, no. 13 (2025): 1546–52. https://dx.doi.org/10.1200/JCO.24.01124.

Handel, E. E., J. McKeown, J. Wei, R. A. Kankaria, H. Burnette, D. B. Johnson, A. Lawless, J. Czapla, R. J. Sullivan, L. J. Albrecht, L. Zimmer, J. Mangana, R. Dummer, J. I. Kessels, B. Neyns, C. Allayous, C. Lebbe, C. Boatwright, J. M. Mehnert, M. Ottaviano, P. A. Ascierto, A. M. Czarnecka, P. Rutkowski, S. N. Lo, G. V. Long, A. M. Menzies, and M. S. Carlino. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma. Eur J Cancer 215 (2025): 115171. https://dx.doi.org/10.1016/j.ejca.2024.115171.

2025

2024

Gide, T. N., Y. Mao, R. A. Scolyer, G. V. Long, and J. S. Wilmott. Tissue-based profiling techniques to achieve precision medicine in cancer: Opportunities and challenges in melanoma. Clin Cancer Res 30, no. 23 (2024): 5270–80. https://dx.doi.org/10.1158/1078-0432.CCR-24-1109.

Dempsey, K., R. Saw, I. Bartula, S. N. Lo, A. M. Menzies, G. V. Long, C. Lawn, J. Chung, T. Pennington, F. Boyle, A. Spillane, M. Dieng, D. Saks, J. Lai-Kwon, J. R. Thompson, and R. L. Morton. Patient and staff experiences of embedding electronic patient reported outcome measures for distress screening and quality of life assessment, into routine melanoma care: A mixed-methods study. Psychooncology 33, no. 12 (2024): e70053. https://dx.doi.org/10.1002/pon.70053.

Lai, B., H. P. Soyer, L. Zhu, P. M. Ferguson, B. O'Brien, T. Dodds, R. A. Scolyer, G. Ferrara, G. Argenziano, and K. J. L. Bell. Impact of clinical information on melanocytic skin lesion pathology diagnosis: A scoping review. JAMA Dermatol 160, no. 12 (2024): 1345–52. https://dx.doi.org/10.1001/jamadermatol.2024.4281.

Dimitriou, F., M. M. Orloff, E. C. Koch Hein, P. F. Cheng, I. F. Hughes, E. Simeone, K. Montazeri, P. Grover, I. Mehmi, C. L. Gerard, C. Gaudy-Marqueste, J. J. Grob, O. Michielin, O. Hamid, G. V. Long, R. Sullivan, E. Kapiteijn, D. B. Johnson, P. A. Ascierto, A. M. Joshua, R. D. Carvajal, M. O. Butler, J. C. Hassel, and R. Dummer. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. Eur J Cancer 214 (2025): 115161. https://dx.doi.org/10.1016/j.ejca.2024.115161.

Elewaut, A., G. Estivill, F. Bayerl, L. Castillon, M. Novatchkova, E. Pottendorfer, L. Hoffmann-Haas, M. Schönlein, T. V. Nguyen, M. Lauss, F. Andreatta, M. Vulin, I. Krecioch, J. Bayerl, A. M. Pedde, N. Fabre, F. Holstein, S. M. Cronin, S. Rieser, D. D. Laniti, D. Barras, G. Coukos, C. Quek, X. Bai, I. Ordoño M. Muñoz, T. Wiesner, J. Zuber, G. Jönsson, J. P. Böttcher, S. Vanharanta, and A. C. Obenauf. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature 637, no. 8046 (2025): 716–25. https://dx.doi.org/10.1038/s41586-024-08257-4.

Reijers, I. L. M., A. M. Menzies, M. Lopez-Yurda, J. M. Versluis, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, E. Kapiteijn, A. A. M. van der Veldt, K. P. M. Suijkerbuijk, H. Eriksson, G. A. P. Hospers, W. M. C. Klop, A. Torres Acosta, L. Grijpink-Ongering, M. Gonzalez, A. van der Wal, A. Al-Mamgani, A. J. Spillane, R. A. Scolyer, B. A. van de Wiel, A. C. J. van Akkooi, G. V. Long, and C. U. Blank. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer 214 (2025): 115141. https://dx.doi.org/10.1016/j.ejca.2024.115141.

Pham, J. P., R. Staeger, A. M. Joshua, J. Liu, I. P. da Silva, R. Dummer, and S. M. Goldinger. An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma. Eur J Cancer 214 (2025): 115121. https://dx.doi.org/10.1016/j.ejca.2024.115121.

Robert, C., G. V. Long, J. Larkin, J. D. Wolchok, J. C. Hassel, D. Schadendorf, F. S. Hodi, C. Lebbe, J. J. Grob, J. R. Hyngstrom, J. Wagstaff, J. Chesney, M. O. Butler, O. Bechter, I. Marquez-Rodas, A. C. Pavlick, P. Durani, M. Pe Benito, P. Wang, M. A. Postow, and P. A. Ascierto. Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients. Eur J Cancer 214 (2025): 115119. https://dx.doi.org/10.1016/j.ejca.2024.115119.

Amaral, T., M. Ottaviano, A. Arance, C. Blank, V. Chiarion-Sileni, M. Donia, R. Dummer, C. Garbe, J. E. Gershenwald, H. Gogas, M. Guckenberger, J. Haanen, O. Hamid, A. Hauschild, C. Holler, C. Lebbe, R. J. Lee, G. V. Long, P. Lorigan, E. Munoz Couselo, P. Nathan, C. Robert, E. Romano, D. Schadendorf, V. Sondak, K. P. M. Suijkerbuijk, A. C. J. van Akkooi, O. Michielin, P. A. Ascierto, and Esmo Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up. Ann Oncol 36, no. 1 (2025): 10–30. https://dx.doi.org/10.1016/j.annonc.2024.11.006.

Melhoranse Gouveia, B., P. M. Ferguson, S. N. Lo, H. Collgros, L. K. Martin, C. Sinz, A. K. Smit, B. Gallo, G. Ho, A. Glanz, R. A. Scolyer, A. E. Cust, and P. Guitera. In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis. J Eur Acad Dermatol Venereol 39, no. 3 (2025): 555–65. https://dx.doi.org/10.1111/jdv.20389.

DePalo, D. K., M. M. Dugan, S. M. H. Naqvi, D. W. Ollila, T. J. Hieken, M. S. Block, W. J. van Houdt, Mwjm Wouters, S. J. M. Reijers, N. Asher, K. K. Broman, Z. Duncan, M. Anderson, D. E. Gyorki, H. Snow, J. Held, J. M. Farma, J. T. Vetto, J. Y. C. Hui, M. Kolbow, R. P. M. Saw, S. N. Lo, G. V. Long, J. F. Thompson, Y. Kim, L. Karapetyan, L. Ny, A. C. J. van Akkooi, R. Olofsson Bagge, and J. S. Zager. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. Cancer 131, no. 1 (2025): e35636. https://dx.doi.org/10.1002/cncr.35636.

Conway, K., S. N. Edmiston, A. Vondras, A. Reiner, D. L. Corcoran, R. Shen, E. A. Parrish, H. Hao, L. Lin, J. M. Kenney, G. Ilelaboye, C. E. Kostrzewa, P. F. Kuan, K. J. Busam, C. Lezcano, T. K. Lee, E. Hernando, P. B. Googe, D. W. Ollila, S. Moschos, I. Gorlov, C. I. Amos, M. S. Ernstoff, A. E. Cust, J. S. Wilmott, R. A. Scolyer, G. J. Mann, I. A. Vergara, J. Ko, J. R. Rees, S. Yan, E. Nagore, M. Bosenberg, B. G. Rothberg, I. Osman, J. E. Lee, Y. Saenger, P. Bogner, C. L. Thompson, M. Gerstenblith, S. L. Holmen, P. Funchain, E. Brunsgaard, N. D. Depcik-Smith, L. Luo, T. Boyce, I. Orlow, C. B. Begg, M. Berwick, and N. E. Thomas. DNA methylation classes of stage II and III primary melanomas and their clinical and prognostic significance. JCO Precis Oncol 8 (2024): e2400375. https://dx.doi.org/10.1200/po-24-00375.

Long, G. V., J. Larkin, D. Schadendorf, J. J. Grob, C. D. Lao, I. Marquez-Rodas, J. Wagstaff, C. Lebbe, J. Pigozzo, C. Robert, P. A. Ascierto, V. Atkinson, M. A. Postow, M. B. Atkins, M. Sznol, M. K. Callahan, S. L. Topalian, J. A. Sosman, S. Kotapati, P. K. Thakkar, C. Ritchings, M. Pe Benito, S. Re, S. Soleymani, and F. S. Hodi. Pooled long-term outcomes with nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. J Clin Oncol 43, no. 8 (2025): 938–48. https://dx.doi.org/10.1200/JCO.24.00400.

Maher, N. G., R. A. Scolyer, and S. Liu. Computer vision methods under rapid evolution for pathology image tasks. Histopathology 86, no. 2 (2025): 199–203. https://dx.doi.org/10.1111/his.15352.

Dempsey, K., G. Ho, S. N. Lo, J. McKeown, C. G. Watts, A. E. Cust, P. Guitera, R. A. Scolyer, J. F. Thompson, and R. L. Morton. Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia. JAAD Int 18 (2025): 90–100. https://dx.doi.org/10.1016/j.jdin.2024.08.024.

Lim, S. Y., I. P. da Silva, N. A. Adegoke, S. N. Lo, A. M. Menzies, M. S. Carlino, R. A. Scolyer, G. V. Long, J. H. Lee, and H. Rizos. Size matters: Integrating tumour volume and immune activation signatures predicts immunotherapy response. Mol Cancer 23, no. 1 (2024): 228. https://dx.doi.org/10.1186/s12943-024-02146-0.

Jackett, L. A., J. P. Gullifer, and R. A. Scolyer. Evaluation of multiple tissue levels frequently upstages patients with clinically localized thin primary cutaneous melanoma. J Cutan Pathol (2024). https://dx.doi.org/10.1111/cup.14726.

Potter, A. J., P. M. Ferguson, S. N. Lo, T. Ahmed, R. V. Rawson, J. F. Thompson, G. V. Long, and R. A. Scolyer. The prognostic significance of tumoral melanosis. J Cutan Pathol 0, no. 0 (2024): 1–11. https://dx.doi.org/10.1111/cup.14727.

Banerjee, S., C. M. Booth, E. Bruera, M. W. Buchler, A. Drilon, T. J. Fry, I. M. Ghobrial, L. Gianni, R. K. Jain, G. Kroemer, J. M. Llovet, G. V. Long, K. Pantel, K. Pritchard-Jones, H. I. Scher, J. Tabernero, R. R. Weichselbaum, M. Weller, and Y. L. Wu. Two decades of advances in clinical oncology – lessons learned and future directions. Nat Rev Clin Oncol 21, no. 11 (2024): 771–80. https://dx.doi.org/10.1038/s41571-024-00945-4.

Hotchkiss, K. M., P. Karschnia, K. C. Schreck, M. Geurts, T. F. Cloughesy, J. Huse, E. S. Duke, J. Lathia, D. M. Ashley, E. K. Nduom, G. V. Long, K. Singh, A. Chalmers, M. S. Ahluwalia, A. Heimberger, S. Bagley, T. Todo, R. Verhaak, P. D. Kelly, S. Hervey-Jumper, J. de Groot, A. Patel, P. Fecci, I. Parney, V. Wykes, C. Watts, T. C. Burns, N. Sanai, M. Preusser, J. C. Tonn, K. J. Drummond, M. Platten, S. Das, K. Tanner, M. A. Vogelbaum, M. Weller, J. R. Whittle, M. S. Berger, and M. Khasraw. A brave new framework for glioma drug development. Lancet Oncol 25, no. 10 (2024): e512–9. https://dx.doi.org/10.1016/S1470-2045(24)00190-6.

Woodford, R., J. McKeown, L. L. Hoeijmakers, J. Mangana, F. Dimitriou, C. Allayous, F. Zaman, F. Aya, J. Marsiglio, R. Goodman, V. Rayson, J. Placzke, J. Kessels, E. Ramalyte, W. Haque, I. Wilson, C. Trojaniello, N. Benannoune, R. Roberts-Thomson, C. Robert, C. U. Blank, R. Dummer, C. Lebbe, A. Haydon, A. Arance, S. Hu-Lieskovan, D. B. Johnson, G. A. McArthur, P. Rutkowski, B. Neyns, R. J. Sullivan, J. Weber, M. S. Carlino, P. A. Ascierto, S. Lo, G. V. Long, and A. M. Menzies. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. Eur J Cancer 212, no. 115055 (2024): 115055. https://dx.doi.org/10.1016/j.ejca.2024.115055.

Li, Y., S. Cherepanoff, R. M. Conway, L. B. Hesson, G. V. Long, N. Garg, and A. T. Fung. Choroidal melanoma in a patient with multiple endocrine neoplasia type 1. Can J Ophthalmol 60, no. 1 (2025): e173–e76. https://dx.doi.org/10.1016/j.jcjo.2024.08.017.

Long, G. V., M. S. Carlino, C. McNeil, A. Ribas, C. Gaudy-Marqueste, J. Schachter, M. Nyakas, D. Kee, T. M. Petrella, A. Blaustein, M. Lotem, A. M. Arance, A. I. Daud, O. Hamid, J. Larkin, L. Yao, R. Singh, R. Lal, and C. Robert. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol 35, no. 12 (2024): 1191–99. https://dx.doi.org/10.1016/j.annonc.2024.08.2330.

Wolchok, J. D., V. Chiarion-Sileni, P. Rutkowski, C. L. Cowey, D. Schadendorf, J. Wagstaff, P. Queirolo, R. Dummer, M. O. Butler, A. G. Hill, M. A. Postow, C. Gaudy-Marqueste, T. Medina, C. D. Lao, J. Walker, I. Marquez-Rodas, Jbag Haanen, M. Guidoboni, M. Maio, P. Schoffski, M. S. Carlino, S. Sandhu, C. Lebbe, P. A. Ascierto, G. V. Long, C. Ritchings, A. Nassar, M. Askelson, M. P. Benito, W. Wang, F. S. Hodi, J. Larkin, and the CheckMate Investigators. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 392, no. 1 (2025): 11–22. https://dx.doi.org/10.1056/NEJMoa2407417.

Eggermont, A. M., M. Kicinski, C. U. Blank, M. Mandala, G. V. Long, V. Atkinson, S. Dalle, A. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, P. Lorigan, D. Grebennik, C. Kreplere, S. Marreaud, S. Suciu, and C. Robert. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC 1325/KEYNOTE-054 trial. Eur J Cancer 211, no. 114327 (2024): 114327. https://dx.doi.org/10.1016/j.ejca.2024.114327.

Li, A. T., J. X. Xu, T. R. Blah, S. N. Lo, R. P. Saw, A. H. Varey, A. Van Akkooi, M. S. Carlino, I. P. da Silva, A. M. Menzies, K. F. Shannon, G. V. Long, R. A. Scolyer, J. F. Thompson, and S. Ch'ng. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy. J Am Acad Dermatol 92, no. 1 (2025): 58–67. https://dx.doi.org/10.1016/j.jaad.2024.06.107.

Martin, L. K., P. Guitera, G. V. Long, R. A. Scolyer, and A. E. Cust. Towards evidence-based skin checks. Med J Aust 221, no. 8 (2024): 407–09. https://dx.doi.org/10.5694/mja2.52443.

Mandala, M., A. Ferrari, I. B. Brecht, K. P. Suijkerbuijk, L. Maschke, D. Giannarelli, A. Indini, M. Ubaldi, G. Pecci, V. Atkinson, H. Helgadottir, S. Chiaravalli, N. Benannoune, C. Robert, P. Teterycz, P. Rutkowski, S. Puig, G. Madonna, R. Kebudi, S. Grynberg, L. M. Arantes, E. Bien, M. Krawczyk, M. D. Pasquale, M. P. Dierselhuis, D. Massi, G. V. Long, P. A. Ascierto, A. M. M. Eggermont, and the MELCAYA Consortium. Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study). Eur J Cancer 211, no. 114305 (2024): 114305. https://dx.doi.org/10.1016/j.ejca.2024.114305.

Cust, A. E., R. A. Scolyer, and G. V. Long. What is behind the declining incidence of melanoma in younger Australians? Med J Aust 221, no. 5 (2024): 246–47. https://dx.doi.org/10.5694/mja2.52411.

Maher, N. G., H. Danaei Mehr, C. Cong, N. A. Adegoke, I. A. Vergara, S. Liu, and R. A. Scolyer. Weakly supervised deep learning image analysis can differentiate melanoma from naevi on haematoxylin and eosin-stained histopathology slides. J Eur Acad Dermatol Venereol 38, no. 12 (2024): 2250–58. https://dx.doi.org/10.1111/jdv.20307.

Lim, S. Y., Y. Lin, J. H. Lee, B. Pedersen, A. Stewart, R. A. Scolyer, G. V. Long, J. Y. H. Yang, and H. Rizos. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors. EBioMedicine 107, no. 105308 (2024): 105308. https://dx.doi.org/10.1016/j.ebiom.2024.105308.

Dimitriou, F., P. F. Cheng, A. Saltari, K. Schaper-Gerhardt, R. Staeger, V. Haunerdinger, F. Sella, A. Tastanova, C. Urban, S. Dettwiler, D. Mihic-Probst, C. M. Matter, O. Michielin, R. Gutzmer, G. V. Long, B. Becher, M. P. Levesque, and R. Dummer. A targetable type III immune response with increase of IL-17A expressing CD4(+) T cells is associated with immunotherapy-induced toxicity in melanoma. Nat Cancer 5, no. 9 (2024): 1390–408. https://dx.doi.org/10.1038/s43018-024-00810-4.

Chan, W. Y., J. H. Lee, A. Stewart, R. J. Diefenbach, M. Gonzalez, A. M. Menzies, C. Blank, R. A. Scolyer, G. V. Long, and H. Rizos. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy. J Exp Clin Cancer Res 43, no. 1 (2024): 238. https://dx.doi.org/10.1186/s13046-024-03153-1.

Long, G. V., E. J. Lipson, F. S. Hodi, P. A. Ascierto, J. Larkin, C. Lao, J. J. Grob, F. Ejzykowicz, A. Moshyk, V. Garcia-Horton, Z. Y. Zhou, Y. Xin, J. Palaia, L. McDonald, S. Keidel, A. Salvatore, D. Patel, L. A. Sakkal, H. Tawbi, and D. Schadendorf. First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: An indirect treatment comparison using RELATIVITY-047 and CheckMate 067 trial data. J Clin Oncol 42, no. 33 (2024): 3926–34. https://dx.doi.org/10.1200/JCO.24.01125.

Buhrer, E., M. Kicinski, M. Mandala, M. Pe, G. V. Long, V. Atkinson, C. U. Blank, A. Haydon, S. Dalle, A. Khattak, M. S. Carlino, A. Meshcheryakov, S. Sandhu, S. Puig, D. Schadendorf, R. Jamal, P. Rutkowski, A. J. M. van den Eertwegh, C. Coens, D. Grebennik, C. Krepler, C. Robert, and A. M. M. Eggermont. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): Long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 25, no. 9 (2024): 1202–12. https://dx.doi.org/10.1016/S1470-2045(24)00338-3.

Weber, J., M. Del Vecchio, M. Mandala, H. Gogas, A. M. Arance, S. Dalle, C. L. Cowey, M. Schenker, J. J. Grob, V. Chiarion-Sileni, I. Marquez-Rodas, M. O. Butler, A. M. Di Giacomo, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, L. A. Fecher, M. Millward, N. I. Khushalani, P. Queirolo, G. V. Long, M. Lobo, M. Askelson, P. A. Ascierto, and J. Larkin. Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238. J Clin Oncol 42, no. 31 (2024): 3702–12. https://dx.doi.org/10.1200/JCO.23.01448.

Quek, C., A. Pratapa, X. Bai, G. Al-Eryani, I. P. da Silva, A. Mayer, N. Bartonicek, K. Harvey, N. G. Maher, J. W. Conway, R. J. Kasalo, B. Ben Cheikh, O. Braubach, U. Palendira, R. P. M. Saw, J. R. Stretch, K. F. Shannon, A. M. Menzies, R. A. Scolyer, G. V. Long, A. Swarbrick, and J. S. Wilmott. Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Rep 43, no. 7 (2024): 114392. https://dx.doi.org/10.1016/j.celrep.2024.114392.

Gogas, H., S. Ravimohan, A. Datta, A. Chhibber, E. M. Couselo, A. Diab, C. Pereira, G. Quereux, S. Sandhu, B. Curti, N. I. Khushalani, M. H. Taylor, G. A. Daniels, A. Spreafico, T. Meniawy, A. J. M. Van Den Eertwegh, Y. Sun, Y. Arriaga, M. Zhou, G. V. Long, and C. Lebbe. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab. NPJ Precis Oncol 8, no. 1 (2024): 150. https://dx.doi.org/10.1038/s41698-024-00641-7.

Wu, M., N. Maher, R. A. Scolyer, A. M. Menzies, and T. E. Pennington. Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: A very rare occurrence and literature review. Pathology 56, no. 7 (2024): 1055–59. https://dx.doi.org/10.1016/j.pathol.2024.05.004.

da Silva, I. P., I. Li, S. Ugurel, P. Serra-Bellver, A. Andhale, H. Burnette, F. Aya, J. W. Conway, J. Braden, M. S. Carlino, A. M. Menzies, M. Weichenthal, P. Mohr, R. Gutzmer, A. M. Arance, D. B. Johnson, P. Lorigan, D. Schadendorf, S. N. Lo, and G. V. Long. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases. Eur J Cancer 205, no. 1 (2024): 114101. https://dx.doi.org/10.1016/j.ejca.2024.114101.

Chan, S., P. Guitera, P. Ferguson, M. A. El Sharouni, R. Teh, R. A. Scolyer, and A. Glanz. Predictors of malignancy in melanocytic lesions presenting as new lesions compared to baseline total body photography: A case-control study. J Eur Acad Dermatol Venereol 39, no. 3 (2025): 594–603. https://dx.doi.org/10.1111/jdv.20188.

Pinkham, M. B., A. Herschtal, A. M. Hong, M. S. Chua, R. A. Scolyer, S. Cumming, A. Pullar, J. Nobes, C. A. Barker, B. A. Guadagnolo, G. B. Fogarty, B. H. Burmeister, and M. C. Foote. ASO Author Reflections: The role of postoperative radiation therapy following wide excision of neurotropic melanoma of the head and neck: Now and into the future. Ann Surg Oncol 31, no. 9 (2024): 6118–19. https://dx.doi.org/10.1245/s10434-024-15657-3.

Long, G. V., M. S. Carlino, G. Au-Yeung, A. J. Spillane, K. F. Shannon, D. E. Gyorki, E. Hsiao, R. Kapoor, J. R. Thompson, I. Batula, J. Howle, S. Ch'ng, M. Gonzalez, R. P. M. Saw, T. E. Pennington, S. N. Lo, R. A. Scolyer, and A. M. Menzies. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: The randomized phase 2 NeoTrio trial. Nat Med 30, no. 9 (2024): 2540–48. https://dx.doi.org/10.1038/s41591-024-03077-5.

Long, G. V., A. Hauschild, M. Santinami, J. M. Kirkwood, V. Atkinson, M. Mandala, B. Merelli, V. C. Sileni, M. Nyakas, A. Haydon, C. Dutriaux, C. Robert, L. Mortier, J. Schachter, D. Schadendorf, T. Lesimple, R. Plummer, J. Larkin, M. Tan, S. B. Adnaik, P. Burgess, T. Jandoo, and R. Dummer. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 391, no. 18 (2024): 1709–20. https://dx.doi.org/10.1056/NEJMoa2404139.

Zemek, R. M., V. Anagnostou, I. P. da Silva, G. V. Long, and W. J. Lesterhuis. Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer 24, no. 7 (2024): 480–97. https://dx.doi.org/10.1038/s41568-024-00699-2.

Pinkham, M. B., A. Herschtal, A. M. Hong, M. S. Chua, R. A. Scolyer, S. Cumming, A. Pullar, J. Nobes, C. A. Barker, B. A. Guadagnolo, G. B. Fogarty, B. H. Burmeister, and M. C. Foote. Randomized trial of postoperative radiation therapy after wide excision of neurotropic melanoma of the head and neck (RTN2 trial 01.09). Ann Surg Oncol 31, no. 9 (2024): 6088–96. https://dx.doi.org/10.1245/s10434-024-15569-2.

Williams, G. J., T. Quinn, S. N. Lo, P. Guitera, R. A. Scolyer, J. F. Thompson, and S. Ch'ng. Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses. J Eur Acad Dermatol Venereol 39, no. 2 (2025): 416–25. https://dx.doi.org/10.1111/jdv.20138.

Blank, C. U., M. W. Lucas, R. A. Scolyer, B. A. van de Wiel, A. M. Menzies, M. Lopez-Yurda, L. L. Hoeijmakers, R. P. M. Saw, J. M. Lijnsvelt, N. G. Maher, S. M. Pulleman, M. Gonzalez, A. Torres Acosta, W. J. van Houdt, S. N. Lo, A. M. J. Kuijpers, A. Spillane, W. M. C. Klop, T. E. Pennington, C. L. Zuur, K. F. Shannon, B. A. Seinstra, R. V. Rawson, Jbag Haanen, S. Ch'ng, K. A. T. Naipal, J. Stretch, J. V. van Thienen, M. A. Rtshiladze, S. Wilgenhof, R. Kapoor, A. Meerveld-Eggink, L. G. Grijpink-Ongering, A. C. J. van Akkooi, I. L. M. Reijers, D. E. Gyorki, D. J. Grunhagen, F. M. Speetjens, S. B. Vliek, J. Placzke, L. Spain, R. C. Stassen, M. Amini-Adle, C. Lebbe, M. B. Faries, C. Robert, P. A. Ascierto, R. van Rijn, Fwpj van den Berkmortel, D. Piersma, A. van der Westhuizen, G. Vreugdenhil, M. J. B. Aarts, M. A. M. Stevense-den Boer, V. Atkinson, M. Khattak, M. C. Andrews, A. J. M. van den Eertwegh, M. J. Boers-Sonderen, G. A. P. Hospers, M. S. Carlino, J. B. de Groot, E. Kapiteijn, K. P. M. Suijkerbuijk, P. Rutkowski, S. Sandhu, A. A. M. van der Veldt, and G. V. Long. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med 391, no. 18 (2024): 1696–708. https://dx.doi.org/10.1056/NEJMoa2402604.

Luke, J. J., G. V. Long, C. Robert, M. S. Carlino, T. K. Choueiri, N. B. Haas, M. O'Brien, L. Paz-Ares, S. Peters, T. Powles, M. A. Leiby, J. Lin, Y. Zhao, C. Krepler, R. F. Perini, M. Catherine Pietanza, A. Samkari, T. Gruber, N. Ibrahim, and A. M. M. Eggermont. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma. Eur J Cancer 207, no. 114146 (2024): 114146. https://dx.doi.org/10.1016/j.ejca.2024.114146.

Winder, A. A., Z. Boyer, S. Ch'ng, J. R. Stretch, R. P. M. Saw, K. F. Shannon, T. E. Pennington, O. E. Nieweg, A. H. R. Varey, R. A. Scolyer, J. F. Thompson, A. E. Cust, S. N. Lo, A. J. Spillane, and A. L. Smith. Impact of an online risk calculator for sentinel node positivity on management of patients with T1 and T2 melanomas. Ann Surg Oncol 31, no. 8 (2024): 5331–39. https://dx.doi.org/10.1245/s10434-024-15456-w.

Zijlker, L. P., H. Chen, A. J. Spillane, M. Gonzalez, T. E. Pennington, A. M. Menzies, S. N. Lo, P. Ferguson, R. Rawson, A. J. Colebatch, J. R. Stretch, J. F. Thompson, S. Ch'ng, O. Nieweg, K. F. Shannon, G. V. Long, R. A. Scolyer, R. P. M. Saw, and A. C. J. van Akkooi. The effect of neoadjuvant systemic therapy on surgical outcomes after lymph node dissections for stage III melanoma: An Australian cohort. Ann Surg Oncol 31, no. 8 (2024): 5324–30. https://dx.doi.org/10.1245/s10434-024-15274-0.

Robert, C., B. Gastman, H. Gogas, P. Rutkowski, G. V. Long, M. F. Chaney, H. Joshi, Y. L. Lin, W. Snyder, and J. A. Chesney. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Eur J Cancer 207, no. 114120 (2024): 114120. https://dx.doi.org/10.1016/j.ejca.2024.114120.

Menzies, A. M., S. N. Lo, R. P. M. Saw, M. Gonzalez, S. Ch'ng, O. E. Nieweg, K. F. Shannon, P. M. Ferguson, J. Lee, L. Emmett, R. Kapoor, R. V. Rawson, J. R. Stretch, J. F. Thompson, A. J. Spillane, H. Rizos, R. A. Scolyer, and G. V. Long. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Ann Oncol 35, no. 8 (2024): 739–46. https://dx.doi.org/10.1016/j.annonc.2024.05.002.

Versluis, J. M., S. A. Blankenstein, P. Dimitriadis, J. S. Wilmott, R. Elens, W. A. M. Blokx, W. van Houdt, A. M. Menzies, Y. M. Schrage, Mwjm Wouters, J. Sanders, A. Broeks, R. A. Scolyer, K. P. M. Suijkerbuijk, G. V. Long, A C. J. van Akkooi, and C. U. Blank. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. J Immunother Cancer 12, no. 4 (2024): e008125. https://dx.doi.org/10.1136/jitc-2023-008125.

Tian, J., X. Bai, and C. Quek. Single-cell informatics for tumor microenvironment and immunotherapy. Int J Mol Sci 25, no. 8 (2024). https://dx.doi.org/10.3390/ijms25084485.

Luke, J. J., D. Davar, R. H. Andtbacka, N. Bhardwaj, J. D. Brody, J. Chesney, R. Coffin, T. de Baere, T. D. de Gruijl, M. Fury, G. Goldmacher, K. J. Harrington, H. Kaufman, C. M. Kelly, A. D. Khilnani, K. Liu, S. Loi, G. V. Long, I. Melero, M. Middleton, B. Neyns, D. J. Pinato, R. A. Sheth, S. B. Solomon, P. Szapary, and A. Marabelle. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): From premalignant to metastatic disease. J Immunother Cancer 12, no. 4 (2024): e008378. https://dx.doi.org/10.1136/jitc-2023-008378.

Tian, J., and C. Quek. Understanding the tumor microenvironment in melanoma patients with in-transit metastases and its impacts on immune checkpoint immunotherapy responses. Int J Mol Sci 25, no. 8 (2024). https://dx.doi.org/10.3390/ijms25084243.

Chen, A., N. Sharma, P. Patel, S. Olivares, A. Bahrami, R. L. Barnhill, W. A. M. Blokx, M. Bosenberg, K. J. Busam, A. de La Fouchardière, L. M. Duncan, D. E. Elder, J. S. Ko, G. Landman, A. J. Lazar, C. Lezcano, L. Lowe, N. G. Maher, D. Massi, J. Messina, D. Mihic-Probst, D. C. Parker, M. Redpath, R. A. Scolyer, C. R. Shea, A. Spatz, V. Tron, X. Xu, I. Yeh, S. Jung Yun, A. Zembowicz, and P. Gerami. The impact of next-generation sequencing on interobserver agreement and diagnostic accuracy of desmoplastic melanocytic neoplasms. Am J Surg Pathol 48, no. 6 (2024): 708–18. https://dx.doi.org/10.1097/pas.0000000000002226.

Bai, X., G. H. Attrill, T. N. Gide, P. M. Ferguson, K. J. Nahar, P. Shang, I. A. Vergara, U. Palendira, I. P. da Silva, M. S. Carlino, A. M. Menzies, G. V. Long, R. A. Scolyer, J. S. Wilmott, and C. Quek. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma. Nat Commun 15, no. 1 (2024): 3014. https://dx.doi.org/10.1038/s41467-024-47301-9.

Stassen, R. C., Cchm Maas, A. A. M. van der Veldt, S. N. Lo, R. P. M. Saw, A. H. R. Varey, R. A. Scolyer, G. V. Long, J. F. Thompson, P. Rutkowski, U. Keilholz, A. C. J. van Akkooi, C. Verhoef, D. van Klaveren, and D. J. Grunhagen. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: An international, retrospective, multicentre analysis. Lancet Oncol 25, no. 4 (2024): 509–17. https://dx.doi.org/10.1016/S1470-2045(24)00076-7.

Gerami, P., A. Chen, N. Sharma, P. Patel, M. Hagstrom, P. Kancherla, T. Geraminejad, S. Olivares, A. Biswas, M. Bosenberg, K. J. Busam, A. de La Fouchardière, L. M. Duncan, D. E. Elder, J. Ko, G. Landman, A. J. Lazar, L. Lowe, D. Massi, D. Mihic-Probst, D. C. Parker, R. A. Scolyer, C. R. Shea, A. Zembowicz, S. J. Yun, W. A. M. Blokx, and R. L. Barnhill. BRAF mutated and morphologically spitzoid tumors, a subgroup of melanocytic neoplasms difficult to distinguish from true Spitz neoplasms. Am J Surg Pathol 48, no. 5 (2024): 538–45. https://dx.doi.org/10.1097/pas.0000000000002194.

Maher, N. G., I. A. Vergara, G. V. Long, and R. A. Scolyer. Prognostic and predictive biomarkers in melanoma. Pathology 56, no. 2 (2024): 259–73. https://dx.doi.org/10.1016/j.pathol.2023.11.004.

Menzies, A. M., G. V. Long, A. Kohn, H. Tawbi, J. Weber, K. Flaherty, G. A. McArthur, P. A. Ascierto, Y. Pfluger, K. Lewis, K. K. Tsai, O. Hamid, H. Prenen, L. Fein, E. Wang, C. Guenzel, F. Zhang, J. F. Kleha, A. di Pietro, and M. A. Davies. POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. Neurooncol Adv 6, no. 1 (2024): vdae033. https://dx.doi.org/10.1093/noajnl/vdae033.

Schadendorf, D., J. J. Luke, P. A. Ascierto, G. V. Long, P. Rutkowski, A. Khattak, M. Del Vecchio, L. de la Cruz-Merino, J. Mackiewicz, V. C. Sileni, J. M. Kirkwood, C. Robert, J. J. Grob, R. Dummer, M. S. Carlino, Y. Zhao, M. Kalabis, C. Krepler, A. Eggermont, and R. A. Scolyer. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer 12, no. 3 (2024): e007501. https://dx.doi.org/10.1136/jitc-2023-007501.

Luke, J. J., P. A. Ascierto, M. A. Khattak, L. de la Cruz Merino, M. Del Vecchio, P. Rutkowski, F. Spagnolo, J. Mackiewicz, V. Chiarion-Sileni, J. M. Kirkwood, C. Robert, J. J. Grob, F. de Galitiis, D. Schadendorf, M. S. Carlino, X. L. Wu, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, and G. V. Long. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol 42, no. 14 (2024): 1619–24. https://dx.doi.org/10.1200/JCO.23.02355.

Albrecht, L. J., F. Dimitriou, P. Grover, J. C. Hassel, M. Erdmann, A. Forschner, D. B. Johnson, R. Varaljai, G. Lodde, J. M. Placke, F. Krefting, A. Zaremba, S. Ugurel, A. Roesch, C. Schulz, C. Berking, C. Pottgen, A. M. Menzies, G. V. Long, R. Dummer, E. Livingstone, D. Schadendorf, and L. Zimmer. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. Eur J Cancer 202, no. 113976 (2024): 113976. https://dx.doi.org/10.1016/j.ejca.2024.113976.

Olofsson Bagge, R., R. Mikiver, M. A. Marchetti, S. N. Lo, A. C. J. van Akkooi, D. G. Coit, C. Ingvar, K. Isaksson, R. A. Scolyer, J. F. Thompson, A. H. R. Varey, S. L. Wong, J. Lyth, and E. K. Bartlett. Population-based validation of the MIA and MSKCC tools for predicting sentinel lymph node status. JAMA Surg 159, no. 3 (2024): 260–68. https://dx.doi.org/10.1001/jamasurg.2023.6904.

Rogiers, A., F. Dimitriou, I. Lobon, C. Harvey, I. A. Vergara, I. P. da Silva, S. N. Lo, R. A. Scolyer, M. S. Carlino, A. M. Menzies, and G. V. Long. Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. Eur J Cancer 198, no. 113506 (2024): 113506. https://dx.doi.org/10.1016/j.ejca.2023.113506.

Kirkwood, J. M., M. D. Vecchio, J. Weber, C. Hoeller, J. J. Grob, P. Mohr, C. Loquai, C. Dutriaux, V. Chiarion-Sileni, J. Mackiewicz, P. Rutkowski, P. Arenberger, G. Quereux, T. M. Meniawy, P. A. Ascierto, A. M. Menzies, P. Durani, M. Lobo, F. Campigotto, B. Gastman, and G. V. Long. Plain language summary of the CheckMate 76K study results: Nivolumab given after stage 2B/2C melanoma is removed by surgery. Future Oncol 20, no. 15 (2024): 959–68. https://dx.doi.org/10.2217/fon-2023-0977.

Maul, L. V., D. Jamiolkowski, R. A. Lapides, A. M. Mueller, A. Hauschild, C. Garbe, P. Lorigan, J. E. Gershenwald, P. A. Ascierto, G. V. Long, M. Wang-Evers, R. A. Scolyer, B. Saravi, M. Augustin, A. A. Navarini, S. Legge, I. B. Nemeth, A. J. Janosi, S. Mocellin, A. Feller, D. Manstein, A. Zink, J. T. Maul, A. Buja, K. Adhikari, and E. Roider. Health economic consequences associated with COVID-19-related delay in melanoma diagnosis in Europe. JAMA Netw Open 7, no. 2 (2024): e2356479. https://dx.doi.org/10.1001/jamanetworkopen.2023.56479.

Varey, A. H. R., I. Li, M. A. El Sharouni, J. Simon, A. Dedeilia, S. Ch'ng, R. P. M. Saw, A. J. Spillane, K. F. Shannon, T. E. Pennington, M. Rtshiladze, J. R. Stretch, O. E. Nieweg, A. van Akkooi, R. J. Sullivan, G. M. Boland, J. E. Gershenwald, P. J. van Diest, R. A. Scolyer, G. V. Long, J. F. Thompson, and S. N. Lo. Predicting recurrence-free and overall survival for patients with stage II melanoma: The MIA calculator. J Clin Oncol 42, no. 10 (2024): 1169–80. https://dx.doi.org/10.1200/JCO.23.01020.

Kennedy, O. J., N. Glassee, M. Kicinski, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. D. Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, S. Gandini, E. Buhrer, S. Suciu, C. Robert, A. M. M. Eggermont, M. Mandala, P. Lorigan, and S. Valpione. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 201, no. 113585 (2024): 113585. https://dx.doi.org/10.1016/j.ejca.2024.113585.

Harvey, C., K. J. Nahar, J. McKeown, S. N. Lo, S. Farag, N. Yousaf, K. Young, L. Tas, A. Meerveld-Eggink, C. Blank, A. Thomas, J. McQuade, B. Schilling, D. B. Johnson, R. M. Huertas, A. Arance, J. Lee, L. Zimmer, G. V. Long, M. S. Carlino, Y. Wang, and A. M. Menzies. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series. J Immunother Cancer 12, no. 1 (2024): e008232. https://dx.doi.org/10.1136/jitc-2023-008232.

Jacques, S. K., J. McKeown, P. Grover, D. B. Johnson, A. Zaremba, F. Dimitriou, R. Weiser, M. Farid, K. Namikawa, R. J. Sullivan, P. Rutkowski, C. Lebbe, O. Hamid, J. S. Zager, O. Michielin, B. Neyns, Y. Nakamura, C. Robert, J. Mehnert, P. A. Ascierto, P. Bhave, B. Park, L. Zimmer, J. Mangana, M. Mooradian, J. Placzke, C. Allayous, I. C. Glitza Oliva, I. Mehmi, D. Depalo, A. Wicky, J. K. Schwarze, S. Roy, C. Boatwright, V. Vanella, G. V. Long, A. M. Menzies, S. N. Lo, and M. S. Carlino. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur J Cancer 199, no. 113563 (2024): 113563. https://dx.doi.org/10.1016/j.ejca.2024.113563.

Taylor, A. M., J. McKeown, F. Dimitriou, S. K. Jacques, L. Zimmer, C. Allayous, H. L. Yeoh, A. Haydon, J. M. Ressler, C. Galea, R. Woodford, K. Kahler, A. Hauschild, L. Festino, C. Hoeller, J. K. Schwarze, B. Neyns, A. Wicky, O. Michielin, J. Placzke, P. Rutkowski, D. B. Johnson, C. Lebbe, R. Dummer, P. A. Ascierto, S. N. Lo, G. V. Long, M. S. Carlino, and A. M. Menzies. Efficacy and safety of 'second adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy. Eur J Cancer 199, no. 113561 (2024): 113561. https://dx.doi.org/10.1016/j.ejca.2024.113561.

Bai, X., A. R. Lawless, J. A. Czapla, S. C. Gerstberger, B. C. Park, S. Jung, R. Johnson, N. Yamazaki, D. Ogata, Y. Umeda, C. Li, J. Guo, K. T. Flaherty, Y. Nakamura, K. Namikawa, G. V. Long, A. M. Menzies, D. B. Johnson, R. J. Sullivan, G. M. Boland, and L. Si. Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study. JAAD Int 15 (2024): 105–14. https://dx.doi.org/10.1016/j.jdin.2023.11.014.

Bawden, E. G., T. Wagner, J. Schröder, M. Effern, D. Hinze, L. Newland, G. H. Attrill, A. R. Lee, S. Engel, D. Freestone, M. de Lima Moreira, E. Gressier, N. McBain, A. Bachem, A. Haque, R. Dong, A. L. Ferguson, J. J. Edwards, P. M. Ferguson, R. A. Scolyer, J. S. Wilmott, C. M. Jewell, A. G. Brooks, D. E. Gyorki, U. Palendira, S. Bedoui, J. Waithman, K. Hochheiser, M. Hölzel, and T. Gebhardt. CD4(+) T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. Sci Immunol 9, no. 91 (2024): eadi9517. https://dx.doi.org/10.1126/sciimmunol.adi9517.

Mandala, M., P. Lorigan, M. C. Sergi, N. Benannoune, P. Serra, M. G. Vitale, D. Giannarelli, A. M. Arance, E. M. Couselo, B. Neyns, M. Tucci, M. Guida, F. Spagnolo, E. Rossi, M. Occelli, P. Queirolo, P. Quaglino, R. Depenni, B. Merelli, J. Placzke, A. M. Di Giacomo, M. Del Vecchio, A. Indini, I. P. da Silva, A. M. Menzies, G. V. Long, C. Robert, P. Rutkowski, and P. A. Ascierto. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Eur J Cancer 199, no. 113542 (2024): 113542. https://dx.doi.org/10.1016/j.ejca.2024.113542.

Weber, J. S., M. S. Carlino, A. Khattak, T. Meniawy, G. Ansstas, M. H. Taylor, K. B. Kim, M. McKean, G. V. Long, R. J. Sullivan, M. Faries, T. T. Tran, C. L. Cowey, A. Pecora, M. Shaheen, J. Segar, T. Medina, V. Atkinson, G. T. Gibney, J. J. Luke, S. Thomas, E. I. Buchbinder, J. A. Healy, M. Huang, M. Morrissey, I. Feldman, V. Sehgal, C. Robert-Tissot, P. Hou, L. Zhu, M. Brown, P. Aanur, R. S. Meehan, and T. Zaks. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet 403, no. 10427 (2024): 632–44. https://dx.doi.org/10.1016/S0140-6736(23)02268-7.

Brahmer, J. R., G. V. Long, O. Hamid, E. B. Garon, R. S. Herbst, T. Andre, P. Armand, D. Bajorin, J. Bellmunt, B. Burtness, T. K. Choueiri, E. E. W. Cohen, L. A. Diaz, Jr., K. Shitara, G. Kulkarni, D. McDermott, M. Shah, J. Tabernero, A. Vogel, P. L. Zinzani, N. Jafari, S. Bird, E. Snyder, C. Gause, O. L. Bracco, M. C. Pietanza, T. Gruber, and A. Ribas. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8,937 patients. Eur J Cancer 199, no. 113530 (2024): 113530. https://dx.doi.org/10.1016/j.ejca.2024.113530.

Lo, S. N., A. H. R. Varey, M. A. El Sharouni, R. A. Scolyer, and J. F. Thompson. Knowledge of sentinel lymph node status improves accuracy when predicting melanoma mortality and selecting patients for adjuvant immunotherapy. J Eur Acad Dermatol Venereol 38, no. 7 (2024): e638–e39. https://dx.doi.org/10.1111/jdv.19709.

Ertl, C., T. Ruf, D. Mentzer, M. Kong, R. Kramer, M. V. Bergwelt-Baildon, M. Subklewe, D. Tomsitz, P. A. Ascierto, R. Dummer, H. Gogas, C. Lebbe, G. V. Long, G. McArthur, T. G. Neilan, A. Ribas, C. Robert, D. Schadendorf, L. Zimmer, T. Eigentler, S. Grabbe, A. Forschner, K. C. Kahler, V. Milani, C. Pfohler, J. Hassel, R. Gutzmer, C. Loquai, B. Routy, A. J. S. Furness, C. Blank, J. D. Wolchok, L. E. French, A. Hauschild, and L. Heinzerling. The side effect registry immuno-oncology (SERIO) – a tool for systematic analysis of immunotherapy-induced side effects. Eur J Cancer 199, no. 113505 (2024): 113505. https://dx.doi.org/10.1016/j.ejca.2023.113505.

Busam, K. J., P. Gerami, and R. A. Scolyer. Perspectives and strategies to minimize harm from melanoma diagnosis. JAMA Dermatol 159, no. 12 (2023): 1307–09. https://dx.doi.org/10.1001/jamadermatol.2023.4324.

Paver, E. C., T. Ahmed, H. Burke, R. P. M. Saw, J. R. Stretch, A. J. Spillane, K. F. Shannon, I. A. Vergara, D. E. Elder, S. N. Lo, J. F. Thompson, and R. A. Scolyer. Prognostic significance of incipient ulceration in primary cutaneous melanoma. JAMA Dermatol 159, no. 12 (2023): 1359–67. https://dx.doi.org/10.1001/jamadermatol.2023.4193.

Wu, L., M. S. Carlino, D. A. Brown, G. V. Long, R. Clifton-Bligh, R. Mellor, K. Moore, S. C. Sasson, A. M. Menzies, V. Tsang, and J. E. Gunton. Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy. J Clin Endocrinol Metab 109, no. 5 (2024): 1301–07. https://dx.doi.org/10.1210/clinem/dgad685.

Hepner, A., J. M. Versluis, R. Wallace, C. Allayous, L. J. Brown, C. Trojaniello, C. L. Gerard, Y. J. Jansen, P. Bhave, B. Neyns, A. Haydon, O. Michielin, J. Mangana, O. Klein, A. N. Shoushtari, A. B. Warner, P. A. Ascierto, J. L. McQuade, M. S. Carlino, L. Zimmer, C. Lebbe, D. B. Johnson, S. Sandhu, V. Atkinson, C. U. Blank, S. N. Lo, G. V. Long, and A. M. Menzies. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. Eur J Cancer 196, no. 113441 (2024): 113441. https://dx.doi.org/10.1016/j.ejca.2023.113441.

Soon, J. A., Y. H. To, M. Alexander, K. Trapani, P. A. Ascierto, S. Athan, M. P. Brown, M. Burge, A. Haydon, B. Hughes, M. Itchins, T. John, S. Kao, M. Koopman, B. T. Li, G. V. Long, J. M. Loree, B. Markman, T. M. Meniawy, A. M. Menzies, L. Nott, N. Pavlakis, T. M. Petrella, S. Popat, J. Tie, W. Xu, D. Yip, J. Zalcberg, B. J. Solomon, P. Gibbs, G. A. McArthur, F. Franchini, and I. Jzerman M. A tailored approach to horizon scanning for cancer medicines. J Cancer Policy 38, no. 100441 (2023): 100441. https://dx.doi.org/10.1016/j.jcpo.2023.100441.

Gjorup, C. A., R. Woodford, I. Li, M. S. Carlino, S. Ch'ng, D. Chung, E. Hsiao, S. N. Lo, K. London, G. V. Long, A. M. Menzies, O. E. Nieweg, T. E. Pennington, M. A. Rtshiladze, R. P. M. Saw, R. A. Scolyer, K. F. Shannon, A. J. Spillane, J. R. Stretch, J. F. Thompson, A. H. R. Varey, and A. C. J. van Akkooi. Role of concurrent ultrasound surveillance of sentinel node-positive node fields in melanoma patients having routine cross-sectional imaging. Ann Surg Oncol 31, no. 3 (2024): 1857–64. https://dx.doi.org/10.1245/s10434-023-14526-9.

Fraterman, I., I. L. M. Reijers, P. Dimitriadis, A. Broeks, M. Gonzalez, A. M. Menzies, M. Lopez-Yurda, E. Kapiteijn, A. A. M. van der Veldt, K. P. M. Suijkerbuijk, G. A. P. Hospers, G. V. Long, C. U. Blank, and L. V. van de Poll-Franse. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. Nat Med 29, no. 12 (2023): 3090–99. https://dx.doi.org/10.1038/s41591-023-02631-x.

Lian, B., Z. Li, N. Wu, M. Li, X. Chen, H. Zheng, M. Gao, D. Wang, X. Sheng, H. Tian, L. Si, Z. Chi, X. Wang, Y. Lai, T. Sun, Q. Zhang, Y. Kong, G. V. Long, J. Guo, and C. Cui. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann Oncol 35, no. 2 (2024): 211–20. https://dx.doi.org/10.1016/j.annonc.2023.10.793.

Long, G. V., J. Durante, M. Browne, and R. A. Scolyer. Affecting change as a clinical academic. Trends Cancer 10, no. 2 (2024): 93–96. https://dx.doi.org/10.1016/j.trecan.2023.10.003.

2023

Bai, X., A. Shaheen, C. Grieco, P. D. d'Arienzo, F. Mina, J. A. Czapla, A. R. Lawless, E. Bongiovanni, U. Santaniello, H. Zappi, D. Dulak, A. Williamson, R. Lee, A. Gupta, C. Li, L. Si, M. Ubaldi, N. Yamazaki, D. Ogata, R. Johnson, B. C. Park, S. Jung, G. Madonna, J. Hochherz, Y. Umeda, Y. Nakamura, C. Gebhardt, L. Festino, M. Capone, P. A. Ascierto, D. B. Johnson, S. N. Lo, G. V. Long, A. M. Menzies, K. Namikawa, M. Mandala, J. Guo, P. Lorigan, Y. G. Najjar, A. Haydon, P. Quaglino, G. M. Boland, R. J. Sullivan, A. J. S. Furness, R. Plummer, and K. T. Flaherty. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: A multicenter, retrospective cohort study. EClinicalMedicine 65, no. 102290 (2023): 102290. https://dx.doi.org/10.1016/j.eclinm.2023.102290.

Handelsman, D. J., A. Idan, S. Sleiman, F. Bacha, G. V. Long, A. M. Menzies, T. Vaishnav, N. Litkouhi, X. Volckmar, W. Ledger, and A. Anazodo. Testicular function after non-cytotoxic and immunotherapy drug treatment. Andrology 12, no. 4 (2024): 891–98. https://dx.doi.org/10.1111/andr.13546.

Mallardo, D., R. Woodford, A. M. Menzies, L. Zimmer, A. Williamson, E. Ramelyte, F. Dimitriou, A. Wicky, R. Wallace, M. Mallardo, A. Cortellini, A. Budillon, V. Atkinson, S. Sandhu, M. Olivier, R. Dummer, P. Lorigan, D. Schadendorf, G. V. Long, E. Simeone, and P. A. Ascierto. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. J Transl Med 21, no. 1 (2023): 753. https://dx.doi.org/10.1186/s12967-023-04607-4.

Simpson, R. C., E. R. Shanahan, R. A. Scolyer, and G. V. Long. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol 20, no. 10 (2023): 697–715. https://dx.doi.org/10.1038/s41571-023-00803-9.

Conway, J. W., J. Braden, S. N. Lo, R. A. Scolyer, M. S. Carlino, A. M. Menzies, G. V. Long, and I. P. da Silva. VEGF inhibitors improve survival outcomes in patients with liver metastases across cancer types – a meta-analysis. Cancers (Basel) 15, no. 20 (2023): 5012. https://dx.doi.org/10.3390/cancers15205012.

Kirkwood, J. M., M. Del Vecchio, J. Weber, C. Hoeller, J. J. Grob, P. Mohr, C. Loquai, C. Dutriaux, V. Chiarion-Sileni, J. Mackiewicz, P. Rutkowski, P. Arenberger, G. Quereux, T. M. Meniawy, P. A. Ascierto, A. M. Menzies, P. Durani, M. Lobo, F. Campigotto, B. Gastman, and G. V. Long. Adjuvant nivolumab in resected stage IIB/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 29, no. 11 (2023): 2835–43. https://dx.doi.org/10.1038/s41591-023-02583-2.

Lo, S. N., A. H. R. Varey, M. A. El Sharouni, R. A. Scolyer, and J. F. Thompson. Online tools for predicting melanoma survival: Including sentinel node status as a variable improves prediction accuracy. J Eur Acad Dermatol Venereol 38, no. 2 (2024): e182–e84. https://dx.doi.org/10.1111/jdv.19524.

Gide, T. N., E. C. Paver, Z. Yaseen, N. G. Maher, N. A. Adegoke, A. M. Menzies, I. P. da Silva, J. S. Wilmott, G. V. Long, and R. A. Scolyer. LAG-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-LAG-3 plus anti-PD-1-based immunotherapies. Oncoimmunology 12, no. 1 (2023): 2261248. https://dx.doi.org/10.1080/2162402X.2023.2261248.

Ong, J. S., M. Seviiri, J. C. Dusingize, Y. Wu, X. Han, J. Shi, C. M. Olsen, R. E. Neale, J. F. Thompson, R. P. M. Saw, K. F. Shannon, G. J. Mann, N. G. Martin, S. E. Medland, S. D. Gordon, R. A. Scolyer, G. V. Long, M. M. Iles, M. T. Landi, D. C. Whiteman, S. MacGregor, and M. H. Law. Uncovering the complex relationship between balding, testosterone, and skin cancers in men. Nat Commun 14, no. 1 (2023): 5962. https://dx.doi.org/10.1038/s41467-023-41231-8.

Adegoke, N. A., T. N. Gide, Y. Mao, C. Quek, E. Patrick, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, I. A. Vergara, G. V. Long, R. A. Scolyer, and J. S. Wilmott. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. J Immunother Cancer 11, no. 10 (2023): e007144. https://dx.doi.org/10.1136/jitc-2023-007144.

Menzies, S. W., C. Sinz, M. Menzies, S. N. Lo, W. Yolland, J. Lingohr, M. Razmara, P. Tschandl, P. Guitera, R. A. Scolyer, F. Boltz, L. Borik-Heil, H. Herbert Chan, D. Chromy, D. J. Coker, H. Collgros, M. Eghtedari, M. Corral Forteza, E. Forward, B. Gallo, S. Geisler, M. Gibson, A. Hampel, G. Ho, L. Junez, P. Kienzl, A. Martin, F. J. Moloney, A. Regio Pereira, J. M. Ressler, S. Richter, K. Silic, T. Silly, M. Skoll, J. Tittes, P. Weber, W. Weninger, D. Weiss, P. Woo-Sampson, C. Zilberg, and H. Kittler. Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: A multicentre, prospective, diagnostic, clinical trial. Lancet Digit Health 5, no. 10 (2023): e679–e91. https://dx.doi.org/10.1016/s2589-7500(23)00130-9.

Goodman, R. S., L. Di Guardo, A. Maurichi, B. Kirwin, A. Khattak, V. Vanella, J. Lee, A. Lawless, J. Czapla, A. Spagnoletti, M. Ambrosini, E. Livingstone, G. V. Long, R. J. Sullivan, M. S. Carlino, V. Atkinson, C. Trojanello, P. A. Ascierto, D. Schadendorf, L. Warburton, A. M. Menzies, M. Santinami, and D. B. Johnson. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. Eur J Cancer 194, no. 113354 (2023): 113354. https://dx.doi.org/10.1016/j.ejca.2023.113354.

Ni, Y., C. G. Watts, R. A. Scolyer, C. Madronio, B. K. Armstrong, R. L. Morton, S. W. Menzies, G. J. Mann, J. F. Thompson, A. E. Cust, and S. N. Lo. Prognosis for people with multiple primary melanomas compared with a single primary melanoma. J Am Acad Dermatol 90, no. 1 (2024): 170–74. https://dx.doi.org/10.1016/j.jaad.2023.08.089.

van Akkooi, A. C., A. Hauschild, G. V. Long, M. Mandala, M. Kicinski, A. S. Govaerts, I. Klauck, M. Ouali, P. C. Lorigan, and A. M. Eggermont. COLUMBUS-AD: Phase III study of adjuvant encorafenib plus binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future Oncol 19, no. 30 (2023): 2017–27. https://dx.doi.org/10.2217/fon-2023-0414.

Diab, A., H. Gogas, S. Sandhu, G. V. Long, P. A. Ascierto, J. Larkin, M. Sznol, F. Franke, T. E. Ciuleanu, C. Pereira, E. Munoz Couselo, F. Bronzon Damian, M. Schenker, A. Perfetti, C. Lebbe, G. Quereux, F. Meier, B. D. Curti, C. Rojas, Y. Arriaga, H. Yang, M. Zhou, S. Ravimohan, P. Statkevich, M. A. Tagliaferri, and N. I. Khushalani. Bempegaldesleukin plus nivolumab in untreated advanced melanoma: The open-label, phase III PIVOT IO 001 trial results. J Clin Oncol 41, no. 30 (2023): 4756–67. https://dx.doi.org/10.1200/JCO.23.00172.

Vergara, I. A., and M. S. Stark. One step closer to improving melanoma diagnosis and prognosis with liquid biopsies. Br J Dermatol 189, no. 3 (2023): 255–59. https://dx.doi.org/10.1093/bjd/ljad185.

Schmitt, C., E. P. Hoefsmit, T. Fangmeier, N. Kramer, C. Kabakci, J. Vera Gonzalez, J. M. Versluis, A. Compter, T. Harrer, H. Mijocevic, S. Schubert, T. Hundsberger, A. M. Menzies, R. A. Scolyer, G. V. Long, L. E. French, C. U. Blank, and L. M. Heinzerling. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. Cancer Immunol Immunother 72, no. 11 (2023): 3475–89. https://dx.doi.org/10.1007/s00262-023-03498-0.

Shteinman, E. R., I. A. Vergara, R. V. Rawson, S. N. Lo, N. Maeda, K. Koyama, I. P. da Silva, G. V. Long, R. A. Scolyer, J. S. Wilmott, and A. M. Menzies. Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma. Pathology 55, no. 5 (2023): 629–36. https://dx.doi.org/10.1016/j.pathol.2023.03.007.

Gjorup, C. A., I. P. da Silva, L. Martin, J. R. Stretch, R. A. Scolyer, G. V. Long, and A. Hong. Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose. Melanoma Res 33, no. 5 (2023): 422–24. https://dx.doi.org/10.1097/CMR.0000000000000905.

Goodman, R. S., A. Lawless, R. Woodford, F. Fa'ak, A. Tipirneni, J. R. Patrinely, H. L. Yeoh, S. Rapisuwon, A. Haydon, I. Osman, J. M. Mehnert, G. V. Long, R. J. Sullivan, M. S. Carlino, A. M. Menzies, and D. B. Johnson. Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Netw Open 6, no. 8 (2023): e2327145. https://dx.doi.org/10.1001/jamanetworkopen.2023.27145.

Gupta, R., C. I. Selinger, B. Ashford, M. S. T. Chua, J. R. Clark, D. L. Damian, L. A. Jackett, C. James, S. Johnson, R. Ladwa, D. Lambie, C. McKenzie, S. T. Tan, and R. A. Scolyer. Implementing structured pathology reporting protocol for non-melanocytic skin cancers: Practical considerations. Pathology 55, no. 6 (2023): 743–59. https://dx.doi.org/10.1016/j.pathol.2023.07.003.

McKenzie, C. A., R. Gupta, L. Jackett, L. Anderson, V. Chen, J. E. Dahlstrom, M. Dray, G. Farshid, C. Hemmings, R. Karim, J. G. Kench, S. Klebe, N. Kramer, P. Kumarasinghe, F. Maclean, A. Morey, M. A. Nguyen, S. O'Toole, B. Rowbotham, E. L. C. Salisbury, R. A. Scolyer, K. Stewart, L. Waring, C. L. Cooper, and W. A. Cooper. Looking beyond workforce parity: Addressing gender inequity in pathology. Pathology 55, no. 6 (2023): 760–71. https://dx.doi.org/10.1016/j.pathol.2023.07.002.

Long, G. V., S. M. Swetter, A. M. Menzies, J. E. Gershenwald, and R. A. Scolyer. Cutaneous melanoma. Lancet 402, no. 10400 (2023): 485–502. https://dx.doi.org/10.1016/S0140-6736(23)00821-8.

Huang, C., H. Burke, R. A. Scolyer, and P. Guitera. Lentigo maligna and lentigo maligna melanoma in young patients in Australian tertiary centres. Clin Exp Dermatol 48, no. 7 (2023): 799–800. https://dx.doi.org/10.1093/ced/llad089.

Lee, H., A. L. Ferguson, C. Quek, I. A. Vergara, I. P. da Silva, R. Allen, T. N. Gide, J. W. Conway, L. T. Koufariotis, N. K. Hayward, N. Waddell, M. S. Carlino, A. M. Menzies, R. P. M. Saw, E. Shklovskaya, H. Rizos, S. Lo, R. A. Scolyer, G. V. Long, U. Palendira, and J. S. Wilmott. Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy. Clin Cancer Res 29, no. 13 (2023): 2513–24. https://dx.doi.org/10.1158/1078-0432.CCR-22-2657.

Cass, S. H., J. W. D. Tobin, Y. D. Seo, G. Gener-Ricos, E. Z. Keung, E. M. Burton, M. A. Davies, J. L. McQuade, A. J. Lazar, R. Mason, M. Millward, S. Sandhu, C. Khoo, L. Warburton, V. Guerra, A. Haydon, H. Dearden, A. M. Menzies, M. S. Carlino, J. L. Smith, P. Mollee, M. Burgess, S. Mapp, C. Keane, V. Atkinson, S. A. Parikh, S. N. Markovic, W. Ding, T. G. Call, P. J. Hampel, G. V. Long, J. A. Wargo, and A. Ferrajoli. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol 34, no. 9 (2023): 796–805. https://dx.doi.org/10.1016/j.annonc.2023.06.007.

Cust, A. E., and R. A. Scolyer. Melanoma in situ – getting the diagnosis and prognosis right. JAMA Dermatol 159, no. 7 (2023): 699–701. https://dx.doi.org/10.1001/jamadermatol.2023.1485.

Blake, S. C., P. Guitera, A. E. Cust, C. Galea, S. N. Lo, R. A. Scolyer, B. K. Armstrong, J. F. Thompson, S. W. Menzies, C. Madronio, R. L. Morton, G. J. Mann, and C. G. Watts. The association of dermatologist demographic density with melanoma survival in New South Wales, Australia. Australas J Dermatol 64, no. 3 (2023): 425–29. https://dx.doi.org/10.1111/ajd.14113.

Livingstone, A., K. Howard, A. M. Menzies, G. V. Long, M. R. Stockler, and R. L. Morton. Preferences for adjuvant immunotherapy in adults with resected stage III melanoma – a discrete choice experiment. Patient 16, no. 5 (2023): 497–513. https://dx.doi.org/10.1007/s40271-023-00635-w.

Robert, C., M. S. Carlino, C. McNeil, A. Ribas, J. J. Grob, J. Schachter, M. Nyakas, D. Kee, T. M. Petrella, A. Blaustein, M. Lotem, A. Arance, A. I. Daud, O. Hamid, J. Larkin, J. Anderson, C. Krepler, D. Grebennik, and G. V. Long. Seven-year follow-up of the phase III KEYNOTE-006 study: Pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol 41, no. 24 (2023): 3998–4003. https://dx.doi.org/10.1200/JCO.22.01599.

Maher, N. G., N. Prosser, K. Aivazian, A. J. Colebatch, P. M. Ferguson, R. Z. Karim, C. A. McKenzie, R. V. Rawson, S. N. Lo, and R. A. Scolyer. Inter-rater concordance of basal cell carcinoma subtypes: Influences on reporting format and opportunities for further classification modifications. Pathology 55, no. 6 (2023): 800–05. https://dx.doi.org/10.1016/j.pathol.2023.04.003.

Garbe, C., R. Dummer, T. Amaral, R. N. Amaria, P. A. Ascierto, E. M. Burton, B. Dreno, A. M. M. Eggermont, A. Hauschild, C. Hoeller, R. Kaufmann, C. Lebbe, M. Mandala, A. M. Menzies, D. Moreno, O. Michielin, P. Nathan, S. P. Patel, C. Robert, D. Schadendorf, P. C. Lorigan, R. A. Scolyer, H. A. Tawbi, B. A. van de Wiel, C. Blank, and G. V. Long. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med 29, no. 6 (2023): 1310–12. https://dx.doi.org/10.1038/s41591-023-02336-1.

Manolios, N., S. Pham, G. Hou, J. Du, C. Quek, and D. Hibbs. Non-antigenic modulation of antigen receptor (TCR) cβ-fg loop modulates signalling: Implications of external factors influencing T-cell responses. Int J Mol Sci 24, no. 11 (2023). https://dx.doi.org/10.3390/ijms24119334.

Ni, Y., C. G. Watts, R. A. Scolyer, C. Madronio, B. K. Armstrong, R. L. Morton, S. W. Menzies, G. J. Mann, J. F. Thompson, S. N. Lo, and A. E. Cust. Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort. Br J Dermatol 188, no. 6 (2023): 814–16. https://dx.doi.org/10.1093/bjd/ljad076.

El Zarif, T., A. H. Nassar, E. Adib, B. G. Fitzgerald, J. Huang, T. H. Mouhieddine, P. G. Rubinstein, T. Nonato, R. R. McKay, M. Li, A. Mittra, D. H. Owen, R. A. Baiocchi, M. Lorentsen, C. Dittus, N. Dizman, A. Falohun, N. Abdel-Wahab, A. Diab, A. Bankapur, A. Reed, C. Kim, A. Arora, N. J. Shah, E. El-Am, E. Kozaily, W. Abdallah, A. Al-Hader, B. Abu Ghazal, A. Saeed, C. Drolen, M. G. Lechner, A. Drakaki, J. Baena, C. A. Nebhan, T. Haykal, M. A. Morse, A. Cortellini, D. J. Pinato, A. Dalla Pria, E. Hall, V. Bakalov, N. Bahary, A. Rajkumar, A. Mangla, V. Shah, P. Singh, F. Aboubakar Nana, N. Lopetegui-Lia, D. Dima, R. W. Dobbs, P. Funchain, R. Saleem, R. Woodford, G. V. Long, A. M. Menzies, C. Genova, G. Barletta, S. Puri, V. Florou, D. Idossa, M. Saponara, P. Queirolo, G. Lamberti, A. Addeo, M. Bersanelli, D. Freeman, W. Xie, E. G. Reid, E. Y. Chiao, E. Sharon, D. B. Johnson, R. Ramaswami, M. Bower, B. Emu, T. U. Marron, T. K. Choueiri, L. R. Baden, K. Lurain, G. P. Sonpavde, and A. R. Naqash. Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV International CATCH-IT consortium. J Clin Oncol 41, no. 21 (2023): 3712–23. https://dx.doi.org/10.1200/JCO.22.02459.

Lee, R., M. Mandala, G. V. Long, A. M. M. Eggermont, A. C. J. van Akkooi, S. Sandhu, C. Garbe, and P. Lorigan. Adjuvant therapy for stage II melanoma: The need for further studies. Eur J Cancer 189, no. 112914 (2023): 112914. https://dx.doi.org/10.1016/j.ejca.2023.05.003.

Li, A. T., J. Law, S. Ch'ng, R. A. Scolyer, J. F. Thompson, S. N. Lo, and A. H. R. Varey. External validation in an Australian population of the EORTC-decog nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes. Eur J Cancer 189 (2023): 112901. https://dx.doi.org/10.1016/j.ejca.2023.04.017.

Thompson, J. R., J. Lai-Kwon, R. L. Morton, A. D. Guminski, M. Gonzalez, V. Atkinson, S. Sandhu, M. P. Brown, A. M. Menzies, G. A. McArthur, S. N. Lo, G. V. Long, and I. Bartula. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy 15, no. 8 (2023): 593–610. https://dx.doi.org/10.2217/imt-2022-0262.

Kennedy, O. J., M. Kicinski, S. Valpione, S. Gandini, S. Suciu, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, C. Robert, A. M. M. Eggermont, P. Lorigan, and M. Mandala. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 189, no. 112900 (2023): 112900. https://dx.doi.org/10.1016/j.ejca.2023.04.016.

Long, G. V., A. M. Menzies, and R. A. Scolyer. Neoadjuvant checkpoint immunotherapy and melanoma: The time is now. J Clin Oncol 41, no. 17 (2023): 3236–48. https://dx.doi.org/10.1200/JCO.22.02575.

Hoefsmit, E. P., F. Vollmy, E. A. Rozeman, I. L. M. Reijers, J. M. Versluis, L. Hoekman, A. C. J. van Akkooi, G. V. Long, D. Schadendorf, R. Dummer, M. Altelaar, and C. U. Blank. Systemic LRG1 expression in melanoma is associated with disease progression and recurrence. Cancer Res Commun 3, no. 4 (2023): 672–83. https://dx.doi.org/10.1158/2767-9764.CRC-23-0015.

Versluis, J. M., A. M. Menzies, K. Sikorska, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, H. Eriksson, W. M. C. Klop, S. Ch'ng, J. V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, A. van der Wal, A. Bruining, B. A. van de Wiel, R. A. Scolyer, Jbag Haanen, T. N. Schumacher, A. C. J. van Akkooi, G. V. Long, and C. U. Blank. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 34, no. 4 (2023): 420–30. https://dx.doi.org/10.1016/j.annonc.2023.01.004.

Mao, Y., T. N. Gide, N. A. Adegoke, C. Quek, N. Maher, A. Potter, E. Patrick, R. P. M. Saw, J. F. Thompson, A. J. Spillane, K. F. Shannon, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, G. V. Long, R. A. Scolyer, and J. S. Wilmott. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. J Transl Med 21, no. 1 (2023): 257. https://dx.doi.org/10.1186/s12967-023-04092-9.

Miller, J. R., 3rd, S. N. Lo, M. Nosrati, J. R. Stretch, A. J. Spillane, R. P. M. Saw, K. F. Shannon, O. E. Nieweg, S. Ch'ng, K. B. Kim, S. P. Leong, J. F. Thompson, R. A. Scolyer, and M. Kashani-Sabet. Improving selection for sentinel lymph node biopsy among patients with melanoma. JAMA Netw Open 6, no. 4 (2023): e236356. https://dx.doi.org/10.1001/jamanetworkopen.2023.6356.

Orlow, I., K. D. Sadeghi, S. N. Edmiston, J. M. Kenney, C. Lezcano, J. S. Wilmott, A. E. Cust, R. A. Scolyer, G. J. Mann, T. K. Lee, H. Burke, V. Jakrot, P. Shang, P. M. Ferguson, T. W. Boyce, J. S. Ko, P. Ngo, P. Funchain, J. R. Rees, K. O'Connell, H. Hao, E. Parrish, K. Conway, P. B. Googe, D. W. Ollila, S. J. Moschos, E. Hernando, D. Hanniford, D. Argibay, C. I. Amos, J. E. Lee, I. Osman, L. Luo, P. F. Kuan, A. Aurora, B. E. Gould Rothberg, M. W. Bosenberg, M. R. Gerstenblith, C. Thompson, P. N. Bogner, I. P. Gorlov, S. L. Holmen, E. K. Brunsgaard, Y. M. Saenger, R. Shen, V. Seshan, E. Nagore, M. S. Ernstoff, K. J. Busam, C. B. Begg, N. E. Thomas, and M. Berwick. InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLoS One 18, no. 4 (2023): e0269324. https://dx.doi.org/10.1371/journal.pone.0269324.

Kvorning Ternov, N., M. Tolsgaard, L. Konge, A. N. Christensen, S. I. P. Kristensen, L. R. Hölmich, J. Stretch, R. A. Scolyer, T. Vestergaard, P. Guitera, and A. H. Chakera. Effect of histopathological explanations for dermoscopic criteria on learning curves in skin cancer training: A randomized controlled trial. Dermatol Pract Concept 13, no. 2 (2023). https://dx.doi.org/10.5826/dpc.1302a105.

Moscarella, E., P. Guitera, R. A. Scolyer, L. Rocha, L. Thomas, A. Ronchi, C. Scharf, G. Brancaccio, and G. Argenziano. Junctional nevus and early melanoma on sun-damaged skin of the head/neck: A clinico-pathologic challenge. Dermatol Pract Concept 13, no. 2 (2023). https://dx.doi.org/10.5826/dpc.1302a122.

Pham, J. P., A. M. Joshua, I. P. da Silva, R. Dummer, and S. M. Goldinger. Chemotherapy in cutaneous melanoma: Is there still a role? , Curr Oncol Rep 25, no. 6 (2023): 609–21. https://dx.doi.org/10.1007/s11912-023-01385-6.

Gouveia, B. M., G. Carlos, A. Wadell, C. Sinz, T. Ahmed, S. N. Lo, R. V. Rawson, P. M. Ferguson, R. A. Scolyer, and P. Guitera. In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study. J Eur Acad Dermatol Venereol 37, no. 7 (2023): 1293–301. https://dx.doi.org/10.1111/jdv.18998.

Long, G. V., F. Stephen Hodi, E. J. Lipson, D. Schadendorf, P. A. Ascierto, L. Matamala, P. Salman, E. Castillo Gutierrez, P. Rutkowski, H. J. Gogas, C. D. Lao, J. Janoski De Menezes, S. Dalle, A. Arance, J. J. Grob, S. Keidel, A. Shaikh, A. M. Sobiesk, S. Dolfi, and H. A. Tawbi. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid 2, no. 4 (2023): EVIDoa2200239. https://dx.doi.org/10.1056/EVIDoa2200239.

Schadendorf, D., H. Tawbi, E. J. Lipson, F. Stephen Hodi, P. Rutkowski, H. Gogas, C. D. Lao, J. J. Grob, A. Moshyk, J. Lord-Bessen, M. Hamilton, S. Guo, L. Shi, S. Keidel, and G. V. Long. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer 187 (2023): 164–73. https://dx.doi.org/10.1016/j.ejca.2023.03.014.

Lim, S. Y., E. Shklovskaya, J. H. Lee, B. Pedersen, A. Stewart, Z. Ming, M. Irvine, B. Shivalingam, R. P. M. Saw, A. M. Menzies, M. S. Carlino, R. A. Scolyer, G. V. Long, and H. Rizos. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat Commun 14, no. 1 (2023): 1516. https://dx.doi.org/10.1038/s41467-023-36979-y.

Reijers, I. L. M., D. Rao, J. M. Versluis, A. M. Menzies, P. Dimitriadis, M. W. Wouters, A. J. Spillane, W. M. C. Klop, A. Broeks, L. J. W. Bosch, M. Lopez-Yurda, W. J. van Houdt, R. V. Rawson, L. G. Grijpink-Ongering, M. Gonzalez, S. Cornelissen, J. Bouwman, J. Sanders, E. Plasmeijer, Y. S. Elshot, R. A. Scolyer, B. A. van de Wiel, D. S. Peeper, A. C. J. van Akkooi, G. V. Long, and C. U. Blank. IFN-gamma signature enables selection of neoadjuvant treatment in patients with stage III melanoma. J Exp Med 220, no. 5 (2023): e20221952. https://dx.doi.org/10.1084/jem.20221952.

Lai-Kwon, J., S. Jacques, M. Carlino, N. Benannoune, C. Robert, C. Allayous, B. Baroudjian, C. Lebbe, L. Zimmer, Z. Eroglu, T. O. Topcu, F. Dimitriou, A. Haydon, S. N. Lo, A. M. Menzies, and G. V. Long. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma. Eur J Cancer 186 (2023): 12–21. https://dx.doi.org/10.1016/j.ejca.2023.03.006.

Park, B. C., S. Narayanan, A. Gavraldis, F. Ye, R. Fan, R. J. Sullivan, G. Boland, K. L. Reynolds, J. M. Balko, M. S. Carlino, G. V. Long, L. Zubiri, A. M. Menzies, and D. B. Johnson. Rare immune-related adverse events in patients with melanoma: Incidence, spectrum, and clinical presentations. Oncoimmunology 12, no. 1 (2023): 2188719. https://dx.doi.org/10.1080/2162402X.2023.2188719.

Allen, N. C., A. J. Martin, V. A. Snaidr, R. Eggins, A. H. Chong, P. Fernandéz-Peñas, D. Gin, S. Sidhu, V. L. Paddon, L. A. Banney, A. Lim, E. Upjohn, H. Schaider, A. D. Ganhewa, J. Nguyen, C. A. McKenzie, S. Prakash, C. McLean, A. Lochhead, J. Ibbetson, A. Dettrick, A. Landgren, K. J. Allnutt, C. Allison, R. B. Davenport, B. P. Mumford, B. Wong, B. Stagg, A. Tedman, H. Gribbin, H. A. Edwards, N. De Rosa, T. Stewart, B. J. Doolan, Y. Kok, K. Simpson, Z. M. Low, T. Kovitwanichkanont, R. A. Scolyer, H. M. Dhillon, J. L. Vardy, S. J. Chadban, D. G. Bowen, A. C. Chen, and D. L. Damian. Nicotinamide for skin-cancer chemoprevention in transplant recipients. N Engl J Med 388, no. 9 (2023): 804–12. https://dx.doi.org/10.1056/NEJMoa2203086.

Bhave, P., A. Hong, S. N. Lo, R. Johnson, J. Mangana, D. B. Johnson, O. Dulgar, Z. Eroglu, H. L. Yeoh, A. Haydon, G. C. Lodde, E. Livingstone, A. Khattak, K. Kahler, A. Hausschild, G. A. McArthur, A. M. Menzies, G. V. Long, W. Wang, and M. S. Carlino. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. J Immunother Cancer 11, no. 3 (2023): e006629. https://dx.doi.org/10.1136/jitc-2022-006629.

Allen, N. C., E. C. Paver, N. Agar, R. A. Scolyer, and F. J. Moloney. A sheep in wolf's clothing: Agminated blue naevi masquerading as in-transit melanoma metastases. Australas J Dermatol 64, no. 2 (2023): e196–e99. https://dx.doi.org/10.1111/ajd.14002.

Chatterton, S., S. Xi, J. X. Jia, M. Krause, G. V. Long, V. Atkinson, A. M. Menzies, S. L. Fernando, T. Boyle, S. Kwok, A. Duggins, D. Karikios, and J. D. E. Parratt. Case series: Immune checkpoint inhibitor-induced transverse myelitis. Front Neurol 14 (2023): 1130313. https://dx.doi.org/10.3389/fneur.2023.1130313.

Ascierto, P. A., E. J. Lipson, R. Dummer, J. Larkin, G. V. Long, R. E. Sanborn, V. Chiarion-Sileni, B. Dreno, S. Dalle, D. Schadendorf, M. K. Callahan, M. Nyakas, V. Atkinson, C. A. Gomez-Roca, N. Yamazaki, H. A. Tawbi, N. Sarkis, D. Warad, S. Dolfi, P. Mitra, S. Suryawanshi, and J. J. Grob. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: Results from the phase 1/2a RELATIVITY-020 trial. J Clin Oncol 41, no. 15 (2023): 2724–35. https://dx.doi.org/10.1200/JCO.22.02072.

Sharouni, M. E., S. N. Lo, A. H. Varey, S. G. Elias, A. J. Witkamp, V. Sigurdsson, K. P. Suijkerbuijk, P. J. van Diest, C. H. van Gils, W. A. Blokx, R. A. Scolyer, and J. F. Thompson. Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return: A plain language summary of publication. Future Oncol 19, no. 2 (2023): 97–102. https://dx.doi.org/10.2217/fon-2022-0525.

Ming, Z., S. Y. Lim, A. Stewart, B. Pedersen, E. Shklovskaya, A. M. Menzies, M. S. Carlino, R. F. Kefford, J. H. Lee, R. A. Scolyer, G. V. Long, and H. Rizos. IFN-gamma signaling sensitizes melanoma cells to BH3 mimetics. J Invest Dermatol 143, no. 7 (2023): 1246–56. https://dx.doi.org/10.1016/j.jid.2023.01.017.

Wilmott, J. S., H. Tawbi, J. A. Engh, N. M. Amankulor, B. Shivalingam, H. Banerjee, I. A. Vergara, H. Lee, P. A. Johansson, P. M. Ferguson, P. Saiag, C. Robert, J. J. Grob, L. H. Butterfield, R. A. Scolyer, J. M. Kirkwood, G. V. Long, and M. A. Davies. Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases. Clin Cancer Res 29, no. 3 (2023): 521–31. https://dx.doi.org/10.1158/1078-0432.CCR-22-2581.

Weppler, A. M., L. Da Meda, I. P. da Silva, W. Xu, G. Grignani, A. M. Menzies, M. S. Carlino, G. V. Long, S. N. Lo, I. Nordman, C. B. Steer, M. Lyle, C. Trojaniello, P. A. Ascierto, C. Lebbe, and S. Sandhu. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. Eur J Cancer 183 (2023): 109–18. https://dx.doi.org/10.1016/j.ejca.2023.01.016.

Quek, C. Genetics and genomics of melanoma: Current progress and future directions. Genes (Basel) 14, no. 1 (2023). https://dx.doi.org/10.3390/genes14010232.

Vergara, I. A., K. Aivazian, M. S. Carlino, A. D. Guminski, N. G. Maher, K. F. Shannon, S. Ch'ng, R. P. M. Saw, G. V. Long, J. S. Wilmott, and R. A. Scolyer. Genomic profiling of metastatic basal cell carcinoma reveals candidate drivers of disease and therapeutic targets. Mod Pathol 36, no. 4 (2023): 100099. https://dx.doi.org/10.1016/j.modpat.2023.100099.

Rawson, R. V., I. A. Vergara, J. R. Stretch, R. P. M. Saw, J. F. Thompson, S. N. Lo, R. A. Scolyer, and K. J. Busam. Representativeness of initial skin biopsies showing pure desmoplastic melanoma: Implications for management. Pathology 55, no. 2 (2023): 214–22. https://dx.doi.org/10.1016/j.pathol.2022.12.346.

Hahn, A. W., A. V. Menk, D. B. Rivadeneira, R. C. Augustin, M. Xu, J. Li, X. Wu, A. K. Mishra, T. N. Gide, C. Quek, Y. Zang, C. N. Spencer, A. M. Menzies, C. R. Daniel, C. W. Hudgens, T. Nowicki, L. E. Haydu, M. A. W. Khan, V. Gopalakrishnan, E. M. Burton, J. Malke, J. M. Simon, C. Bernatchez, N. Putluri, S. E. Woodman, Y. N. Vashisht Gopal, R. Guerrieri, G. M. Fischer, J. Wang, K. M. Wani, J. F. Thompson, J. E. Lee, P. Hwu, N. Ajami, J. E. Gershenwald, G. V. Long, R. A. Scolyer, M. T. Tetzlaff, A. J. Lazar, D. Schadendorf, J. A. Wargo, J. M. Kirkwood, R. J. DeBerardinis, H. Liang, A. Futreal, J. Zhang, J. S. Wilmott, W. Peng, M. A. Davies, G. M. Delgoffe, Y. G. Najjar, and J. L. McQuade. Obesity is associated with altered tumor metabolism in metastatic melanoma. Clin Cancer Res 29, no. 1 (2023): 154–64. https://dx.doi.org/10.1158/1078-0432.Ccr-22-2661.

Meric-Bernstam, F., R. F. Sweis, S. Kasper, O. Hamid, S. Bhatia, R. Dummer, A. Stradella, G. V. Long, A. Spreafico, T. Shimizu, N. Steeghs, J. J. Luke, S. M. McWhirter, T. Muller, N. Nair, N. Lewis, X. Chen, A. Bean, L. Kattenhorn, M. Pelletier, and S. Sandhu. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: An open-label, multicenter, phase Ib study. Clin Cancer Res 29, no. 1 (2023): 110–21. https://dx.doi.org/10.1158/1078-0432.CCR-22-2235.

Barnhill, R. L., D. E. Elder, M. W. Piepkorn, S. R. Knezevich, L. M. Reisch, M. M. Eguchi, B. C. Bastian, W. Blokx, M. Bosenberg, K. J. Busam, R. Carr, A. Cochran, M. G. Cook, L. M. Duncan, R. Elenitsas, A. de la Fouchardière, P. Gerami, I. Johansson, J. Ko, G. Landman, A. J. Lazar, L. Lowe, D. Massi, J. Messina, D. Mihic-Probst, D. C. Parker, B. Schmidt, C. R. Shea, R. A. Scolyer, M. Tetzlaff, X. Xu, I. Yeh, A. Zembowicz, and J. G. Elmore. Revision of the melanocytic pathology assessment tool and hierarchy for diagnosis classification schema for melanocytic lesions: A consensus statement. JAMA Netw Open 6, no. 1 (2023): e2250613. https://dx.doi.org/10.1001/jamanetworkopen.2022.50613.

Lezcano, C., M. Berwick, L. Luo, R. Barnhill, L. M. Duncan, P. Gerami, L. Lowe, J. L. Messina, R. A. Scolyer, B. Wood, I. Yeh, A. Zembowicz, and K. J. Busam. Interobserver agreement in the histopathological classification of desmoplastic melanomas. Pathology 55, no. 2 (2023): 223–26. https://dx.doi.org/10.1016/j.pathol.2022.12.347.

Rawson, R. V., E. R. Shteinman, S. Ansar, I. A. Vergara, J. F. Thompson, G. V. Long, R. A. Scolyer, and J. S. Wilmott. Diagnostic utility of PRAME, p53, and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars, and other histological mimics. Pathology 54, no. 7 (2022): 863–73. https://dx.doi.org/10.1016/j.pathol.2022.05.012.

Maher, N. G., R. A. Scolyer, and A. J. Colebatch. Biology and genetics of acquired and congenital melanocytic naevi. Pathology 55, no. 2 (2023): 169–77. https://dx.doi.org/10.1016/j.pathol.2022.12.344.

Wong, S. K., S. M. Blum, X. Sun, I. P. da Silva, L. Zubiri, F. Ye, K. Bai, K. Zhang, S. Ugurel, L. Zimmer, E. Livingstone, D. Schadendorf, P. Serra-Bellver, E. Munoz-Couselo, C. Ortiz, J. Lostes, R. M. Huertas, A. Arance, L. Pickering, G. V. Long, M. S. Carlino, E. I. Buchbinder, L. Vazquez-Cortes, D. Jara-Casas, I. Marquez-Rodas, I. R. Gonzalez-Espinoza, J. M. Balko, A. M. Menzies, R. J. Sullivan, and D. B. Johnson. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. Eur J Cancer 181 (2023): 188–97. https://dx.doi.org/10.1016/j.ejca.2022.12.013.

El Sharouni, M. A., R. V. Rawson, A. J. Potter, E. C. Paver, J. S. Wilmott, A. J. Witkamp, V. Sigurdsson, P. J. van Diest, R. A. Scolyer, J. F. Thompson, S. N. Lo, and C. H. van Gils. Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. J Am Acad Dermatol 88, no. 3 (2023): 609–16. https://dx.doi.org/10.1016/j.jaad.2022.08.067.

Newell, F., P. A. Johansson, J. S. Wilmott, K. Nones, V. Lakis, A. L. Pritchard, S. N. Lo, R. V. Rawson, S. H. Kazakoff, A. J. Colebatch, L. T. Koufariotis, P. M. Ferguson, S. Wood, C. Leonard, M. H. Law, K. M. Brooks, N. Broit, J. M. Palmer, K. L. Couts, I. A. Vergara, G. V. Long, A. P. Barbour, O. E. Nieweg, B. Shivalingam, W. A. Robinson, J. R. Stretch, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. F. Thompson, G. J. Mann, J. V. Pearson, R. A. Scolyer, N. Waddell, and N. K. Hayward. Comparative genomics provides etiologic and biological insight into melanoma subtypes. Cancer Discov 12, no. 12 (2022): 2856–79. https://dx.doi.org/10.1158/2159-8290.CD-22-0603.

Simpson, R. C., E. R. Shanahan, M. Batten, I. L. M. Reijers, M. Read, I. P. da Silva, J. M. Versluis, R. Ribeiro, A. S. Angelatos, J. Tan, C. Adhikari, A. M. Menzies, R. P. M. Saw, M. Gonzalez, K. F. Shannon, A. J. Spillane, R. Velickovic, A. J. Lazar, A. V. Damania, A. K. Mishra, M. Chelvanambi, A. Banerjee, N. J. Ajami, J. A. Wargo, L. Macia, A. J. Holmes, J. S. Wilmott, C. U. Blank, R. A. Scolyer, and G. V. Long. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med 28, no. 11 (2022): 2344–52. https://dx.doi.org/10.1038/s41591-022-01965-2.

Brown, L. J., I. P. da Silva, T. Moujaber, B. Gao, R. Hui, H. Gurney, M. Carlino, and A. Nagrial. Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. Cancer Med 12, no. 6 (2023): 6788–801. https://dx.doi.org/10.1002/cam4.5468.

Conway, J. W., J. Braden, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front Immunol 13 (2022): 1030147. https://dx.doi.org/10.3389/fimmu.2022.1030147.

Lee, J., T. Ahmed, A. Maurichi, L. Di Guardo, A. M. Stagno, L. Warburton, A. M. Taylor, E. Livingstone, S. Rehman, A. Khattak, K. C. Kahler, V. Vanella, V. Atkinson, M. Millward, D. Schadendorf, D. B. Johnson, P. A. Ascierto, A. Hauschild, S. N. Lo, G. V. Long, A. M. Menzies, and M. S. Carlino. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. Eur J Cancer 179 (2023): 87–97. https://dx.doi.org/10.1016/j.ejca.2022.11.009.

Nahar, K. J., F. Marsh-Wakefield, R. V. Rawson, T. N. Gide, A. L. Ferguson, R. Allen, C. Quek, I. P. da Silva, S. Tattersal, C. J. Kiely, N. Sandanayake, M. S. Carlino, G. McCaughan, J. S. Wilmott, R. A. Scolyer, G. V. Long, A. M. Menzies, and U. Palendira. Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight 7, no. 21 (2022): e157839. https://dx.doi.org/10.1172/jci.insight.157839.

Varey, A. H. R., G. J. Williams, S. N. Lo, C. Y. Taing, A. Maurichi, M. Santinami, R. A. Scolyer, and J. F. Thompson. Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 37, no. 5 (2023): 859–70. https://dx.doi.org/10.1111/jdv.18665.

Sandhu, S., V. Atkinson, M. G. Cao, T. Medina, A. S. Rivas, A. M. Menzies, I. Caro, L. Roberts, Y. Song, Y. Yan, Y. Guo, C. Xue, and G. V. Long. Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF(V600) wild-type melanoma progressing on prior anti-programmed death-1 therapy. Eur J Cancer 178 (2023): 180–90. https://dx.doi.org/10.1016/j.ejca.2022.10.019.

Paver, E., K. Aivazian, F. Maclean, G. V. Long, A. J. Spillane, J. S. Wilmott, and R. A. Scolyer. Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. Pathology 55, no. 4 (2023): 555–60. https://dx.doi.org/10.1016/j.pathol.2022.08.011.

Long, G. V., J. J. Luke, M. A. Khattak, L. de la Cruz Merino, M. Del Vecchio, P. Rutkowski, F. Spagnolo, J. Mackiewicz, V. Chiarion-Sileni, J. M. Kirkwood, C. Robert, J. J. Grob, F. de Galitiis, D. Schadendorf, M. S. Carlino, P. Mohr, R. Dummer, J. E. Gershenwald, C. H. Yoon, X. L. Wu, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, P. A. Ascierto, and the KEYNOTE Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): Distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 23, no. 11 (2022): 1378–88. https://dx.doi.org/10.1016/S1470-2045(22)00559-9.

Serra-Bellver, P., J. M. Versluis, H. K. Oberoi, C. Zhou, T. D. Slattery, Y. Khan, J. R. Patrinely, I. P. da Silva, C. Martinez-Vila, N. Cook, D. M. Graham, M. S. Carlino, A. M. Menzies, A. M. Arance, D. B. Johnson, G. V. Long, L. Pickering, J. M. G. Larkin, C. U. Blank, and P. Lorigan. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: A multicentre retrospective study. Eur J Cancer 176 (2022): 121–32. https://dx.doi.org/10.1016/j.ejca.2022.09.004.

Shteinman, E. R., J. S. Wilmott, I. P. da Silva, G. V. Long, R. A. Scolyer, and I. A. Vergara. Causes, consequences, and clinical significance of aneuploidy across melanoma subtypes. Front Oncol 12 (2022): 988691. https://dx.doi.org/10.3389/fonc.2022.988691.

Khattak, M. A., J. J. Luke, G. V. Long, P. A. Ascierto, P. Rutkowski, D. Schadendorf, C. Robert, J. J. Grob, L. de la Cruz Merino, M. Del Vecchio, F. Spagnolo, J. Mackiewicz, V. Chiarion-Sileni, M. S. Carlino, P. Mohr, F. De Galitiis, M. I. Ross, Z. Eroglu, K. Chen, R. Jiang, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, and J. M. Kirkwood. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. Eur J Cancer 176 (2022): 207–17. https://dx.doi.org/10.1016/j.ejca.2022.08.004.

Shklovskaya, E., B. Pedersen, A. Stewart, J. O. G. Simpson, Z. Ming, M. Irvine, R. A. Scolyer, G. V. Long, and H. Rizos. Durable responses to anti-PD1 and anti-CTLA4 in a preclinical model of melanoma displaying key immunotherapy response biomarkers. Cancers (Basel) 14, no. 19 (2022): 4830. https://dx.doi.org/10.3390/cancers14194830.

Muller-Jensen, L., S. Zierold, J. M. Versluis, W. Boehmerle, P. Huehnchen, M. Endres, R. Mohr, A. Compter, C. U. Blank, T. Hagenacker, F. Meier, L. Reinhardt, A. Gesierich, M. Salzmann, J. C. Hassel, S. Ugurel, L. Zimmer, P. Banks, L. Spain, J. A. Soon, T. Enokida, M. Tahara, K. C. Kahler, R. Seggewiss-Bernhardt, C. Harvey, G. V. Long, F. Schoberl, L. von Baumgarten, T. Hundsberger, M. Schlaak, L. E. French, S. Knauss, and L. M. Heinzerling. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief 45, no. 108649 (2022): 108649. https://dx.doi.org/10.1016/j.dib.2022.108649.

Bai, X., and C. Quek. Unravelling tumour microenvironment in melanoma at single-cell level and challenges to checkpoint immunotherapy. Genes (Basel) 13, no. 10 (2022). https://dx.doi.org/10.3390/genes13101757.

Chakraborty, A., M. Perez, J. D. Carroll, A. Antonopoulos, A. Dell, L. Ortega, N. B. B. Mohammed, M. Wells, C. Staudinger, A. Griswold, K. B. Chandler, C. Marrero, R. Jimenez, Y. Tani, J. S. Wilmott, J. F. Thompson, W. Wang, R. Sackstein, R. A. Scolyer, G. F. Murphy, S. M. Haslam, and C. J. Dimitroff. Hypoxia controls the glycome signature and galectin-8-ligand axis to promote protumorigenic properties of metastatic melanoma. J Invest Dermatol 143, no. 3 (2023): 456–69.e8. https://dx.doi.org/10.1016/j.jid.2022.07.033.

Weber, J. S., D. Schadendorf, M. Del Vecchio, J. Larkin, V. Atkinson, M. Schenker, J. Pigozzo, H. Gogas, S. Dalle, N. Meyer, P. A. Ascierto, S. Sandhu, T. Eigentler, R. Gutzmer, J. C. Hassel, C. Robert, M. S. Carlino, A. M. Di Giacomo, M. O. Butler, E. Munoz-Couselo, M. P. Brown, P. Rutkowski, A. Haydon, J. J. Grob, J. Schachter, P. Queirolo, L. de la Cruz-Merino, A. van der Westhuizen, A. M. Menzies, S. Re, T. Bas, V. de Pril, J. Braverman, D. J. Tenney, H. Tang, and G. V. Long. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB–D or stage IV melanoma (CheckMate 915). J Clin Oncol 41, no. 3 (2023): 517–27. https://dx.doi.org/10.1200/JCO.22.00533.

Smith, J. L., A. M. Menzies, J. V. Cohen, M. Mut-Lloret, A. Ozgun, L. Spain, J. Park, H. T. Quach, L. Pallan, J. McQuade, S. Feng, S. Sandhu, V. Atkinson, K. Tsai, G. V. Long, J. Larkin, Z. Eroglu, D. B. Johnson, R. Sullivan, G. K. Herkes, A. Henderson, and M. S. Carlino. Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: A multicenter case series. Melanoma Res 32, no. 6 (2022): 451–59. https://dx.doi.org/10.1097/CMR.0000000000000825.

Lai-Kwon, J., B. Kelly, S. Lane, R. Biviano, I. Bartula, F. Brennan, I. Kivikoski, J. Thompson, H. M. Dhillon, A. M. Menzies, and G. V. Long. Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE). Support Care Cancer 30, no. 11 (2022): 9587–96. https://dx.doi.org/10.1007/s00520-022-07360-4.

Muller-Jensen, L., S. Zierold, J. M. Versluis, W. Boehmerle, P. Huehnchen, M. Endres, R. Mohr, A. Compter, C. U. Blank, T. Hagenacker, F. Meier, L. Reinhardt, A. Gesierich, M. Salzmann, J. C. Hassel, S. Ugurel, L. Zimmer, P. Banks, L. Spain, J. A. Soon, T. Enokida, M. Tahara, K. C. Kahler, R. Seggewiss-Bernhardt, C. Harvey, G. V. Long, F. Schoberl, L. von Baumgarten, T. Hundsberger, M. Schlaak, L. E. French, S. Knauss, and L. M. Heinzerling. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. Eur J Cancer 175 (2022): 224–35. https://dx.doi.org/10.1016/j.ejca.2022.08.009.

Eggermont, A. M. M., M. Kicinski, C. U. Blank, M. Mandala, G. V. Long, V. Atkinson, S. Dalle, A. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, P. Lorigan, D. Grebennik, C. Krepler, S. Marreaud, S. Suciu, and C. Robert. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid 1, no. 11 (2022): EVIDoa2200214. https://dx.doi.org/10.1056/EVIDoa2200214.

Seviiri, M., R. A. Scolyer, D. T. Bishop, J. A. Newton-Bishop, M. M. Iles, S. N. Lo, J. R. Stretch, R. P. M. Saw, O. E. Nieweg, K. F. Shannon, A. J. Spillane, S. D. Gordon, C. M. Olsen, D. C. Whiteman, M. T. Landi, J. F. Thompson, G. V. Long, S. MacGregor, and M. H. Law. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting. J Transl Med 20, no. 1 (2022): 403. https://dx.doi.org/10.1186/s12967-022-03613-2.

Conway, J. W., R. V. Rawson, S. Lo, T. Ahmed, I. A. Vergara, T. N. Gide, G. H. Attrill, M. S. Carlino, R. P. M. Saw, J. F. Thompson, A. J. Spillane, K. F. Shannon, B. Shivalingam, A. M. Menzies, J. S. Wilmott, G. V. Long, R. A. Scolyer, and I. P. da Silva. Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. J Immunother Cancer 10, no. 9 (2022): e004884. https://dx.doi.org/10.1136/jitc-2022-004884.

Crystal, J. S., J. F. Thompson, J. Hyngstrom, C. Caracò, J. S. Zager, T. Jahkola, T. L. Bowles, E. Pennacchioli, P. D. Beitsch, H. J. Hoekstra, M. Moncrieff, C. Ingvar, A. van Akkooi, M. S. Sabel, E. A. Levine, D. Agnese, M. Henderson, R. Dummer, R. I. Neves, C. R. Rossi, J. M. Kane, 3rd, S. Trocha, F. Wright, D. R. Byrd, M. Matter, E. C. Hsueh, A. MacKenzie-Ross, M. Kelley, P. Terheyden, T. L. Huston, J. D. Wayne, H. Neuman, B. M. Smithers, C. E. Ariyan, D. Desai, J. E. Gershenwald, S. Schneebaum, A. Gesierich, L. K. Jacobs, J. M. Lewis, K. M. McMasters, C. O'Donoghue, A. van der Westhuizen, A. Sardi, R. Barth, R. Barone, J. G. McKinnon, C. L. Slingluff, J. M. Farma, E. Schultz, R. P. Scheri, S. Vidal-Sicart, M. Molina, A. A. E. Testori, L. J. Foshag, L. Van Kreuningen, H. J. Wang, M. S. Sim, R. A. Scolyer, D. E. Elashoff, A. J. Cochran, and M. B. Faries. Therapeutic value of sentinel lymph node biopsy in patients with melanoma: A randomized clinical trial. JAMA Surg 157, no. 9 (2022): 835–42. https://dx.doi.org/10.1001/jamasurg.2022.2055.

Long, G. V., P. F. Ferrucci, A. Khattak, T. M. Meniawy, P. A. Ott, M. Chisamore, T. Trolle, A. Hyseni, and E. Heegaard. KEYNOTE-D36: Personalized immunotherapy with a neoepitope vaccine, EVX-01, and pembrolizumab in advanced melanoma. Future Oncol 18, no. 31 (2022): 3473–80. https://dx.doi.org/10.2217/fon-2022-0694.

Busam, K. J., M. J. Judge, C. K. Bichakjian, D. Coit, H. Kutzner, L. Requena, R. A. Scolyer, C. M. Stefanato, B. A. Wood, and N. M. Walsh. Dataset for the reporting of Merkel cell carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Am J Surg Pathol 46, no. 11 (2022): 1583–91. https://dx.doi.org/10.1097/pas.0000000000001959.

Hanna, S., E. Marinos, D. Bryan, T. Ahmed, S. N. Lo, M. S. Carlino, A. Smith, G. Cairns, K. Shannon, G. V. Long, R. A. Scolyer, and R. P. M. Saw. Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge, and behaviour of Australian high-school students towards sun safety: A prospective study. Clin Exp Dermatol 47, no. 11 (2022): 1956–67. https://dx.doi.org/10.1111/ced.15220.

Chesney, J. A., A. Ribas, G. V. Long, J. M. Kirkwood, R. Dummer, I. Puzanov, C. Hoeller, T. F. Gajewski, R. Gutzmer, P. Rutkowski, L. Demidov, P. Arenberger, S. J. Shin, P. F. Ferrucci, A. Haydon, J. Hyngstrom, J. V. van Thienen, S. Haferkamp, J. M. Guilera, B. L. Rapoport, A. VanderWalde, S. J. Diede, J. R. Anderson, S. Treichel, E. L. Chan, S. Bhatta, J. Gansert, F. S. Hodi, and H. Gogas. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol 41, no. 3 (2023): 528–40. https://dx.doi.org/10.1200/JCO.22.00343.

2022

Watts, C., A. Spillane, M. A. Henderson, A. Cust, J. Braithwaite, D. E. Gyorki, A. M. Hong, J. W. Kelly, G. V. Long, V. J. Mar, A. M. Menzies, R. L. Morton, F. Rapport, R. P. M. Saw, H. Schmid, R. A. Scolyer, A. L. Smith, A. Winder, and G. J. Mann. Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Med J Aust 217, no. 4 (2022): 208–09. https://dx.doi.org/10.5694/mja2.51424.

Luo, L., R. Shen, A. Arora, I. Orlow, K. J. Busam, C. Lezcano, T. K. Lee, E. Hernando, I. Gorlov, C. Amos, M. S. Ernstoff, V. E. Seshan, A. E. Cust, J. S. Wilmott, R. A. Scolyer, G. Mann, E. Nagore, P. Funchain, J. Ko, P. Ngo, S. N. Edmiston, K. Conway, P. B. Googe, D. Ollila, J. E. Lee, S. Fang, J. R. Rees, C. L. Thompson, M. Gerstenblith, M. Bosenberg, B. Gould Rothberg, I. Osman, Y. Saenger, A. Z. Reynolds, M. Schwartz, T. Boyce, S. Holmen, E. Brunsgaard, P. Bogner, P. F. Kuan, C. Wiggins, N. E. Thomas, C. B. Begg, and M. Berwick. Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. Pigment Cell Melanoma Res 35, no. 6 (2022): 605–12. https://dx.doi.org/10.1111/pcmr.13058.

Larkin, J., J. Weber, M. Del Vecchio, H. Gogas, A. M. Arance, S. Dalle, C. L. Cowey, M. Schenker, J. J. Grob, V. Chiarion-Sileni, I. Marquez-Rodas, M. O. Butler, A. M. Di Giacomo, M. R. Middleton, L. De la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, L. A. Fecher, M. Millward, N. I. Khushalani, P. Queirolo, G. V. Long, M. Lobo, M. Askelson, P. A. Ascierto, and M. Mandala. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer 173 (2022): 285–96. https://dx.doi.org/10.1016/j.ejca.2022.06.041.

Attrill, G. H., H. Lee, A. T. Tasker, N. A. Adegoke, A. L. Ferguson, I. P. da Silva, R. P. M. Saw, J. F. Thompson, U. Palendira, G. V. Long, P. M. Ferguson, R. A. Scolyer, and J. S. Wilmott. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. Front Immunol 13 (2022): 979993. https://dx.doi.org/10.3389/fimmu.2022.979993.

Colebatch, A. J., E. C. Paver, I. A. Vergara, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology 54, no. 5 (2022): 533–40. https://dx.doi.org/10.1016/j.pathol.2021.12.289.

Colebatch, A. J., C. Adhikari, R. J. Diefenbach, R. V. Rawson, P. M. Ferguson, H. Rizos, G. V. Long, S. W. McCarthy, J. F. Thompson, J. S. Wilmott, and R. A. Scolyer. Comprehensive clinical, histopathologic, and molecular analysis and long-term follow-up of patients with Nodal blue nevi. Am J Surg Pathol 46, no. 8 (2022): 1048–59. https://dx.doi.org/10.1097/PAS.0000000000001902.

Arance, A., L. de la Cruz-Merino, T. M. Petrella, R. Jamal, L. Ny, A. Carneiro, A. Berrocal, I. Marquez-Rodas, A. Spreafico, V. Atkinson, F. Costa Svedman, A. Mant, M. A. Khattak, C. Mihalcioiu, S. Jang, C. L. Cowey, A. D. Smith, N. Hawk, K. Chen, S. J. Diede, C. Krepler, and G. V. Long. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol 41, no. 1 (2023): 75–85. https://dx.doi.org/10.1200/JCO.22.00221.

Moncrieff, M. D., S. N. Lo, R. A. Scolyer, M. J. Heaton, J. P. Nobes, A. P. Snelling, M. J. Carr, C. Nessim, R. Wade, A. H. Peach, R. Kisyova, J. Mason, E. D. Wilson, G. Nolan, R. Pritchard Jones, I. Johansson, R. Olofsson Bagge, L. J. Wright, N. G. Patel, V. K. Sondak, J. F. Thompson, and J. S. Zager. Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: Implications for the management of American Joint Committee on Cancer IIIA disease. J Clin Oncol 40, no. 34 (2022): 3940–51. https://dx.doi.org/10.1200/jco.21.02488.

Aung, T. N., S. Shafi, J. S. Wilmott, S. Nourmohammadi, I. Vathiotis, N. Gavrielatou, A. Fernandez, V. Yaghoobi, T. Sinnberg, T. Amaral, K. Ikenberg, K. Khosrotehrani, I. Osman, B. Acs, Y. Bai, S. Martinez-Morilla, M. Moutafi, J. F. Thompson, R. A. Scolyer, and D. L. Rimm. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine 82 (2022): 104143. https://dx.doi.org/10.1016/j.ebiom.2022.104143.

Wang, K. Y. X., G. M. Pupo, V. Tembe, E. Patrick, D. Strbenac, S. J. Schramm, J. F. Thompson, R. A. Scolyer, S. Muller, G. Tarr, G. J. Mann, and J. Y. H. Yang. Cross-platform omics prediction procedure: A statistical machine learning framework for wider implementation of precision medicine. NPJ Digit Med 5, no. 1 (2022): 85. https://dx.doi.org/10.1038/s41746-022-00618-5.

Bhave, P., T. Ahmed, S. N. Lo, A. Shoushtari, A. Zaremba, J. M. Versluis, J. Mangana, M. Weichenthal, L. Si, T. Lesimple, C. Robert, C. Trojanello, A. Wicky, R. Heywood, L. Tran, K. Batty, F. Dimitriou, A. Stansfeld, C. Allayous, J. K. Schwarze, M. J. Mooradian, O. Klein, I. Mehmi, R. Roberts-Thomson, A. Maurichi, H. L. Yeoh, A. Khattak, L. Zimmer, C. U. Blank, E. Ramelyte, K. C. Kahler, S. Roy, P. A. Ascierto, O. Michielin, P. C. Lorigan, D. B. Johnson, R. Plummer, C. Lebbe, B. Neyns, R. Sullivan, O. Hamid, M. Santinami, G. A. McArthur, A. M. Haydon, G. V. Long, A. M. Menzies, and M. S. Carlino. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J Immunother Cancer 10, no. 7 (2022): e004668. https://dx.doi.org/10.1136/jitc-2022-004668.

da Silva, I. P., D. Zakria, T. Ahmed, C. Trojanello, F. Dimitriou, C. Allayous, C. Gerard, L. Zimmer, S. N. Lo, O. Michielin, C. Lebbe, J. Mangana, P. A. Ascierto, D. B. Johnson, M. Carlino, A. M. Menzies, and G. V. Long. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer 10, no. 7 (2022): e004610. https://dx.doi.org/10.1136/jitc-2022-004610.

Lawless, A. K., D. J. Coker, S. N. Lo, T. Ahmed, R. A. Scolyer, S. Ch'ng, O. E. Nieweg, K. Shannon, A. Spillane, J. R. Stretch, J. F. Thompson, and R. P. M. Saw. Clinicopathological characteristics predicting further recurrence and survival following resection of in-transit melanoma metastases. Ann Surg Oncol 29, no. 11 (2022): 7019–28. https://dx.doi.org/10.1245/s10434-022-11997-0.

Dimitriou, F., K. Namikawa, I. L. M. Reijers, E. I. Buchbinder, J. A. Soon, A. Zaremba, P. Teterycz, M. J. Mooradian, E. Armstrong, Y. Nakamura, M. G. Vitale, L. E. Tran, X. Bai, C. Allayous, S. Provent-Roy, A. Indini, P. Bhave, M. Farid, K. C. Kahler, I. Mehmi, V. Atkinson, O. Klein, C. J. Stonesifer, F. Zaman, A. Haydon, R. D. Carvajal, O. Hamid, R. Dummer, A. Hauschild, M. S. Carlino, M. Mandala, C. Robert, C. Lebbe, J. Guo, D. B. Johnson, P. A. Ascierto, A. N. Shoushtari, R. J. Sullivan, B. Cybulska-Stopa, P. Rutkowski, L. Zimmer, S. Sandhu, C. U. Blank, S. N. Lo, A. M. Menzies, and G. V. Long. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: An international, retrospective, cohort study. Ann Oncol 33, no. 9 (2022): 968–80. https://dx.doi.org/10.1016/j.annonc.2022.06.004.

Gaetano, L., B. Domenico, S. N. Lo, T. Hamed, A. J. Potter, J. F. Thompson, R. A. Scolyer, and P. Guitera. Association between excision margins and local recurrence in 1,407 patients with primary in situ melanomas. JAAD Int 8 (2022): 102–08. https://dx.doi.org/10.1016/j.jdin.2022.06.001.

Garbe, C., U. Keim, T. Amaral, C. Berking, T. K. Eigentler, L. Flatz, A. Gesierich, U. Leiter, R. Stadler, C. Sunderkotter, T. Tuting, J. Utikal, U. Wollina, L. Zimmer, C. C. Zouboulis, P. A. Ascierto, A. M. M. Eggermont, J. J. Grob, A. Hauschild, L. K. Sekulovic, G. V. Long, J. J. Luke, O. Michielin, K. Peris, D. Schadendorf, J. M. Kirkwood, P. C. Lorigan, and Registry Central Malignant Melanoma. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: Implications for adjuvant treatment. J Clin Oncol 40, no. 32 (2022): 3741–49. https://dx.doi.org/10.1200/JCO.22.00202.

Burton, E. M., R. N. Amaria, T. Cascone, M. Chalabi, N. D. Gross, E. A. Mittendorf, R. A. Scolyer, P. Sharma, and P. A. Ascierto. Neoadjuvant immunotherapy across cancers: Meeting report from the Immunotherapy Bridge – December 1st–2nd, 2021. J Transl Med 20, no. 1 (2022): 271. https://dx.doi.org/10.1186/s12967-022-03472-x.

Vellano, C. P., M. G. White, M. C. Andrews, M. Chelvanambi, R. G. Witt, J. R. Daniele, M. Titus, J. L. McQuade, F. Conforti, E. M. Burton, M. J. Lastrapes, G. Ologun, A. P. Cogdill, G. Morad, P. Prieto, A. J. Lazar, Y. Chu, G. Han, M. A. W. Khan, B. Helmink, M. A. Davies, R. N. Amaria, J. J. Kovacs, S. E. Woodman, S. Patel, P. Hwu, M. Peoples, J. E. Lee, Z. A. Cooper, H. Zhu, G. Gao, H. Banerjee, M. Lau, J. E. Gershenwald, A. Lucci, E. Z. Keung, M. I. Ross, L. Pala, E. Pagan, R. L. Segura, Q. Liu, M. S. Borthwick, E. Lau, M. S. Yates, S. N. Westin, K. Wani, M. T. Tetzlaff, L. E. Haydu, M. Mahendra, X. Ma, C. Logothetis, Z. Kulstad, S. Johnson, C. W. Hudgens, N. Feng, L. Federico, G. V. Long, P. A. Futreal, S. Arur, H. A. Tawbi, A. E. Moran, L. Wang, T. P. Heffernan, J. R. Marszalek, and J. A. Wargo. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606, no. 7915 (2022): 797–803. https://dx.doi.org/10.1038/s41586-022-04833-8.

Barnhill, R., S. van Laere, P. Vermeulen, S. Roman-Roman, S. Gardrat, S. Alsafadi, M. Tarin, G. Champenois, A. Nicolas, A. Matet, N. Cassoux, V. Servois, M. Rodrigues, R. A. Scolyer, A. Lazar, E. Romano, S. Piperno-Neumann, P. Mariani, and C. Lugassy. L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. Lab Invest 102, no. 11 (2022): 1214–24. https://dx.doi.org/10.1038/s41374-022-00803-w.

Reijers, I. L. M., A. M. Menzies, A. C. J. van Akkooi, J. M. Versluis, N. M. J. van den Heuvel, R. P. M. Saw, T. E. Pennington, E. Kapiteijn, A. A. M. van der Veldt, K. P. M. Suijkerbuijk, G. A. P. Hospers, E. A. Rozeman, W. M. C. Klop, W. J. van Houdt, K. Sikorska, J. A. van der Hage, D. J. Grunhagen, M. W. Wouters, A. J. Witkamp, C. L. Zuur, J. M. Lijnsvelt, A. Torres Acosta, L. G. Grijpink-Ongering, M. Gonzalez, K. Jozwiak, C. Bierman, K. F. Shannon, S. Ch'ng, A. J. Colebatch, A. J. Spillane, Jbag Haanen, R. V. Rawson, B. A. van de Wiel, L. V. van de Poll-Franse, R. A. Scolyer, A. H. Boekhout, G. V. Long, and C. U. Blank. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial. Nat Med 28, no. 6 (2022): 1178–88. https://dx.doi.org/10.1038/s41591-022-01851-x.

Attrill, G. H., C. N. Owen, T. Ahmed, I. A. Vergara, A. J. Colebatch, J. W. Conway, K. J. Nahar, J. F. Thompson, I. P. da Silva, M. S. Carlino, A. M. Menzies, S. Lo, U. Palendira, R. A. Scolyer, G. V. Long, and J. S. Wilmott. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. J Immunother Cancer 10, no. 6 (2022): e004771. https://dx.doi.org/10.1136/jitc-2022-004771.

Tawbi, H. A., C. Robert, J. C. Brase, D. Gusenleitner, E. Gasal, J. Garrett, A. Savchenko, G. Gorgun, K. T. Flaherty, A. Ribas, R. Dummer, D. Schadendorf, G. V. Long, P. D. Nathan, and P. A. Ascierto. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: Exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer 10, no. 6 (2022): e004226. https://dx.doi.org/10.1136/jitc-2021-004226.

Moschos, S. J., S. Sandhu, K. D. Lewis, R. J. Sullivan, I. Puzanov, D. B. Johnson, H. A. Henary, H. Wong, V. V. Upreti, G. V. Long, and K. T. Flaherty. Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in metastatic melanoma: A phase 1 study. Invest New Drugs 40, no. 5 (2022): 1051–65. https://dx.doi.org/10.1007/s10637-022-01253-3.

Holmberg, C. J., L. Ny, T. J. Hieken, M. S. Block, M. J. Carr, V. K. Sondak, C. Ortenwall, D. Katsarelias, F. Dimitriou, A. M. Menzies, R. P. M. Saw, A. Rogiers, R. J. Straker, 3rd, G. Karakousis, R. Applewaite, L. Pallan, D. Han, J. T. Vetto, D. E. Gyorki, E. N. Tie, M. G. Vitale, P. A. Ascierto, R. Dummer, J. Cohen, J. Y. Hui, J. Schachter, N. Asher, H. Helgadottir, H. Chai, H. Kroon, B. Coventry, L. D. Rothermel, J. Sun, M. S. Carlino, Z. Duncan, K. Broman, J. Weber, A. Y. Lee, R. S. Berman, J. Teras, D. W. Ollila, G. V. Long, J. S. Zager, A. C. J. van Akkooi, and R. Olofsson Bagge. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – a multicenter cohort study. Eur J Cancer 169 (2022): 210–22. https://dx.doi.org/10.1016/j.ejca.2022.03.041.

Bai, X., A. N. Shoushtari, A. Betof Warner, L. Si, B. Tang, C. Cui, X. Yang, X. Wei, H. T. Quach, C. G. Cann, M. Z. Zhang, L. Pallan, C. Harvey, M. S. Kim, G. Kasumova, T. Sharova, J. V. Cohen, D. P. Lawrence, C. Freedman, R. M. Fadden, K. M. Rubin, D. T. Frederick, K. T. Flaherty, G. V. Long, A. M. Menzies, R. J. Sullivan, G. M. Boland, D. B. Johnson, and J. Guo. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: An international multicentre observational study. Br J Dermatol 187, no. 3 (2022): 401–10. https://dx.doi.org/10.1111/bjd.21241.

Yaseen, Z., T. N. Gide, J. W. Conway, A. J. Potter, C. Quek, A. M. Hong, G. V. Long, R. A. Scolyer, and J. S. Wilmott. Validation of an accurate automated multiplex immunofluorescence method for immuno-profiling melanoma. Front Mol Biosci 9 (2022): 810858. https://dx.doi.org/10.3389/fmolb.2022.810858.

Li, A. T., J. Miin Yip, H. Choksi, K. London, A. J. Potter, S. N. Lo, R. P. M. Saw, K. F. Shannon, I. P. da Silva, A. H. R. Varey, A. M. Menzies, G. V. Long, B. Shivalingam, R. A. Scolyer, J. F. Thompson, and S. Ch'ng. Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Res 32, no. 4 (2022): 260–68. https://dx.doi.org/10.1097/CMR.0000000000000827.

Moncrieff, M. D., S. N. Lo, R. A. Scolyer, M. J. Heaton, J. P. Nobes, A. P. Snelling, M. J. Carr, C. Nessim, R. Wade, A. H. Peach, R. Kisyova, J. Mason, E. D. Wilson, G. Nolan, R. Pritchard Jones, V. K. Sondak, J. F. Thompson, and J. S. Zager. Evaluation of the indications for sentinel node biopsy in early-stage melanoma with the advent of adjuvant systemic therapy: An international, multicenter study. Ann Surg Oncol 29, no. 9 (2022): 5937–45. https://dx.doi.org/10.1245/s10434-022-11761-4.

Dey, A., N. Manolios, G. V. Long, M. S. Carlino, R. Kefford, and L. Schrieber. Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy. Intern Med J 52, no. 5 (2022): 818–27. https://dx.doi.org/10.1111/imj.15123.

Pizzolla, A., S. P. Keam, I. A. Vergara, F. Caramia, N. Thio, M. Wang, N. Kocovski, D. Tantalo, J. Jabbari, G. Au-Yeung, S. Sandhu, D. E. Gyorki, A. Weppler, M. Perdicchio, G. A. McArthur, A. T. Papenfuss, and P. J. Neeson. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. J Immunother Cancer 10, no. 5 (2022). https://dx.doi.org/10.1136/jitc-2022-004574.

Jobson, D., B. Roffey, C. Arnold, A. Azzi, A. Button-Sloan, T. Dawson, P. Fernandez-Penas, P. Fishburn, D. E. Gyorki, E. L. Hiscutt, V. Jakrot, A. Lilleyman, A. Lochhead, G. V. Long, S. Mailer, G. Mann, C. J. McCormack, J. Muir, G. F. Pratt, R. A. Scolyer, M. Shackelton, S. Shumack, H. P. Soyer, C. G. Tan, A. Webb, J. Zalcberg, R. Morton, and V. Mar. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. Australas J Dermatol 63, no. 3 (2022): 344–51. https://dx.doi.org/10.1111/ajd.13848.

Menzies, A. M., I. P. da Silva, C. Trojaniello, E. Vieu, R. N. Amaria, L. Zimmer, S. N. Lo, E. M. Burton, H. A. Tawbi, D. Schadendorf, J. J. Grob, P. A. Ascierto, and G. V. Long. CTLA-4 blockade resistance after relatlimab and nivolumab. N Engl J Med 386, no. 17 (2022): 1668–69. https://dx.doi.org/10.1056/NEJMc2119768.

Kaptein, P., C. Jacoberger-Foissac, P. Dimitriadis, P. Voabil, M. de Bruijn, S. Brokamp, I. Reijers, J. Versluis, G. Nallan, H. Triscott, E. McDonald, J. Tay, G. V. Long, C. U. Blank, D. S. Thommen, and M. W. L. Teng. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Sci Transl Med 14, no. 642 (2022): eabj9779. https://dx.doi.org/10.1126/scitranslmed.abj9779.

Muir, C. A., C. C. G. Wood, R. J. Clifton-Bligh, G. V. Long, R. A. Scolyer, M. S. Carlino, A. M. Menzies, and V. H. M. Tsang. Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events. J Clin Endocrinol Metab 107, no. 5 (2022): e1843–9. https://dx.doi.org/10.1210/clinem/dgac059.

Diefenbach, R. J., J. H. Lee, A. Stewart, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. R. Stretch, G. V. Long, R. A. Scolyer, and H. Rizos. Anchored multiplex PCR custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Front Oncol 12 (2022): 820510. https://dx.doi.org/10.3389/fonc.2022.820510.

Marsland, M., A. Dowdell, C. C. Jiang, J. S. Wilmott, R. A. Scolyer, X. D. Zhang, H. Hondermarck, and S. Faulkner. Expression of NGF/proNGF and their receptors TrkA, p75(NTR) and sortilin in melanoma. Int J Mol Sci 23, no. 8 (2022). https://dx.doi.org/10.3390/ijms23084260.

da Silva, I. P., T. Ahmed, J. L. McQuade, C. A. Nebhan, J. J. Park, J. M. Versluis, P. Serra-Bellver, Y. Khan, T. Slattery, H. K. Oberoi, S. Ugurel, L. E. Haydu, R. Herbst, J. Utikal, C. Pfohler, P. Terheyden, M. Weichenthal, R. Gutzmer, P. Mohr, R. Rai, J. L. Smith, R. A. Scolyer, A. M. Arance, L. Pickering, J. Larkin, P. Lorigan, C. U. Blank, D. Schadendorf, M. A. Davies, M. S. Carlino, D. B. Johnson, G. V. Long, S. N. Lo, and A. M. Menzies. Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma. J Clin Oncol 40, no. 10 (2022): 1068–80. https://dx.doi.org/10.1200/JCO.21.01701.

Semsarian, C. R., T. Ma, B. Nickel, R. A. Scolyer, P. M. Ferguson, H. P. Soyer, L. Parker, A. Barratt, J. F. Thompson, and K. J. L. Bell. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? , Br J Dermatol 186, no. 6 (2022): 1030–32. https://dx.doi.org/10.1111/bjd.21010.

Star, P., L. A. Jackett, K. Cheung, J. S. Wilmott, G. Ho, A. Smith, G. V. Long, R. A. Scolyer, and L. K. Martin. Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis, and treatment. Dermatol Ther 35, no. 6 (2022): e15472. https://dx.doi.org/10.1111/dth.15472.

Dimitriou, F., A. Hauschild, J. M. Mehnert, and G. V. Long. Double trouble: Immunotherapy doublets in melanoma-approved and novel combinations to optimize treatment in advanced melanoma. Am Soc Clin Oncol Educ Book 42, no. 42 (2022): 1–22. https://dx.doi.org/10.1200/EDBK_351123.

Luke, J. J., P. Rutkowski, P. Queirolo, M. Del Vecchio, J. Mackiewicz, V. Chiarion-Sileni, L. de la Cruz Merino, M. A. Khattak, D. Schadendorf, G. V. Long, P. A. Ascierto, M. Mandala, F. De Galitiis, A. Haydon, R. Dummer, J. J. Grob, C. Robert, M. S. Carlino, P. Mohr, A. Poklepovic, V. K. Sondak, R. A. Scolyer, J. M. Kirkwood, K. Chen, S. J. Diede, S. Ahsan, N. Ibrahim, A. M. M. Eggermont, and the KEYNOTE Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial. Lancet 399, no. 10336 (2022): 1718–29. https://dx.doi.org/10.1016/S0140-6736(22)00562-1.

Reijers, I. L. M., R. V. Rawson, A. J. Colebatch, E. A. Rozeman, A. M. Menzies, A. C. J. van Akkooi, K. F. Shannon, M. W. Wouters, R. P. M. Saw, W. J. van Houdt, C. L. Zuur, O. E. Nieweg, S. Ch'ng, W. M. C. Klop, A. J. Spillane, G. V. Long, R. A. Scolyer, B. A. van de Wiel, and C. U. Blank. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg 157, no. 4 (2022): 335–42. https://dx.doi.org/10.1001/jamasurg.2021.7554.

Wang, M., S. Zadeh, A. Pizzolla, K. Thia, D. E. Gyorki, G. A. McArthur, R. A. Scolyer, G. V. Long, J. S. Wilmott, M. C. Andrews, G. Au-Yeung, A. Weppler, S. Sandhu, J. A. Trapani, M. J. Davis, and P. J. Neeson. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. J Immunother Cancer 10, no. 4 (2022): e004095. https://dx.doi.org/10.1136/jitc-2021-004095.

Weiss, J. M., M. V. Hunter, N. M. Cruz, A. Baggiolini, M. Tagore, Y. Ma, S. Misale, M. Marasco, T. Simon-Vermot, N. R. Campbell, F. Newell, J. S. Wilmott, P. A. Johansson, J. F. Thompson, G. V. Long, J. V. Pearson, G. J. Mann, R. A. Scolyer, N. Waddell, E. D. Montal, T. H. Huang, P. Jonsson, M. T. A. Donoghue, C. C. Harris, B. S. Taylor, T. Xu, R. Chaligne, P. V. Shliaha, R. Hendrickson, A. A. Jungbluth, C. Lezcano, R. Koche, L. Studer, C. E. Ariyan, D. B. Solit, J. D. Wolchok, T. Merghoub, N. Rosen, N. K. Hayward, and R. M. White. Anatomic position determines oncogenic specificity in melanoma. Nature 604, no. 7905 (2022): 354–61. https://dx.doi.org/10.1038/s41586-022-04584-6.

Ho, G., R. J. Schwartz, A. Regio Pereira, F. Dimitrou, E. Paver, C. McKenzie, R. P. M. Saw, R. A. Scolyer, G. V. Long, and P. Guitera. Reflectance confocal microscopy – a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. J Eur Acad Dermatol Venereol 36, no. 7 (2022): e583–5. https://dx.doi.org/10.1111/jdv.18076.

El Sharouni, M. A., R. A. Scolyer, C. H. van Gils, S. Ch'ng, O. E. Nieweg, T. E. Pennington, R. P. M. Saw, K. Shannon, A. Spillane, J. Stretch, A. J. Witkamp, V. Sigurdsson, J. F. Thompson, P. J. van Diest, and S. N. Lo. Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: Effects on the sentinel node positivity rate and survival outcomes. Eur J Cancer 167 (2022): 123–32. https://dx.doi.org/10.1016/j.ejca.2021.12.035.

Potter, A. J., A. J. Colebatch, R. V. Rawson, P. M. Ferguson, W. A. Cooper, R. Gupta, S. O'Toole, R. P. M. Saw, S. Ch'ng, A. M. Menzies, G. V. Long, and R. A. Scolyer. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: Experience at a specialist melanoma treatment centre. Pathology 54, no. 5 (2022): 526–32. https://dx.doi.org/10.1016/j.pathol.2021.12.290.

Kennedy, O. J., M. Kicinski, S. Valpione, S. Gandini, S. Suciu, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, R. Koornstra, L. Hernandez-Aya, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, C. Robert, A. M. M. Eggermont, P. Lorigan, and M. Mandala. Prognostic and predictive value of beta-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 165 (2022): 97–112. https://dx.doi.org/10.1016/j.ejca.2022.01.017.

El Sharouni, M. A., R. A. Scolyer, C. H. van Gils, S. Ch'ng, O. E. Nieweg, T. E. Pennington, R. P. Saw, K. Shannon, A. Spillane, J. Stretch, A. J. Witkamp, V. Sigurdsson, J. F. Thompson, P. J. van Diest, and S. N. Lo. Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. Eur J Cancer 167 (2022): 133–41. https://dx.doi.org/10.1016/j.ejca.2021.12.036.

Pennington, T. E., C. Y. Zhao, A. J. Colebatch, P. Fernandez-Penas, P. Guitera, H. Burke, R. A. Scolyer, A. M. Menzies, M. S. Carlino, S. Lo, G. V. Long, and R. P. Saw. Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australas J Dermatol 63, no. 2 (2022): e133–7. https://dx.doi.org/10.1111/ajd.13807.

Regio Pereira, A., M. Corral-Forteza, H. Collgros, M. A. El Sharouni, P. M. Ferguson, R. A. Scolyer, and P. Guitera. Dermoscopic features and screening strategies for the detection of small-diameter melanomas. Clin Exp Dermatol 47, no. 5 (2022): 932–41. https://dx.doi.org/10.1111/ced.15094.

Cochran, A. J., D. R. Wen, R. R. Huang, P. Abrishami, C. Smart, S. Binder, R. A. Scolyer, J. F. Thompson, S. Stern, L. Van Kreuningen, D. E. Elashoff, M. S. Sim, H. J. Wang, and M. B. Faries. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first multicenter selective lymphadenectomy trial (MSLT-I). Eur J Surg Oncol 48, no. 6 (2022): 1280–87. https://dx.doi.org/10.1016/j.ejso.2022.01.021.

El Sharouni, M. A., R. V. Rawson, V. Sigurdsson, A. J. Witkamp, C. H. van Gils, R. A. Scolyer, J. F. Thompson, P. J. van Diest, and S. N. Lo. The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness). J Am Acad Dermatol 87, no. 2 (2022): 298–305. https://dx.doi.org/10.1016/j.jaad.2022.01.040.

Schwartz, R. J., G. Ho, A. Smith, H. Collgros, A. Regio Pereira, B. Gouveia, G. V. Long, A. M. Menzies, A. J. Potter, E. Paver, P. Star, R. A. Scolyer, and L. K. Martin. Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy. J Eur Acad Dermatol Venereol 36, no. 6 (2022): e445–8. https://dx.doi.org/10.1111/jdv.17940.

van Akkooi, A. C. J., T. J. Hieken, E. M. Burton, C. Ariyan, P. A. Ascierto, Svma Asero, C. U. Blank, M. S. Block, G. M. Boland, C. Caraco, S. Chng, B. S. Davidson, J. P. Duprat Neto, M. B. Faries, J. E. Gershenwald, D. J. Grunhagen, D. E. Gyorki, D. Han, A. J. Hayes, W. J. van Houdt, G. C. Karakousis, W. M. C. Klop, G. V. Long, M. C. Lowe, A. M. Menzies, R. Olofsson Bagge, T. E. Pennington, P. Rutkowski, R. P. M. Saw, R. A. Scolyer, K. F. Shannon, V. K. Sondak, H. Tawbi, A. A. E. Testori, M. T. Tetzlaff, J. F. Thompson, J. S. Zager, C. L. Zuur, J. A. Wargo, A. J. Spillane, M. I. Ross, and the International Neoadjuvant Melanoma Consortium. Neoadjuvant systemic therapy (NAST) in patients with melanoma: Surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 29, no. 6 (2022): 3694–708. https://dx.doi.org/10.1245/s10434-021-11236-y.

Eggermont, A. M., P. A. Ascierto, N. I. Khushalani, D. Schadendorf, G. Boland, J. Weber, K. D. Lewis, D. Johnson, G. Rivalland, A. Khattak, M. Majem, H. Gogas, G. V. Long, S. L. Currie, D. Chien, M. A. Tagliaferri, M. S. Carlino, and A. Diab. PIVOT-12: A phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol 18, no. 8 (2022): 903–13. https://dx.doi.org/10.2217/fon-2021-1286.

Newell, F., I. P. da Silva, P. A. Johansson, A. M. Menzies, J. S. Wilmott, V. Addala, M. S. Carlino, H. Rizos, K. Nones, J. J. Edwards, V. Lakis, S. H. Kazakoff, P. Mukhopadhyay, P. M. Ferguson, C. Leonard, L. T. Koufariotis, S. Wood, C. U. Blank, J. F. Thompson, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. V. Pearson, G. J. Mann, N. K. Hayward, R. A. Scolyer, N. Waddell, and G. V. Long. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 40, no. 1 (2022): 88–102. https://dx.doi.org/10.1016/j.ccell.2021.11.012.

Lô, S. N., J. Ma, M. Manuguerra, M. Moreno-Betancur, R. A. Scolyer, and J. F. Thompson. Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models. Stat Methods Med Res 31, no. 5 (2022): 978–94. https://dx.doi.org/10.1177/09622802211070254.

Dummer, R., G. V. Long, C. Robert, H. A. Tawbi, K. T. Flaherty, P. A. Ascierto, P. D. Nathan, P. Rutkowski, O. Leonov, C. Dutriaux, M. Mandala, P. Lorigan, P. F. Ferrucci, J. J. Grob, N. Meyer, H. Gogas, D. Stroyakovskiy, A. Arance, J. C. Brase, S. Green, T. Haas, A. Masood, E. Gasal, A. Ribas, and D. Schadendorf. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol 40, no. 13 (2022): 1428–38. https://dx.doi.org/10.1200/JCO.21.01601.

Scolyer, R. A. Pathology: The next chapter. Pathology 54, no. 1 (2022): 4–5. https://dx.doi.org/10.1016/j.pathol.2021.12.001.

Tawbi, H. A., D. Schadendorf, E. J. Lipson, P. A. Ascierto, L. Matamala, E. Castillo Gutierrez, P. Rutkowski, H. J. Gogas, C. D. Lao, J. J. De Menezes, S. Dalle, A. Arance, J. J. Grob, S. Srivastava, M. Abaskharoun, M. Hamilton, S. Keidel, K. L. Simonsen, A. M. Sobiesk, B. Li, F. S. Hodi, G. V. Long, and the RELATIVITY Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386, no. 1 (2022): 24–34. https://dx.doi.org/10.1056/NEJMoa2109970.

Vergara, I. A., J. S. Wilmott, G. V. Long, and R. A. Scolyer. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Exp Dermatol 31, no. 1 (2022): 13–30. https://dx.doi.org/10.1111/exd.14287.

Goldinger, S. M., K. Buder-Bakhaya, S. N. Lo, A. Forschner, M. McKean, L. Zimmer, C. Khoo, R. Dummer, Z. Eroglu, E. I. Buchbinder, P. A. Ascierto, R. Gutzmer, E. A. Rozeman, C. Hoeller, D. B. Johnson, A. Gesierich, P. Kolblinger, N. Bennannoune, J. V. Cohen, K. C. Kahler, M. A. Wilson, J. Cebon, V. Atkinson, J. L. Smith, O. Michielin, G. V. Long, J. C. Hassel, B. Weide, L. E. Haydu, D. Schadendorf, G. McArthur, P. A. Ott, C. Blank, C. Robert, R. Sullivan, A. Hauschild, M. S. Carlino, C. Garbe, M. A. Davies, and A. M. Menzies. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: A retrospective multicentre analysis. Eur J Cancer 162 (2022): 22–33. https://dx.doi.org/10.1016/j.ejca.2021.11.022.

Scolyer, R. A., V. Atkinson, D. E. Gyorki, D. Lambie, S. O'Toole, R. P. M. Saw, B. Amanuel, C. M. Angel, A. E. Button-Sloan, M. S. Carlino, S. Ch'ng, A. J. Colebatch, D. Daneshvar, I. P. da Silva, T. Dawson, P. M. Ferguson, E. Foster-Smith, S. B. Fox, A. J. Gill, R. Gupta, M. A. Henderson, A. M. Hong, J. R. Howle, L. A. Jackett, C. James, C. S. Lee, A. Lochhead, D. Loh, G. A. McArthur, C. A. McLean, A. M. Menzies, O. E. Nieweg, B. H. O'Brien, T. E. Pennington, A. J. Potter, S. Prakash, R. V. Rawson, R. L. Read, M. A. Rtshiladze, K. F. Shannon, B. M. Smithers, A. J. Spillane, J. R. Stretch, J. F. Thompson, P. Tucker, A. H. R. Varey, R. E. Vilain, B. A. Wood, and G. V. Long. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: Practical guidance for the Australian setting. Pathology 54, no. 1 (2022): 6–19. https://dx.doi.org/10.1016/j.pathol.2021.11.002.

Benton, S., J. Zhao, B. Zhang, A. Bahrami, R. L. Barnhill, K. Busam, L. Cerroni, M. G. Cook, A. de la Fouchardière, D. E. Elder, I. Johansson, G. Landman, A. Lazar, P. LeBoit, L. Lowe, D. Massi, L. M. Duncan, J. Messina, D. Mihic-Probst, M. C. Mihm, Jr., M. W. Piepkorn, B. Schmidt, R. A. Scolyer, C. R. Shea, M. T. Tetzlaff, V. A. Tron, X. Xu, I. Yeh, S. J. Yun, A. Zembowicz, and P. Gerami. Impact of next-generation sequencing on interobserver agreement and diagnosis of spitzoid neoplasms. Am J Surg Pathol 45, no. 12 (2021): 1597–605. https://dx.doi.org/10.1097/pas.0000000000001753.

Watts, C. G., K. McLoughlin, C. Goumas, C. H. van Kemenade, J. F. Aitken, H. P. Soyer, P. Fernandez Peñas, P. Guitera, R. A. Scolyer, R. L. Morton, S. W. Menzies, M. Caruana, Y. J. Kang, G. J. Mann, A. H. Chakera, C. M. Madronio, B. K. Armstrong, J. F. Thompson, and A. E. Cust. Association between melanoma detected during routine skin checks and mortality. JAMA Dermatol 157, no. 12 (2021): 1425–36. https://dx.doi.org/10.1001/jamadermatol.2021.3884.

Ackermann, D. M., M. Dieng, E. Medcalf, M. C. Jenkins, C. H. van Kemenade, M. Janda, R. M. Turner, A. E. Cust, R. L. Morton, L. Irwig, P. Guitera, H. P. Soyer, V. Mar, J. K. Hersch, D. Low, C. Low, R. P. M. Saw, R. A. Scolyer, D. Drabarek, D. Espinoza, A. Azzi, A. M. Lilleyman, A. K. Smit, P. Murchie, J. F. Thompson, and K. J. L. Bell. Assessing the potential for patient-led surveillance after treatment of localized melanoma (MEL-SELF): A pilot randomized clinical trial. JAMA Dermatol 158, no. 1 (2022): 33–42. https://dx.doi.org/10.1001/jamadermatol.2021.4704.

Wolchok, J. D., V. Chiarion-Sileni, R. Gonzalez, J. J. Grob, P. Rutkowski, C. D. Lao, C. L. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. F. Ferrucci, M. Smylie, M. O. Butler, A. Hill, I. Marquez-Rodas, Jbag Haanen, M. Guidoboni, M. Maio, P. Schoffski, M. S. Carlino, C. Lebbe, G. McArthur, P. A. Ascierto, G. A. Daniels, G. V. Long, T. Bas, C. Ritchings, J. Larkin, and F. S. Hodi. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40, no. 2 (2022): 127–37. https://dx.doi.org/10.1200/JCO.21.02229.

Liyanage, U. E., S. MacGregor, D. T. Bishop, J. Shi, J. An, J. S. Ong, X. Han, R. A. Scolyer, N. G. Martin, S. E. Medland, E. M. Byrne, A. C. Green, R. P. M. Saw, J. F. Thompson, J. Stretch, A. Spillane, Y. Jiang, C. Tian, Team andMe Research, S. G. Gordon, D. L. Duffy, C. M. Olsen, D. C. Whiteman, G. V. Long, M. M. Iles, M. T. Landi, and M. H. Law. Multi-trait genetic analysis identifies autoimmune loci associated with cutaneous melanoma. J Invest Dermatol 142, no. 6 (2022): 1607–16. https://dx.doi.org/10.1016/j.jid.2021.08.449.

2021

Haefliger, S., P. Guitera, B. Melhoranse Gouveia, A. J. Colebatch, R. A. Scolyer, M. Rtshiladze, and L. K. Martin. Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children. Pediatr Dermatol 38, no. 6 (2021): 1549–52. https://dx.doi.org/10.1111/pde.14846.

Long, G. V., A. Arance, L. Mortier, P. Lorigan, C. Blank, P. Mohr, J. Schachter, J. J. Grob, M. Lotem, M. R. Middleton, B. Neyns, N. Steven, A. Ribas, E. Walpole, M. S. Carlino, C. Lebbe, M. Sznol, E. Jensen, M. A. Leiby, N. Ibrahim, and C. Robert. Antitumor activity of ipilimumab or BRAF±MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: Analysis from KEYNOTE-006. Ann Oncol 33, no. 2 (2022): 204–15. https://dx.doi.org/10.1016/j.annonc.2021.10.010.

Dimitriou, F., S. N. Lo, A. C. Tan, L. Emmett, R. Kapoor, M. S. Carlino, G. V. Long, and A. M. Menzies. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 33, no. 1 (2022): 99–106. https://dx.doi.org/10.1016/j.annonc.2021.10.003.

Srinivasan, M., A. M. Taylor, G. V. Long, G. Herkes, and G. G. King. Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy. Respir Med Case Rep 34, no. 101533 (2021): 101533. https://dx.doi.org/10.1016/j.rmcr.2021.101533.

Zaremba, A., R. Kramer, V. De Temple, S. Bertram, M. Salzmann, A. Gesierich, L. Reinhardt, B. Baroudjian, M. M. Sachse, G. Mechtersheimer, D. B. Johnson, A. M. Weppler, L. Spain, C. Loquai, M. Dudda, C. Pfohler, A. Hepner, G. V. Long, A. M. Menzies, M. S. Carlino, C. Lebbe, T. Enokida, M. Tahara, P. J. Brockelmann, T. Eigentler, K. C. Kahler, R. Gutzmer, C. Berking, S. Ugurel, N. Stadtler, A. Sucker, J. C. Becker, E. Livingstone, F. Meier, J. C. Hassel, D. Schadendorf, M. Hanoun, L. Heinzerling, and L. Zimmer. Grade 4 neutropenia secondary to immune checkpoint inhibition – a descriptive observational retrospective multicenter analysis. Front Oncol 11 (2021): 765608. https://dx.doi.org/10.3389/fonc.2021.765608.

Eggermont, A. M., A. Meshcheryakov, V. Atkinson, C. U. Blank, M. Mandala, G. V. Long, C. Barrow, A. M. Di Giacomo, R. Fisher, S. Sandhu, R. Kudchadkar, P. L. Ortiz Romero, I. M. Svane, J. Larkin, S. Puig, P. Hersey, P. Quaglino, P. Queirolo, D. Stroyakovskiy, L. Bastholt, P. Mohr, M. Hernberg, V. Chiarion-Sileni, M. Strother, A. Hauschild, N. Yamazaki, A. C. van Akkooi, P. Lorigan, C. Krepler, N. Ibrahim, S. Marreaud, M. Kicinski, S. Suciu, and C. Robert. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/KEYNOTE-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur J Cancer 158 (2021): 156–68. https://dx.doi.org/10.1016/j.ejca.2021.09.023.

Quek, C., X. Bai, G. V. Long, R. A. Scolyer, and J. S. Wilmott. High-dimensional single-cell transcriptomics in melanoma and cancer immunotherapy. Genes (Basel) 12, no. 10 (2021): 1629. https://dx.doi.org/10.3390/genes12101629.

Peri, A., E. Greenstein, M. Alon, J. A. Pai, T. Dingjan, S. Reich-Zeliger, E. Barnea, C. Barbolin, R. Levy, C. Arnedo-Pac, S. Kalaora, B. Dassa, E. Feldmesser, P. Shang, P. Greenberg, Y. Levin, G. Benedek, M. P. Levesque, D. J. Adams, M. Lotem, J. S. Wilmott, R. A. Scolyer, G. B. Jönsson, A. Admon, S. A. Rosenberg, C. J. Cohen, M. Y. Niv, N. Lopez-Bigas, A. T. Satpathy, N. Friedman, and Y. Samuels. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. J Clin Invest 131, no. 20 (2021). https://dx.doi.org/10.1172/jci129466.

Cho, K. K., A. E. Cust, Y. M. Foo, G. V. Long, A. M. Menzies, and G. D. Eslick. Metastatic acral melanoma treatment outcomes: A systematic review and meta-analysis. Melanoma Res 31, no. 5 (2021): 482–86. https://dx.doi.org/10.1097/CMR.0000000000000764.

Halle, B. R., A. Betof Warner, F. Y. Zaman, A. Haydon, P. Bhave, A. K. Dewan, F. Ye, R. Irlmeier, P. Mehta, N. R. Kurtansky, M. E. Lacouture, J. C. Hassel, J. S. Choi, J. A. Sosman, S. Chandra, T. S. Otto, R. Sullivan, M. J. Mooradian, S. T. Chen, F. Dimitriou, G. V. Long, M. Carlino, A. Menzies, D. B. Johnson, and V. M. Rotemberg. Immune checkpoint inhibitors in patients with pre-existing psoriasis: Safety and efficacy. J Immunother Cancer 9, no. 10 (2021): e003066. https://dx.doi.org/10.1136/jitc-2021-003066.

Lau, P. K. H., B. Feran, L. Smith, A. Lasocki, R. Molania, K. Smith, A. Weppler, C. Angel, D. Kee, P. Bhave, B. Lee, R. J. Young, A. Iravani, H. A. Yeang, I. A. Vergara, D. Kok, K. Drummond, P. J. Neeson, K. E. Sheppard, T. Papenfuss, B. J. Solomon, S. Sandhu, and G. A. McArthur. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). J Immunother Cancer 9, no. 10 (2021). https://dx.doi.org/10.1136/jitc-2021-002995.

Long, G. V., C. Robert, M. O. Butler, F. Couture, M. S. Carlino, S. O'Day, V. Atkinson, J. S. Cebon, M. P. Brown, S. Dalle, A. G. Hill, G. T. Gibney, S. McCune, A. M. Menzies, C. Niu, N. Ibrahim, B. H. Moreno, and A. Diab. Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 Cohort 1C, a phase 2 randomized study of two dosing schedules. Clin Cancer Res 27, no. 19 (2021): 5280–88. https://dx.doi.org/10.1158/1078-0432.CCR-21-0793.

Güvenç, C., A. Antoranz, A. Szumera-Ciećkiewicz, P. P. Teterycz, P. R. Rutkowski, R. V. Rawson, R. A. Scolyer, J. F. Thompson, J. Newton-Bishop, M. Stas, V. Boecxstaens, O. Bechter, J. Vercauteren, M. Garmyn, J. van den Oord, and F. M. Bosisio. Road to metastasis: The tweak pathway as a discriminant between metastasizing and non-metastasizing thick melanomas. Int J Mol Sci 22, no. 19 (2021). https://dx.doi.org/10.3390/ijms221910568.

Hamid, O., C. Robert, A. Daud, M. S. Carlino, T. C. Mitchell, P. Hersey, J. Schachter, G. V. Long, F. S. Hodi, J. D. Wolchok, A. Arance, J. J. Grob, A. M. Joshua, J. S. Weber, L. Mortier, E. Jensen, S. J. Diede, B. H. Moreno, and A. Ribas. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer 157 (2021): 391–402. https://dx.doi.org/10.1016/j.ejca.2021.08.013.

Guitera, P., A. Waddell, E. Paton, G. B. Fogarty, A. Hong, R. A. Scolyer, J. R. Stretch, B. A. O'Donnell, and G. Pellacani. A practical guide on the use of imiquimod cream to treat lentigo maligna. Australas J Dermatol 62, no. 4 (2021): 478–85. https://dx.doi.org/10.1111/ajd.13720.

Dimitriou, F., S. Hogan, A. M. Menzies, R. Dummer, and G. V. Long. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer 157 (2021): 214–24. https://dx.doi.org/10.1016/j.ejca.2021.08.031.

Carlino, M. S., J. Larkin, and G. V. Long. Immune checkpoint inhibitors in melanoma. Lancet 398, no. 10304 (2021): 1002–14. https://dx.doi.org/10.1016/S0140-6736(21)01206-X.

Livingstone, A., K. Dempsey, M. R. Stockler, K. Howard, G. V. Long, M. S. Carlino, A. M. Menzies, and R. L. Morton. Adjuvant immunotherapy recommendations for stage III melanoma: Physician and nurse interviews. BMC Cancer 21, no. 1 (2021): 1014. https://dx.doi.org/10.1186/s12885-021-08752-1.

Potter, A. J., F. Dimitriou, R. Z. Karim, A. Mahar, C. Chan, G. V. Long, and R. A. Scolyer. Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. Pathology 54, no. 3 (2022): 369–71. https://dx.doi.org/10.1016/j.pathol.2021.05.097.

Muir, C. A., R. J. Clifton-Bligh, G. V. Long, R. A. Scolyer, S. N. Lo, M. S. Carlino, V. H. M. Tsang, and A. M. Menzies. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106, no. 9 (2021): e3704–13. https://dx.doi.org/10.1210/clinem/dgab263.

Hodi, F. S., J. D. Wolchok, D. Schadendorf, J. Larkin, G. V. Long, X. Qian, A. Saci, T. C. Young, S. Srinivasan, H. Chang, H. Tang, M. Wind-Rotolo, J. I. Rizzo, D. G. Jackson, and P. A. Ascierto. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. Cancer Immunol Res 9, no. 10 (2021): 1202–13. https://dx.doi.org/10.1158/2326-6066.CIR-20-0983.

Jackett, L. A., L. Satgunaseelan, E. Roper, S. N. Lo, J. F. Thompson, and R. A. Scolyer. Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas. Pathology 54, no. 1 (2022): 71–78. https://dx.doi.org/10.1016/j.pathol.2021.05.094.

Zaremba, A., A. M. M. Eggermont, C. Robert, R. Dummer, S. Ugurel, E. Livingstone, P. A. Ascierto, G. V. Long, D. Schadendorf, and L. Zimmer. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer 155 (2021): 268–80. https://dx.doi.org/10.1016/j.ejca.2021.07.002.

Bai, X., J. Hu, A. Betof Warner, H. T. Quach, C. G. Cann, M. Z. Zhang, L. Si, B. Tang, C. Cui, X. Yang, X. Wei, L. Pallan, C. Harvey, M. P. Manos, O. Ouyang, M. S. Kim, G. Kasumova, J. V. Cohen, D. P. Lawrence, C. Freedman, R. M. Fadden, K. M. Rubin, T. Sharova, D. T. Frederick, K. T. Flaherty, O. E. Rahma, G. V. Long, A. M. Menzies, J. Guo, A. N. Shoushtari, D. B. Johnson, R. J. Sullivan, and G. M. Boland. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin Cancer Res 27, no. 21 (2021): 5993–6000. https://dx.doi.org/10.1158/1078-0432.CCR-21-1283.

Ch'ng, S., R. A. Scolyer, and J. F. Thompson. ASO Author Reflections: Surgical resection may improve the outcome for patients with residual metastatic melanoma when modern systemic therapies have not achieved complete disease control. Ann Surg Oncol 28, no. 11 (2021): 6124–25. https://dx.doi.org/10.1245/s10434-021-10514-z.

Rocha, L. K. F. L, R. E. Vilain, R. A. Scolyer, S. N. Lo, M. Drummond, P. Star, G. B. Fogarty, A. M. Hong, and P. Guitera. Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ. Int J Dermatol 61, no. 2 (2022): 167–74. https://dx.doi.org/10.1111/ijd.15815.

Li, A. T., K. Vakharia, S. N. Lo, A. H. R. Varey, M. S. Carlino, R. P. M. Saw, K. F. Shannon, J. R. Howle, T. E. Pennington, J. R. Stretch, O. E. Nieweg, A. J. Spillane, G. V. Long, A. M. Menzies, R. A. Scolyer, J. F. Thompson, and S. Ch'ng. Survival outcomes of salvage metastasectomy after failure of modern-era systemic therapy for melanoma. Ann Surg Oncol 28, no. 11 (2021): 6109–23. https://dx.doi.org/10.1245/s10434-021-10489-x.

Haas, L., A. Elewaut, C. L. Gerard, C. Umkehrer, L. Leiendecker, M. Pedersen, I. Krecioch, D. Hoffmann, M. Novatchkova, M. Kuttke, T. Neumann, I. P. da Silva, H. Witthock, M. A. Cuendet, S. Carotta, K. J. Harrington, J. Zuber, R. A. Scolyer, G. V. Long, J. S. Wilmott, O. Michielin, S. Vanharanta, T. Wiesner, and A. C. Obenauf. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat Cancer 2, no. 7 (2021): 693–708. https://dx.doi.org/10.1038/s43018-021-00221-9.

Dessinioti, C., A. C. Geller, D. C. Whiteman, C. Garbe, J. J. Grob, J. W. Kelly, R. A. Scolyer, R. V. Rawson, A. Lallas, G. Pellacani, and A. J. Stratigos. Not all melanomas are created equal: A review and call for more research into nodular melanoma. Br J Dermatol 185, no. 4 (2021): 700–10. https://dx.doi.org/10.1111/bjd.20388.

Aivazian, K., T. Ahmed, M. A. El Sharouni, J. R. Stretch, R. P. M. Saw, A. J. Spillane, K. F. Shannon, S. Ch'ng, O. E. Nieweg, J. F. Thompson, S. N. Lo, and R. A. Scolyer. Histological regression in melanoma: Impact on sentinel lymph node status and survival. Mod Pathol 34, no. 11 (2021): 1999–2008. https://dx.doi.org/10.1038/s41379-021-00870-2.

Schadendorf, D., C. Robert, R. Dummer, K. T. Flaherty, H. A. Tawbi, A. M. Menzies, H. Banerjee, M. Lau, and G. V. Long. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer 153 (2021): 234–41. https://dx.doi.org/10.1016/j.ejca.2021.05.005.

Robertson, S. J., L. Orme, R. Teixeira, M. Shamassi, F. Newell, A. M. Patch, I. Yeh, G. Gard, J. S. Wilmott, L. Jackett, P. LeBoit, A. Fellowes, G. MacArthur, S. Fox, N. K. Hayward, B. Bastian, R. A. Scolyer, N. Waddell, A. Penington, and M. Shackleton. Evaluation of crizotinib treatment in a patient with unresectable GOPC-ROS1 fusion agminated Spitz nevi. JAMA Dermatol 157, no. 7 (2021): 836–41. https://dx.doi.org/10.1001/jamadermatol.2021.0025.

Hepner, A., V. G. Atkinson, J. Larkin, R. A. Burrell, M. S. Carlino, D. B. Johnson, L. Zimmer, K. K. Tsai, O. Klein, S. N. Lo, A. Haydon, P. Bhave, M. Lyle, L. Pallan, I. P. da Silva, C. Gerard, O. Michielin, G. V. Long, and A. M. Menzies. Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. Eur J Cancer 153 (2021): 213–22. https://dx.doi.org/10.1016/j.ejca.2021.04.021.

Dearden, H., L. Au, D. Y. Wang, L. Zimmer, Z. Eroglu, J. L. Smith, M. Cuvietto, C. Khoo, V. Atkinson, S. Lo, G. V. Long, S. Sandhu, P. A. Ascierto, M. S. Carlino, D. B. Johnson, J. Larkin, and A. M. Menzies. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur J Cancer 153 (2021): 168–78. https://dx.doi.org/10.1016/j.ejca.2021.04.045.

Gide, T. N., I. P. da Silva, C. Quek, P. M. Ferguson, M. Batten, P. Shang, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. F. Thompson, R. A. Scolyer, G. V. Long, and J. S. Wilmott. Clinical and molecular heterogeneity in patients with innate resistance to anti-PD-1 +/- anti-CTLA-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets. Cancers (Basel) 13, no. 13 (2021). https://dx.doi.org/10.3390/cancers13133186.

Star, P., R. V. Rawson, M. Drummond, S. N. Lo, R. A. Scolyer, and P. Guitera. Lentigo maligna: Defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features. J Eur Acad Dermatol Venereol 35, no. 9 (2021): 1811–20. https://dx.doi.org/10.1111/jdv.17349.

Giblin, W., L. Bringman-Rodenbarger, A. H. Guo, S. Kumar, A. C. Monovich, A. M. Mostafa, M. E. Skinner, M. Azar, A. S. Mady, C. H. Chung, N. Kadambi, K. A. Melong, H. J. Lee, L. Zhang, P. Sajjakulnukit, S. Trefely, E. L. Varner, S. Iyer, M. Wang, J. S. Wilmott, H. P. Soyer, R. A. Sturm, A. L. Pritchard, A. A. Andea, R. A. Scolyer, M. S. Stark, D. A. Scott, D. R. Fullen, M. W. Bosenberg, S. Chandrasekaran, Z. Nikolovska-Coleska, M. E. Verhaegen, N. W. Snyder, M. N. Rivera, A. L. Osterman, C. A. Lyssiotis, and D. B. Lombard. The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. J Clin Invest 131, no. 12 (2021). https://dx.doi.org/10.1172/jci138926.

Li, A. T., A. M. Maw, E. Hsiao, S. Ch'ng, G. V. Long, K. F. Shannon, and E. J. Morrison. Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma. ANZ J Surg 92, no. 1-2 (2022): 247–50. https://dx.doi.org/10.1111/ans.16992.

Ch'ng, S., S. Uyulmaz, M. S. Carlino, T. E. Pennington, K. F. Shannon, M. Rtshiladze, J. R. Stretch, O. E. Nieweg, A. H. R. Varey, E. Hsiao, R. Kapoor, I. P. da Silva, S. N. Lo, A. J. Spillane, R. A. Scolyer, G. V. Long, A. M. Hong, R. P. M. Saw, J. F. Thompson, and A. M. Menzies. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. Eur J Cancer 153 (2021): 8–15. https://dx.doi.org/10.1016/j.ejca.2021.04.037.

Choi, S., A. Hong, T. Wang, S. Lo, B. Chen, I. P. da Silva, R. Kapoor, E. Hsiao, G. B. Fogarty, M. S. Carlino, A. M. Menzies, G. V. Long, and B. S. Shivalingam. Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location. Strahlenther Onkol 197, no. 12 (2021): 1104–12. https://dx.doi.org/10.1007/s00066-021-01798-x.

Brase, J. C., R. F. H. Walter, A. Savchenko, D. Gusenleitner, J. Garrett, T. Schimming, R. Varaljai, D. Castelletti, J. Kim, N. Dakappagari, K. Schultz, C. Robert, G. V. Long, P. D. Nathan, A. Ribas, K. T. Flaherty, B. Karaszewska, J. Schachter, A. Sucker, K. W. Schmid, L. Zimmer, E. Livingstone, E. Gasal, D. Schadendorf, and A. Roesch. Role of tumor-infiltrating B cells in clinical outcome of patients with melanoma treated with dabrafenib plus trametinib. Clin Cancer Res 27, no. 16 (2021): 4500–10. https://dx.doi.org/10.1158/1078-0432.CCR-20-3586.

Parakh, S., A. Musafer, S. Paessler, T. Witkowski, Csnlw Suen, C. S. A. Tutuka, M. S. Carlino, A. M. Menzies, R. A. Scolyer, J. Cebon, A. Dobrovic, G. V. Long, O. Klein, and A. Behren. PDCD1 polymorphisms may predict response to anti-PD-1 blockade in patients with metastatic melanoma. Front Immunol 12 (2021): 672521. https://dx.doi.org/10.3389/fimmu.2021.672521.

Menzies, A. M., R. A. Scolyer, and G. V. Long. Neoadjuvant immunotherapy in melanoma – the new frontier. Clin Cancer Res 27, no. 15 (2021): 4133–35. https://dx.doi.org/10.1158/1078-0432.CCR-21-1236.

Cree, I. A., P. H. Tan, W. D. Travis, P. Wesseling, Y. Yagi, V. A. White, D. Lokuhetty, and R. A. Scolyer. Counting mitoses: Si(ze) matters! , Mod Pathol 34, no. 9 (2021): 1651–57. https://dx.doi.org/10.1038/s41379-021-00825-7.

Gallagher, S. J., T. Bailey, R. V. Rawson, A. M. Mahar, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. Melanoma with osseous or chondroid differentiation: A report of eight cases including SATB2 expression and mutation analysis. Pathology 53, no. 7 (2021): 830–35. https://dx.doi.org/10.1016/j.pathol.2021.02.012.

Friedman, E. B., R. A. Scolyer, G. J. Williams, and J. F. Thompson. Melanoma in situ: A critical review and re-evaluation of current excision margin recommendations. Adv Ther 38, no. 7 (2021): 3506–30. https://dx.doi.org/10.1007/s12325-021-01783-x.

El Sharouni, M. A., T. Ahmed, A. J. Witkamp, V. Sigurdsson, C. H. van Gils, O. E. Nieweg, R. A. Scolyer, J. F. Thompson, P. J. van Diest, and S. N. Lo. Predicting recurrence in patients with sentinel node-negative melanoma: Validation of the EORTC nomogram using population-based data. Br J Surg 108, no. 5 (2021): 550–53. https://dx.doi.org/10.1002/bjs.11946.

da Silva, I. P., T. Ahmed, I. L. M. Reijers, A. M. Weppler, A. Betof Warner, J. R. Patrinely, P. Serra-Bellver, C. Allayous, J. Mangana, K. Nguyen, L. Zimmer, C. Trojaniello, D. Stout, M. Lyle, O. Klein, C. L. Gerard, O. Michielin, A. Haydon, P. A. Ascierto, M. S. Carlino, C. Lebbe, P. Lorigan, D. B. Johnson, S. Sandhu, S. N. Lo, C. U. Blank, A. M. Menzies, and G. V. Long. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study. Lancet Oncol 22, no. 6 (2021): 836–47. https://dx.doi.org/10.1016/S1470-2045(21)00097-8.

Wu, S. Z., D. L. Roden, G. Al-Eryani, N. Bartonicek, K. Harvey, A. S. Cazet, C. L. Chan, S. Junankar, M. N. Hui, E. A. Millar, J. Beretov, L. Horvath, A. M. Joshua, P. Stricker, J. S. Wilmott, C. Quek, G. V. Long, R. A. Scolyer, B. Z. Yeung, D. Segara, C. Mak, S. Warrier, J. E. Powell, S. O'Toole, E. Lim, and A. Swarbrick. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Med 13, no. 1 (2021): 81. https://dx.doi.org/10.1186/s13073-021-00885-z.

El Sharouni, M. A., A. H. R. Varey, A. J. Witkamp, T. Ahmed, V. Sigurdsson, P. J. van Diest, R. A. Scolyer, J. F. Thompson, S. N. Lo, and C. H. van Gils. Predicting sentinel node positivity in patients with melanoma: External validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort. Br J Dermatol 185, no. 2 (2021): 412–18. https://dx.doi.org/10.1111/bjd.19895.

Versluis, J. M., A. M. Hendriks, A. M. Weppler, L. J. Brown, K. de Joode, K. P. M. Suijkerbuijk, L. Zimmer, E. W. Kapiteijn, C. Allayous, D. B. Johnson, A. Hepner, J. Mangana, P. Bhave, Y. J. L. Jansen, C. Trojaniello, V. Atkinson, L. Storey, P. Lorigan, P. A. Ascierto, B. Neyns, A. Haydon, A. M. Menzies, G. V. Long, C. Lebbe, A. A. M. van der Veldt, M. S. Carlino, S. Sandhu, H. van Tinteren, E. G. E. de Vries, C. U. Blank, and M. Jalving. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. Eur J Cancer 151 (2021): 72–83. https://dx.doi.org/10.1016/j.ejca.2021.04.003.

Ackermann, D. M., A. K. Smit, M. Janda, C. H. van Kemenade, M. Dieng, R. L. Morton, R. M. Turner, A. E. Cust, L. Irwig, J. K. Hersch, P. Guitera, H. P. Soyer, V. Mar, R. P. M. Saw, D. Low, C. Low, D. Drabarek, D. Espinoza, J. Emery, P. Murchie, J. F. Thompson, R. A. Scolyer, A. Azzi, A. Lilleyman, and K. J. L. Bell. Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. Trials 22, no. 1 (2021): 324. https://dx.doi.org/10.1186/s13063-021-05231-7.

Attrill, G. H., P. M. Ferguson, U. Palendira, G. V. Long, J. S. Wilmott, and R. A. Scolyer. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res 34, no. 3 (2021): 529–49. https://dx.doi.org/10.1111/pcmr.12926.

Brown, L. J., A. Weppler, P. Bhave, C. Allayous, J. R. Patrinely, Jr., P. Ott, S. Sandhu, A. Haydon, C. Lebbe, D. B. Johnson, G. V. Long, A. M. Menzies, and M. S. Carlino. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer 9, no. 5 (2021): e002121. https://dx.doi.org/10.1136/jitc-2020-002121.

Patrinely, J. R., Jr., R. Johnson, A. R. Lawless, P. Bhave, A. Sawyers, M. Dimitrova, H. L. Yeoh, M. Palmeri, F. Ye, R. Fan, E. J. Davis, S. Rapisuwon, G. V. Long, A. Haydon, I. Osman, J. M. Mehnert, M. S. Carlino, R. J. Sullivan, A. M. Menzies, and D. B. Johnson. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol 7, no. 5 (2021): 744–48. https://dx.doi.org/10.1001/jamaoncol.2021.0051.

Rawson, R. V., J. S. Wilmott, and R. A. Scolyer. Mucosal melanoma: A review emphasizing the molecular landscape and implications for diagnosis and management. Surg Pathol Clin 14, no. 2 (2021): 293–307. https://dx.doi.org/10.1016/j.path.2021.01.005.

Delahunt, B., B. Neill, J. R. Burnett, and R. A. Scolyer. Publication metrics: It really is all about the numbers. Pathology 53, no. 4 (2021): 561–63. https://dx.doi.org/10.1016/j.pathol.2021.03.001.

Bottomley, A., C. Coens, J. Mierzynska, C. U. Blank, M. Mandala, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, S. Puig, P. A. Ascierto, J. Larkin, P. C. Lorigan, P. Rutkowski, D. Schadendorf, R. Koornstra, L. Hernandez-Aya, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, C. Krepler, N. Ibrahim, S. Marreaud, M. Kicinski, S. Suciu, C. Robert, A. M. M. Eggermont, and the EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): Health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 22, no. 5 (2021): 655–64. https://dx.doi.org/10.1016/S1470-2045(21)00081-4.

Eggermont, A. M. M., C. U. Blank, M. Mandala, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, R. Koornstra, L. Hernandez-Aya, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, P. C. Lorigan, A. C. J. van Akkooi, C. Krepler, N. Ibrahim, S. Marreaud, M. Kicinski, S. Suciu, C. Robert, and the EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): Distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 22, no. 5 (2021): 643–54. https://dx.doi.org/10.1016/S1470-2045(21)00065-6.

Park, J. J., R. J. Diefenbach, N. Byrne, G. V. Long, R. A. Scolyer, E. S. Gray, M. S. Carlino, and H. Rizos. Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition. Cancers (Basel) 13, no. 7 (2021): 1740. https://dx.doi.org/10.3390/cancers13071740.

Gibson, M., R. A. Scolyer, H. P. Soyer, P. Ferguson, K. McGeechan, L. Irwig, and K. J. L. Bell. Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma. J Eur Acad Dermatol Venereol 35, no. 7 (2021): 1519–27. https://dx.doi.org/10.1111/jdv.17189.

Dessinioti, C., A. C. Geller, A. Stergiopoulou, N. Dimou, S. N. Lo, U. Keim, J. E. Gershenwald, L. E. Haydu, R. Dummer, J. Mangana, A. Hauschild, F. Egberts, R. Vieira, A. Brinca, I. Zalaudek, T. Deinlein, E. Evangelou, J. F. Thompson, R. A. Scolyer, K. Peris, C. Garbe, and A. J. Stratigos. A multicentre study of naevus-associated melanoma vs de novo melanoma, tumour thickness and body site differences. Br J Dermatol 185, no. 1 (2021): 101–09. https://dx.doi.org/10.1111/bjd.19819.

Eggermont, A. M. M., M. Kicinski, C. U. Blank, M. Mandala, G. V. Long, V. Atkinson, S. Dalle, A. Haydon, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, R. Koornstra, L. Hernandez-Aya, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, P. C. Lorigan, C. Krepler, N. Ibrahim, S. Marreaud, A. van Akkooi, C. Robert, and S. Suciu. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial. JAMA Oncol 6, no. 4 (2020): 519–27. https://dx.doi.org/10.1001/jamaoncol.2019.5570.

Olofsson Bagge, R., L. Ny, P. A. Ascierto, F. S. Hodi, J. Larkin, C. Robert, J. Schachter, J. S. Weber, G. V. Long, and A. C. J. van Akkooi. The efficacy of immunotherapy for in-transit metastases of melanoma: An analysis of randomized controlled trials. Melanoma Res 31, no. 2 (2021): 181–85. https://dx.doi.org/10.1097/CMR.0000000000000719.

Owen, C. N., X. Bai, T. Quah, S. N. Lo, C. Allayous, S. Callaghan, C. Martinez-Vila, R. Wallace, P. Bhave, I. L. M. Reijers, N. Thompson, V. Vanella, C. L. Gerard, S. Aspeslagh, A. Labianca, A. Khattak, M. Mandala, W. Xu, B. Neyns, O. Michielin, C. U. Blank, S. J. Welsh, A. Haydon, S. Sandhu, J. Mangana, J. L. McQuade, P. A. Ascierto, L. Zimmer, D. B. Johnson, A. Arance, P. Lorigan, C. Lebbe, M. S. Carlino, R. J. Sullivan, G. V. Long, and A. M. Menzies. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32, no. 7 (2021): 917–25. https://dx.doi.org/10.1016/j.annonc.2021.03.204.

Dimitriou, F., G. V. Long, and A. M. Menzies. Novel adjuvant options for cutaneous melanoma. Ann Oncol 32, no. 7 (2021): 854–65. https://dx.doi.org/10.1016/j.annonc.2021.03.198.

Lee, H., I. P. da Silva, U. Palendira, R. A. Scolyer, G. V. Long, and J. S. Wilmott. Targeting NK cells to enhance melanoma response to immunotherapies. Cancers (Basel) 13, no. 6 (2021): 1363. https://dx.doi.org/10.3390/cancers13061363.

Rawson, R. V., C. Adhikari, C. Bierman, S. N. Lo, E. Shklovskaya, E. A. Rozeman, A. M. Menzies, A. C. J. van Akkooi, K. F. Shannon, M. Gonzalez, A. D. Guminski, M. T. Tetzlaff, J. R. Stretch, H. Eriksson, J. V. van Thienen, M. W. Wouters, Jbag Haanen, W. M. C. Klop, C. L. Zuur, W. J. van Houdt, O. E. Nieweg, S. Ch'ng, H. Rizos, R. P. M. Saw, A. J. Spillane, J. S. Wilmott, C. U. Blank, G. V. Long, B. A. van de Wiel, and R. A. Scolyer. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Ann Oncol 32, no. 6 (2021): 766–77. https://dx.doi.org/10.1016/j.annonc.2021.03.006.

Knispel, S., M. Gassenmaier, A. M. Menzies, C. Loquai, D. B. Johnson, C. Franklin, R. Gutzmer, J. C. Hassel, C. Weishaupt, T. Eigentler, B. Schilling, P. Schummer, J. Sirokay, F. Kiecker, C. N. Owen, M. I. Fleischer, C. Cann, K. C. Kahler, P. Mohr, L. Bluhm, D. Niebel, K. M. Thoms, S. M. Goldinger, L. Reinhardt, F. Meier, C. Berking, R. Reinhard, L. Susok, P. A. Ascierto, K. Drexler, C. Pfohler, J. Tietze, L. Heinzerling, E. Livingstone, S. Ugurel, G. V. Long, A. Stang, D. Schadendorf, and L. Zimmer. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. Eur J Cancer 148 (2021): 61–75. https://dx.doi.org/10.1016/j.ejca.2021.01.034.

Versluis, J. M., I. L. M. Reijers, E. A. Rozeman, A. M. Menzies, A. C. J. van Akkooi, M. W. Wouters, S. Ch'ng, R. P. M. Saw, R. A. Scolyer, B. A. van de Wiel, B. Schilling, G. V. Long, and C. U. Blank. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer 148 (2021): 51–57. https://dx.doi.org/10.1016/j.ejca.2021.02.012.

Kramer, R., A. Zaremba, A. Moreira, S. Ugurel, D. B. Johnson, J. C. Hassel, M. Salzmann, A. Gesierich, A. Weppler, L. Spain, C. Loquai, M. Dudda, C. Pfohler, A. Hepner, G. V. Long, A. M. Menzies, M. S. Carlino, M. M. Sachse, C. Lebbe, B. Baroudjian, T. Enokida, M. Tahara, M. Schlaak, K. Hayani, P. J. Brockelmann, F. Meier, L. Reinhardt, P. Friedlander, T. Eigentler, K. C. Kahler, C. Berking, L. Zimmer, and L. Heinzerling. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 147 (2021): 170–81. https://dx.doi.org/10.1016/j.ejca.2021.01.013.

Gherardin, N. A., K. Waldeck, A. Caneborg, L. G. Martelotto, S. Balachander, M. Zethoven, P. M. Petrone, A. Pattison, J. S. Wilmott, S. M. Quiñones-Parra, F. Rossello, A. Posner, A. Wong, A. M. Weppler, K. F. Shannon, A. Hong, P. M. Ferguson, V. Jakrot, J. Raleigh, A. Hatzimihalis, P. J. Neeson, P. Deleso, M. Johnston, M. Chua, J. C. Becker, S. Sandhu, G. A. McArthur, A. J. Gill, R. A. Scolyer, R. J. Hicks, D. I. Godfrey, and R. W. Tothill. γδ T cells in Merkel cell carcinomas have a proinflammatory profile prognostic of patient survival. Cancer Immunol Res 9, no. 6 (2021): 612–23. https://dx.doi.org/10.1158/2326-6066.Cir-20-0817.

Vergara, I. A., C. P. Mintoff, S. Sandhu, L. McIntosh, R. J. Young, S. Q. Wong, A. Colebatch, D. L. Cameron, J. L. Kwon, R. Wolfe, A. Peng, J. Ellul, X. Dou, C. Fedele, S. Boyle, G. M. Arnau, J. Raleigh, A. Hatzimihalis, P. Szeto, J. Mooi, D. S. Widmer, P. F. Cheng, V. Amann, R. Dummer, N. Hayward, J. S. Wilmott, R. A. Scolyer, R. J. Cho, D. Bowtell, H. Thorne, K. Alsop, S. Cordner, N. Woodford, J. Leditschke, P. O'Brien, S. J. Dawson, G. A. McArthur, G. J. Mann, M. P. Levesque, A. T. Papenfuss, and M. Shackleton. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nat Commun 12, no. 1 (2021): 1434. https://dx.doi.org/10.1038/s41467-021-21576-8.

Collgros, H., E. Rodriguez-Lomba, A. Regio Pereira, S. N. Lo, R. A. Scolyer, and P. Guitera. Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: Clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre. J Eur Acad Dermatol Venereol 35, no. 6 (2021): 1315–22. https://dx.doi.org/10.1111/jdv.17135.

Hughes, T. M., G. J. Williams, D. E. Gyorki, J. W. Kelly, J. R. Stretch, A. H. R. Varey, A. M. Hong, R. A. Scolyer, and J. F. Thompson. Desmoplastic melanoma: A review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J Eur Acad Dermatol Venereol 35, no. 6 (2021): 1290–98. https://dx.doi.org/10.1111/jdv.17154.

El Sharouni, M. A., T. Ahmed, A. H. R. Varey, S. G. Elias, A. J. Witkamp, V. Sigurdsson, K. P. M. Suijkerbuijk, P. J. van Diest, R. A. Scolyer, C. H. van Gils, J. F. Thompson, W. A. M. Blokx, and S. N. Lo. Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas. J Clin Oncol 39, no. 11 (2021): 1243–52. https://dx.doi.org/10.1200/jco.20.02446.

Garg, M., D. L. Couturier, J. Nsengimana, N. A. Fonseca, M. Wongchenko, Y. Yan, M. Lauss, G. B. Jonsson, J. Newton-Bishop, C. Parkinson, M. R. Middleton, D. T. Bishop, S. McDonald, N. Stefanos, J. Tadross, I. A. Vergara, S. N. Lo, F. Newell, J. S. Wilmott, J. F. Thompson, G. V. Long, R. A. Scolyer, P. Corrie, D. J. Adams, A. Brazma, and R. Rabbie. Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nat Commun 12, no. 1 (2021): 1137. https://dx.doi.org/10.1038/s41467-021-21207-2.

Kelly, G. M., F. Al-Ejeh, R. McCuaig, F. Casciello, N. Ahmad Kamal, B. Ferguson, A. L. Pritchard, S. Ali, I. P. da Silva, J. S. Wilmott, G. V. Long, R. A. Scolyer, S. Rao, N. K. Hayward, F. Gannon, and J. S. Lee. G9a inhibition enhances checkpoint inhibitor blockade response in melanoma. Clin Cancer Res 27, no. 9 (2021): 2624–35. https://dx.doi.org/10.1158/1078-0432.CCR-20-3463.

Syeda, M. M., J. M. Wiggins, B. C. Corless, G. V. Long, K. T. Flaherty, D. Schadendorf, P. D. Nathan, C. Robert, A. Ribas, M. A. Davies, J. J. Grob, E. Gasal, M. Squires, M. Marker, J. Garrett, J. C. Brase, and D. Polsky. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study. Lancet Oncol 22, no. 3 (2021): 370–80. https://dx.doi.org/10.1016/S1470-2045(20)30726-9.

Patrinely, J. R., Jr., B. McGuigan, S. Chandra, S. E. Fenton, A. Chowdhary, L. B. Kennedy, M. J. Mooradian, M. Palmeri, D. Portal, S. N. Horst, E. A. Scoville, G. V. Long, C. Shi, J. M. Mehnert, R. J. Sullivan, A. K. Salama, J. A. Sosman, A. M. Menzies, and D. B. Johnson. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 10, no. 1 (2021): 1875639. https://dx.doi.org/10.1080/2162402X.2021.1875639.

Rozeman, E. A., E. P. Hoefsmit, I. L. M. Reijers, R. P. M. Saw, J. M. Versluis, O. Krijgsman, P. Dimitriadis, K. Sikorska, B. A. van de Wiel, H. Eriksson, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, K. Shannon, Jbag Haanen, J. Stretch, S. Ch'ng, O. E. Nieweg, H. A. MalLo, S. Adriaansz, R. M. Kerkhoven, S. Cornelissen, A. Broeks, W. M. C. Klop, C. L. Zuur, W. J. van Houdt, D. S. Peeper, A. J. Spillane, A. C. J. van Akkooi, R. A. Scolyer, T. N. M. Schumacher, A. M. Menzies, G. V. Long, and C. U. Blank. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 27, no. 2 (2021): 256–63. https://dx.doi.org/10.1038/s41591-020-01211-7.

Simpson, R. C., E. Shanahan, R. A. Scolyer, and G. V. Long. Targeting the microbiome to overcome resistance. Cancer Cell 39, no. 2 (2021): 151–53. https://dx.doi.org/10.1016/j.ccell.2021.01.016.

El Sharouni, M. A., K. Aivazian, A. J. Witkamp, V. Sigurdsson, C. H. van Gils, R. A. Scolyer, J. F. Thompson, P. J. van Diest, and S. N. Lo. Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma. JAMA Dermatol 157, no. 2 (2021): 166–73. https://dx.doi.org/10.1001/jamadermatol.2020.5032.

Mangantig, E., S. MacGregor, M. M. Iles, R. A. Scolyer, A. E. Cust, N. K. Hayward, G. W. Montgomery, D. L. Duffy, J. F. Thompson, A. Henders, L. Bowdler, C. Rowe, G. Cadby, G. J. Mann, D. C. Whiteman, G. V. Long, S. V. Ward, K. Khosrotehrani, J. H. Barrett, and M. H. Law. Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. Hum Mol Genet 29, no. 21 (2021): 3578–87. https://dx.doi.org/10.1093/hmg/ddaa222.

Rogiers, A., I. P. da Silva, C. Tentori, C. A. Tondini, J. M. Grimes, M. H. Trager, S. Nahm, L. Zubiri, M. Manos, P. Bowling, A. Elkrief, N. Papneja, M. G. Vitale, A. A. N. Rose, J. S. W. Borgers, S. Roy, J. Mangana, T. Pimentel Muniz, T. Cooksley, J. Lupu, A. Vaisman, S. D. Saibil, M. O. Butler, A. M. Menzies, M. S. Carlino, M. Erdmann, C. Berking, L. Zimmer, D. Schadendorf, L. Pala, P. Queirolo, C. Posch, A. Hauschild, R. Dummer, J. Haanen, C. U. Blank, C. Robert, R. J. Sullivan, P. A. Ascierto, W. H. Miller, Jr., F. Stephen Hodi, K. P. M. Suijkerbuijk, K. L. Reynolds, O. E. Rahma, P. C. Lorigan, R. D. Carvajal, S. N. Lo, M. Mandala, and G. V. Long. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer 9, no. 1 (2021): e001931. https://dx.doi.org/10.1136/jitc-2020-001931.

Waldstein, C., W. Wang, S. N. Lo, Brindha Shivalingam, Gerald B. Fogarty, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, and A. M. Hong. Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective systemic therapy. Ther Radiol Oncol 5 (2021): 11–11. https://dx.doi.org/10.21037/tro-21-6.

Paver, E. C., W. A. Cooper, A. J. Colebatch, P. M. Ferguson, S. K. Hill, T. Lum, J. S. Shin, S. O'Toole, L. Anderson, R. A. Scolyer, and R. Gupta. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: A guide to immunohistochemistry implementation and interpretation. Pathology 53, no. 2 (2021): 141–56. https://dx.doi.org/10.1016/j.pathol.2020.10.007.

Robert, C., W. J. Hwu, O. Hamid, A. Ribas, J. S. Weber, A. I. Daud, F. S. Hodi, J. D. Wolchok, T. C. Mitchell, P. Hersey, R. Dronca, R. W. Joseph, C. Boutros, L. Min, G. V. Long, J. Schachter, I. Puzanov, R. Dummer, J. Lin, N. Ibrahim, S. J. Diede, M. S. Carlino, and A. M. Joshua. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer 144 (2021): 182–91. https://dx.doi.org/10.1016/j.ejca.2020.11.010.

Papadopoulos, K. P., K. Autio, T. Golan, K. Dobrenkov, E. Chartash, Q. Chen, R. Wnek, and G. V. Long. Phase I study of MK-4166, an anti-human glucocorticoid-induced TNF receptor antibody, alone or with pembrolizumab in advanced solid tumors. Clin Cancer Res 27, no. 7 (2021): 1904–11. https://dx.doi.org/10.1158/1078-0432.CCR-20-2886.

Smith, A. L., C. G. Watts, S. Robinson, H. Schmid, C. Goumas, V. J. Mar, J. F. Thompson, F. Rapport, the Australian Melanoma Centre of Research Excellence Study Group, and A. E. Cust. Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: A mixed methods study. Australas J Dermatol 62, no. 2 (2021): 168–76. https://dx.doi.org/10.1111/ajd.13518.

2020

Ferrucci, P. F., A. M. Di Giacomo, M. Del Vecchio, V. Atkinson, H. Schmidt, J. Schachter, P. Queirolo, G. V. Long, R. Stephens, I. M. Svane, M. Lotem, M. Abu-Amna, E. Gasal, R. Ghori, S. J. Diede, E. S. Croydon, A. Ribas, P. A. Ascierto, and KEYNOTE International Team. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer 8, no. 2 (2020): e001806. https://dx.doi.org/10.1136/jitc-2020-001806.

Hoefsmit, E. P., E. A. Rozeman, T. M. Van, P. Dimitriadis, O. Krijgsman, J. W. Conway, I. P. da Silva, J. E. van der Wal, S. L. C. Ketelaars, K. Bresser, A. Broeks, R. M. Kerkhoven, J. W. Reeves, S. Warren, P. Kvistborg, R. A. Scolyer, E. W. Kapiteijn, D. S. Peeper, G. V. Long, T. N. M. Schumacher, and C. U. Blank. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J Immunother Cancer 8, no. 2 (2020): e001501. https://dx.doi.org/10.1136/jitc-2020-001501.

El Sharouni, M. A., M. D. Stodell, T. Ahmed, K. P. M. Suijkerbuijk, A. E. Cust, A. J. Witkamp, V. Sigurdsson, P. J. van Diest, R. A. Scolyer, J. F. Thompson, C. H. van Gils, and S. N. Lo. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Ann Oncol 32, no. 3 (2021): 375–83. https://dx.doi.org/10.1016/j.annonc.2020.11.015.

Hong, A. M., C. Waldstein, B. Shivalingam, M. S. Carlino, V. Atkinson, R. F. Kefford, G. A. McArthur, A. M. Menzies, J. F. Thompson, and G. V. Long. Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. Eur J Cancer 142 (2021): 10–17. https://dx.doi.org/10.1016/j.ejca.2020.10.013.

Shklovskaya, E., J. H. Lee, S. Y. Lim, A. Stewart, B. Pedersen, P. Ferguson, R. P. Saw, J. F. Thompson, B. Shivalingam, M. S. Carlino, R. A. Scolyer, A. M. Menzies, G. V. Long, R. F. Kefford, and H. Rizos. Tumor MHC expression guides first-line immunotherapy selection in melanoma. Cancers (Basel) 12, no. 11 (2020): 3374. https://dx.doi.org/10.3390/cancers12113374.

Edwards, J. J., P. M. Ferguson, S. N. Lo, I. P. da Silva, A. J. Colebatch, H. Lee, R. P. M. Saw, J. F. Thompson, A. M. Menzies, G. V. Long, F. Newell, J. V. Pearson, N. Waddell, N. K. Hayward, P. A. Johansson, G. J. Mann, R. A. Scolyer, U. Palendira, and J. S. Wilmott. Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas. Cancer Immunol Res 8, no. 11 (2020): 1346–53. https://dx.doi.org/10.1158/2326-6066.CIR-19-0835.

Clark, M. E., H. Rizos, M. R. Pereira, A. C. McEvoy, G. Marsavela, L. Calapre, K. Meehan, O. Ruhen, M. A. Khattak, T. M. Meniawy, G. V. Long, M. S. Carlino, A. M. Menzies, M. Millward, M. Ziman, and E. S. Gray. Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget 11, no. 44 (2020): 4016–27. https://dx.doi.org/10.18632/oncotarget.27790.

Nahar, K. J., R. V. Rawson, T. Ahmed, S. Tattersall, N. Sandanayake, C. J. Kiely, S. Lo, M. Carlino, U. Palendira, R. A. Scolyer, G. V. Long, and A. M. Menzies. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. J Immunother Cancer 8, no. 2 (2020): e001488. https://dx.doi.org/10.1136/jitc-2020-001488.

Varey, A. H. R., S. N. Lo, R. A. Scolyer, and J. F. Thompson. Predicting sentinel node status in patients with melanoma: Does gene expression profiling improve accuracy? , JCO Precis Oncol 4 (2020): 990–91. https://dx.doi.org/10.1200/po.20.00160.

Bhave, P., L. Pallan, G. V. Long, A. M. Menzies, V. Atkinson, J. V. Cohen, R. J. Sullivan, V. Chiarion-Sileni, M. Nyakas, K. Kahler, A. Hauschild, R. Plummer, C. Trojaniello, P. A. Ascierto, L. Zimmer, D. Schadendorf, C. Allayous, C. Lebbe, A. Maurichi, M. Santinami, S. Roy, C. Robert, T. Lesimple, S. Patel, J. M. Versluis, C. U. Blank, A. Khattak, A. van der Westhuizen, M. S. Carlino, M. Shackleton, and A. Haydon. Melanoma recurrence patterns and management after adjuvant targeted therapy: A multicentre analysis. Br J Cancer 124, no. 3 (2021): 574–80. https://dx.doi.org/10.1038/s41416-020-01121-y.

Gide, T. N., I. P. da Silva, C. Quek, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. F. Thompson, M. Batten, G. V. Long, R. A. Scolyer, and J. S. Wilmott. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. Oncoimmunology 9, no. 1 (2020): 1659093. https://dx.doi.org/10.1080/2162402X.2019.1659093.

Marsavela, G., J. Lee, L. Calapre, S. Q. Wong, M. R. Pereira, A. C. McEvoy, A. L. Reid, C. Robinson, L. Warburton, A. Abed, M. A. Khattak, T. M. Meniawy, S. J. Dawson, S. Sandhu, M. S. Carlino, A. M. Menzies, R. A. Scolyer, G. V. Long, B. Amanuel, M. Millward, M. R. Ziman, H. Rizos, and E. S. Gray. Circulating tumor DNA predicts outcome from first- but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy. Clin Cancer Res 26, no. 22 (2020): 5926–33. https://dx.doi.org/10.1158/1078-0432.CCR-20-2251.

Newell, F., J. S. Wilmott, P. A. Johansson, K. Nones, V. Addala, P. Mukhopadhyay, N. Broit, C. M. Amato, R. Van Gulick, S. H. Kazakoff, A. M. Patch, L. T. Koufariotis, V. Lakis, C. Leonard, S. Wood, O. Holmes, Q. Xu, K. Lewis, T. Medina, R. Gonzalez, R. P. M. Saw, A. J. Spillane, J. R. Stretch, R. V. Rawson, P. M. Ferguson, T. J. Dodds, J. F. Thompson, G. V. Long, M. P. Levesque, W. A. Robinson, J. V. Pearson, G. J. Mann, R. A. Scolyer, N. Waddell, and N. K. Hayward. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun 11, no. 1 (2020): 5259. Accessed 2025/10/14. https://dx.doi.org/10.1038/s41467-020-18988-3.

Braun, M., A. R. Aguilera, A. Sundarrajan, D. Corvino, K. Stannard, S. Krumeich, I. Das, L. G. Lima, L. G. Meza Guzman, K. Li, R. Li, N. Salim, M. V. Jorge, S. Ham, G. Kelly, F. Vari, A. Lepletier, A. Raghavendra, S. Pearson, J. Madore, S. Jacquelin, M. Effern, B. Quine, L. T. Koufariotis, M. Casey, K. Nakamura, E. Y. Seo, M. Holzel, M. Geyer, G. Kristiansen, T. Taheri, E. Ahern, B. G. M. Hughes, J. S. Wilmott, G. V. Long, R. A. Scolyer, M. D. Batstone, J. Landsberg, D. Dietrich, O. T. Pop, L. Flatz, W. C. Dougall, A. Veillette, S. E. Nicholson, A. Moller, R. J. Johnston, L. Martinet, M. J. Smyth, and T. Bald. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity 53, no. 4 (2020): 805–23. https://dx.doi.org/10.1016/j.immuni.2020.09.010.

Law, M. H., L. G. Aoude, D. L. Duffy, G. V. Long, P. A. Johansson, A. L. Pritchard, K. Khosrotehrani, G. J. Mann, G. W. Montgomery, M. M. Iles, A. E. Cust, J. M. Palmer, the Melanoma GWAS Consortium, K. F. Shannon, A. J. Spillane, J. R. Stretch, J. F. Thompson, R. P. M. Saw, R. A. Scolyer, N. G. Martin, N. K. Hayward, and S. MacGregor. Multiplex melanoma families are enriched for polygenic risk. Hum Mol Genet 29, no. 17 (2020): 2976–85. https://dx.doi.org/10.1093/hmg/ddaa156.

Rabbie, R., P. Ferguson, K. Wong, D. L. Couturier, U. Moran, C. Turner, P. Emanuel, K. Haas, J. M. Saunus, M. R. Davidson, S. R. Lakhani, B. Shivalingam, G. V. Long, C. Parkinson, I. Osman, R. A. Scolyer, P. Corrie, and D. J. Adams. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. Br J Cancer 124, no. 1 (2021): 156–60. https://dx.doi.org/10.1038/s41416-020-01090-2.

Dummer, R., C. Lebbe, V. Atkinson, M. Mandala, P. D. Nathan, A. Arance, E. Richtig, N. Yamazaki, C. Robert, D. Schadendorf, H. A. Tawbi, P. A. Ascierto, A. Ribas, K. T. Flaherty, N. Pakhle, C. D. Campbell, D. Gusenleitner, A. Masood, J. C. Brase, E. Gasal, and G. V. Long. Combined PD-1, BRAF, and MEK inhibition in advanced BRAF-mutant melanoma: Safety run-in and biomarker cohorts of COMBI-i. Nat Med 26, no. 10 (2020): 1557–63. https://dx.doi.org/10.1038/s41591-020-1082-2.

Fischer, G. M., F. C. L. Carapeto, A. Y. Joon, L. E. Haydu, H. Chen, F. Wang, J. S. Van Arnam, J. L. McQuade, K. Wani, J. M. Kirkwood, J. F. Thompson, M. T. Tetzlaff, A. J. Lazar, H. A. Tawbi, J. E. Gershenwald, R. A. Scolyer, G. V. Long, and M. A. Davies. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med 9, no. 22 (2020): 8650–61. https://dx.doi.org/10.1002/cam4.3474.

Robert, C., G. V. Long, B. Brady, C. Dutriaux, A. M. Di Giacomo, L. Mortier, P. Rutkowski, J. C. Hassel, C. M. McNeil, E. A. Kalinka, C. Lebbe, J. Charles, M. M. Hernberg, K. J. Savage, V. Chiarion-Sileni, C. Mihalcioiu, C. Mauch, A. Arance, F. Cognetti, L. Ny, H. Schmidt, D. Schadendorf, H. Gogas, J. Zoco, S. Re, P. A. Ascierto, and V. Atkinson. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol 38, no. 33 (2020): 3937–46. https://dx.doi.org/10.1200/JCO.20.00995.

Crouch, G., S. Sinha, S. N. Lo, R. P. M. Saw, K. K. Lee, J. Stretch, K. Shannon, P. Guitera, R. A. Scolyer, J. F. Thompson, and S. Ch'ng. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol 47, no. 5 (2021): 1145–51. https://dx.doi.org/10.1016/j.ejso.2020.09.028.

Bailey, M. H., W. U. Meyerson, L. J. Dursi, L. B. Wang, G. Dong, W. W. Liang, A. Weerasinghe, S. Li, Y. Li, S. Kelso, the MC3 Working Group, the PCAWG Novel Somatic Mutation Calling Methods Working Group, G. Saksena, K. Ellrott, M. C. Wendl, D. A. Wheeler, G. Getz, J. T. Simpson, M. B. Gerstein, L. Ding, and the PCAWG Consortium. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11, no. 1 (2020): 4748. https://dx.doi.org/10.1038/s41467-020-18151-y.

Eggermont, A. M. M., C. U. Blank, M. Mandala, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, R. Koornstra, L. Hernandez-Aya, A. M. di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, P. C. Lorigan, A. C. J. van Akkooi, C. Krepler, N. Ibrahim, S. Marreaud, M. Kicinski, S. Suciu, and C. Robert. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J Clin Oncol 38, no. 33 (2020): 3925–36. https://dx.doi.org/10.1200/JCO.20.02110.

Hultin, S., K. J. Nahar, A. M. Menzies, G. V. Long, S. L. Fernando, V. Atkinson, J. Cebon, and M. G. Wong. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: A retrospective case series report. BMC Nephrol 21, no. 1 (2020): 391. https://dx.doi.org/10.1186/s12882-020-02044-9.

Dummer, R., A. Hauschild, M. Santinami, V. Atkinson, M. Mandala, J. M. Kirkwood, V. Chiarion Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, T. Lesimple, R. Plummer, K. Dasgupta, E. Gasal, M. Tan, G. V. Long, and D. Schadendorf. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 383, no. 12 (2020): 1139–48. https://dx.doi.org/10.1056/NEJMoa2005493.

Elder, D. E., G. Karakousis, and R. A. Scolyer. Staging for melanoma – toward a new paradigm? , J Natl Cancer Inst 112, no. 9 (2020): 873–74. https://dx.doi.org/10.1093/jnci/djaa009.

Grossman, D., N. Okwundu, E. K. Bartlett, M. A. Marchetti, M. Othus, D. G. Coit, R. I. Hartman, S. A. Leachman, E. G. Berry, L. Korde, S. J. Lee, M. Bar-Eli, M. Berwick, T. Bowles, E. I. Buchbinder, E. M. Burton, E. Y. Chu, C. Curiel-Lewandrowski, J. A. Curtis, A. Daud, D. C. Deacon, L. K. Ferris, J. E. Gershenwald, K. F. Grossmann, S. Hu-Lieskovan, J. Hyngstrom, J. M. Jeter, R. L. Judson-Torres, K. L. Kendra, C. C. Kim, J. M. Kirkwood, D. H. Lawson, P. D. Leming, G. V. Long, A. A. Marghoob, J. M. Mehnert, M. E. Ming, K. C. Nelson, D. Polsky, R. A. Scolyer, E. A. Smith, V. K. Sondak, M. S. Stark, J. A. Stein, J. A. Thompson, J. F. Thompson, S. S. Venna, M. L. Wei, and S. M. Swetter. Prognostic gene expression profiling in cutaneous melanoma: Identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatol 156, no. 9 (2020): 1004–11. https://dx.doi.org/10.1001/jamadermatol.2020.1729.

Li, C. H., S. D. Prokopec, R. X. Sun, F. Yousif, N. Schmitz, PCAWG Tumour Subtypes and Clinical Translation, P. C. Boutros, and the PCAWG Consortium. Sex differences in oncogenic mutational processes. Nat Commun 11, no. 1 (2020): 4330. https://dx.doi.org/10.1038/s41467-020-17359-2.

Sasson, S. C., J. J. Zaunders, K. J. Nahar, C. M. L. Munier, B. P. Fairfax, A. Olsson-Brown, C. Jolly, S. A. Read, G. Ahlenstiel, U. Palendira, R. A. Scolyer, M. S. Carlino, M. J. Payne, V. T. F. Cheung, T. Gupta, P. Klenerman, G. V. Long, O. Brain, A. M. Menzies, and A. D. Kelleher. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clin Exp Immunol 202, no. 3 (2020): 335–52. https://dx.doi.org/10.1111/cei.13502.

Geva, R., M. Voskoboynik, K. Dobrenkov, K. Mayawala, J. Gwo, R. Wnek, E. Chartash, and G. V. Long. First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer 126, no. 22 (2020): 4926–35. https://dx.doi.org/10.1002/cncr.33133.

Delahunt, B., B. Neill, J. R. Burnett, and R. A. Scolyer. Publication metrics: What do they mean? , Pathology 52, no. 6 (2020): 619–20. https://dx.doi.org/10.1016/j.pathol.2020.07.002.

Kashani-Sabet, M., J. R. Miller, 3rd, S. N. Lo, M. Nosrati, J. R. Stretch, K. F. Shannon, A. J. Spillane, R. P. M. Saw, J. E. Cleaver, K. B. Kim, S. P. Leong, J. F. Thompson, and R. A. Scolyer. Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer 126, no. 21 (2020): 4717–25. https://dx.doi.org/10.1002/cncr.33088.

Diefenbach, R. J., J. H. Lee, A. M. Menzies, M. S. Carlino, G. V. Long, R. P. M. Saw, J. R. Howle, A. J. Spillane, R. A. Scolyer, R. F. Kefford, and H. Rizos. Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Cancers (Basel) 12, no. 8 (2020): 2228. https://dx.doi.org/10.3390/cancers12082228.

Puzanov, I., A. Ribas, C. Robert, J. Schachter, M. Nyakas, A. Daud, A. Arance, M. S. Carlino, S. J. O'Day, G. V. Long, K. A. Margolin, R. Dummer, D. Schadendorf, J. Lutzky, P. A. Ascierto, A. Tarhini, J. Lin, R. Mogg, B. Homet Moreno, N. Ibrahim, and O. Hamid. Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma: Pooled analysis of 3 clinical trials. JAMA Oncol 6, no. 8 (2020): 1256–64. https://dx.doi.org/10.1001/jamaoncol.2020.2288.

Tetzlaff, M. T., C. Adhikari, S. Lo, R. V. Rawson, R. N. Amaria, A. M. Menzies, J. S. Wilmott, P. M. Ferguson, M. I. Ross, A. J. Spillane, K. A. Vu, J. Ma, J. Ning, L. E. Haydu, R. P. M. Saw, J. A. Wargo, H. A. Tawbi, J. E. Gershenwald, G. V. Long, M. A. Davies, and R. A. Scolyer. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol 31, no. 11 (2020): 1569–79. https://dx.doi.org/10.1016/j.annonc.2020.07.016.

Khushalani, N. I., A. Diab, P. A. Ascierto, J. Larkin, S. Sandhu, M. Sznol, H. B. Koon, A. Jarkowski, M. Zhou, P. Statkevich, W. J. Geese, and G. V. Long. Bempegaldesleukin plus nivolumab in untreated, unresectable, or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncol 16, no. 28 (2020): 2165–75. https://dx.doi.org/10.2217/fon-2020-0351.

Carlino, M. S., A. M. Menzies, V. Atkinson, J. S. Cebon, M. B. Jameson, B. M. Fitzharris, C. M. McNeil, A. G. Hill, A. Ribas, M. B. Atkins, J. A. Thompson, W. J. Hwu, F. S. Hodi, A. D. Guminski, R. Kefford, H. Wu, N. Ibrahim, B. Homet Moreno, and G. V. Long. Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res 26, no. 19 (2020): 5086–91. https://dx.doi.org/10.1158/1078-0432.CCR-20-0177.

Zhang, X., L. Yang, P. Szeto, G. K. Abali, Y. Zhang, A. Kulkarni, K. Amarasinghe, J. Li, I. A. Vergara, R. Molania, A. T. Papenfuss, C. McLean, M. Shackleton, and K. F. Harvey. The hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene 39, no. 30 (2020): 5267–81. https://dx.doi.org/10.1038/s41388-020-1362-9.

Lo, S. N., J. Ma, R. A. Scolyer, L. E. Haydu, J. R. Stretch, R. P. M. Saw, O. E. Nieweg, K. F. Shannon, A. J. Spillane, S. Ch'ng, G. J. Mann, J. E. Gershenwald, J. F. Thompson, and A. H. R. Varey. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: The Melanoma Institute Australia nomogram. J Clin Oncol 38, no. 24 (2020): 2719–27. https://dx.doi.org/10.1200/jco.19.02362.

Long, G. V., and R. A. Scolyer. Translating basic cancer discoveries to the clinic: A critical nexus. Cancer Cell 37, no. 6 (2020): 735–37. https://dx.doi.org/10.1016/j.ccell.2020.05.017.

Cipponi, A., D. L. Goode, J. Bedo, M. J. McCabe, M. Pajic, D. R. Croucher, A. G. Rajal, S. R. Junankar, D. N. Saunders, P. Lobachevsky, A. T. Papenfuss, D. Nessem, M. Nobis, S. C. Warren, P. Timpson, M. Cowley, A. C. Vargas, M. R. Qiu, D. G. Generali, S. Keerthikumar, U. Nguyen, N. M. Corcoran, G. V. Long, J. Y. Blay, and D. M. Thomas. MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. Science 368, no. 6495 (2020): 1127–31. https://dx.doi.org/10.1126/science.aau8768.

Atkinson, V., S. Sandhu, G. Hospers, G. V. Long, M. Aglietta, P. F. Ferrucci, S. Tulyte, G. C. A. Cappellini, V. Soriano, S. Ali, A. Poprach, A. Cesas, D. Rodriguez-Abreu, M. Lau, E. de Jong, P. Legenne, D. Stein, B. King, and J. V. van Thienen. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Res 30, no. 3 (2020): 261–67. https://dx.doi.org/10.1097/CMR.0000000000000654.

Watts, C. G., A. L. Smith, S. Robinson, C. S. Chang, C. Goumas, H. Schmid, J. W. Kelly, A. M. Hong, R. A. Scolyer, G. V. Long, A. J. Spillane, M. Henderson, D. E. Gyorki, V. J. Mar, R. L. Morton, R. P. Saw, A. H. Varey, G. J. Mann, J. F. Thompson, and A. E. Cust. Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Aust J Gen Pract 49, no. 6 (2020): 355–62. https://dx.doi.org/10.31128/AJGP-10-19-5138.

Johansson, P. A., K. Brooks, F. Newell, J. M. Palmer, J. S. Wilmott, A. L. Pritchard, N. Broit, S. Wood, M. S. Carlino, C. Leonard, L. T. Koufariotis, V. Nathan, A. B. Beasley, M. Howlie, R. Dawson, H. Rizos, C. W. Schmidt, G. V. Long, H. Hamilton, J. F. Kiilgaard, T. Isaacs, E. S. Gray, O. J. Rolfe, J. J. Park, A. Stark, G. J. Mann, R. A. Scolyer, J. V. Pearson, N. van Baren, N. Waddell, K. W. Wadt, L. A. McGrath, S. K. Warrier, W. Glasson, and N. K. Hayward. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat Commun 11, no. 1 (2020): 2408. https://dx.doi.org/10.1038/s41467-020-16276-8.

Ziemys, A., M. Kim, A. M. Menzies, J. S. Wilmott, G. V. Long, R. A. Scolyer, L. Kwong, A. Holder, and G. Boland. Integration of digital pathologic and transcriptomic analyses connects tumor-infiltrating lymphocyte spatial density with clinical response to BRAF inhibitors. Front Oncol 10 (2020): 757. https://dx.doi.org/10.3389/fonc.2020.00757.

Owen, C. N., A. N. Shoushtari, D. Chauhan, D. J. Palmieri, B. Lee, M. W. Rohaan, J. Mangana, V. Atkinson, F. Zaman, A. Young, C. Hoeller, P. Hersey, R. Dummer, M. A. Khattak, M. Millward, S. P. Patel, A. Haydon, D. B. Johnson, S. Lo, C. U. Blank, S. Sandhu, M. S. Carlino, J. M. G. Larkin, A. M. Menzies, and G. V. Long. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann Oncol 31, no. 8 (2020): 1075–82. https://dx.doi.org/10.1016/j.annonc.2020.04.471.

Harris, C. G., S. N. Lo, T. Ahmed, R. A. Scolyer, P. M. Ferguson, R. Z. Karim, T. K. Lam, K. K. Lee, K. F. Shannon, A. J. Spillane, J. R. Stretch, J. F. Thompson, and R. P. Saw. Primary dermal melanoma: Clinical behaviour, prognosis and treatment. Eur J Surg Oncol 46, no. 11 (2020): 2131–39. https://dx.doi.org/10.1016/j.ejso.2020.04.043.

Nan Tie, E., J. Lai-Kwon, M. A. Rtshiladze, L. Na, J. Bozzi, T. Read, V. Atkinson, G. Au-Yeung, G. V. Long, G. A. McArthur, S. Sandhu, R. Saw, E. Walpole, A. Menzies, M. Smithers, and D. E. Gyorki. Efficacy of immune checkpoint inhibitors for in-transit melanoma. J Immunother Cancer 8, no. 1 (2020): e000440. https://dx.doi.org/10.1136/jitc-2019-000440.

Lepletier, A., J. Madore, J. S. O'Donnell, R. L. Johnston, X. Y. Li, E. McDonald, E. Ahern, A. Kuchel, M. Eastgate, S. A. Pearson, D. Mallardo, P. A. Ascierto, D. Massi, B. Merelli, M. Mandala, J. S. Wilmott, A. M. Menzies, C. Leduc, J. Stagg, B. Routy, G. V. Long, R. A. Scolyer, T. Bald, N. Waddell, W. C. Dougall, M. W. L. Teng, and M. J. Smyth. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clin Cancer Res 26, no. 14 (2020): 3671–81. https://dx.doi.org/10.1158/1078-0432.CCR-19-3925.

Landi, M. T., D. T. Bishop, and S. MacGregor, M. J. Machiela, A. J. Stratigos, P. Ghiorzo, M. Brossard, D. Calista, J. Choi, M. C. Fargnoli, T. Zhang, M. Rodolfo, A. J. Trower, C. Menin, J. Martinez, A. Hadjisavvas, L. Song, I. Stefanaki, R. A. Scolyer, R. Yang, A. M. Goldstein, M. Potrony, K. P. Kypreou, L. Pastorino, P. Queirolo, C. Pellegrini, L. Cattaneo, M. Zawistowski, P. Gimenez-Xavier, A. Rodriguez, L. Elefanti, S. Manoukian, L. Rivoltini, B. H. Smith, M. A. Loizidou, L. Del Regno, D. Massi, M. Mandala, K. Khosrotehrani, L. A. Akslen, C. I. Amos, P. A. Andresen, M. F. Avril, E. Azizi, H. P. Soyer, V. Bataille, B. Dalmasso, L. M. Bowdler, K. P. Burdon, W. V. Chen, V. Codd, J. E. Craig, T. Debniak, M. Falchi, S. Fang, E. Friedman, S. Simi, P. Galan, Z. Garcia-Casado, E. M. Gillanders, S. Gordon, A. Green, N. A. Gruis, J. Hansson, M. Harland, J. Harris, P. Helsing, A. Henders, M. Hocevar, V. Hoiom, D. Hunter, C. Ingvar, R. Kumar, J. Lang, G. M. Lathrop, J. E. Lee, X. Li, J. Lubinski, R. M. Mackie, M. Malt, J. Malvehy, K. McAloney, H. Mohamdi, A. Molven, E. K. Moses, R. E. Neale, S. Novakovic, D. R. Nyholt, H. Olsson, N. Orr, L. G. Fritsche, J. A. Puig-Butille, A. A. Qureshi, G. L. Radford-Smith, J. Randerson-Moor, C. Requena, C. Rowe, N. J. Samani, M. Sanna, D. Schadendorf, H. J. Schulze, L. A. Simms, M. Smithers, F. Song, A. J. Swerdlow, N. van der Stoep, N. A. Kukutsch, A. Visconti, L. Wallace, S. V. Ward, L. Wheeler, R. A. Sturm, A. Hutchinson, K. Jones, M. Malasky, A. Vogt, W. Zhou, K. A. Pooley, D. E. Elder, J. Han, B. Hicks, N. K. Hayward, P. A. Kanetsky, C. Brummett, G. W. Montgomery, C. M. Olsen, C. Hayward, A. M. Dunning, N. G. Martin, E. Evangelou, G. J. Mann, G. V. Long, P. D. P. Pharoah, D. F. Easton, J. H. Barrett, A. E. Cust, G. Abecasis, D. L. Duffy, D. C. Whiteman, H. Gogas, A. De Nicolo, M. A. Tucker, J. A. Newton-Bishop, the GenoMEL Consortium, Q-MEGA QTWIN Investigators, the Athens Melanoma Study Group, 23andMe, the SDH Study Group, IBD Investigators, Essen-Heidelberg Investigators, AMFS Investigators, the MelaNostrum Consortium, K. Peris, S. J. Chanock, F. Demenais, K. M. Brown, S. Puig, E. Nagore, J. Shi, M. M. Iles, and M. H. Law. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet 52, no. 5 (2020): 494–504. https://dx.doi.org/10.1038/s41588-020-0611-8.

Lee, J. H., A. M. Menzies, M. S. Carlino, A. C. McEvoy, S. Sandhu, A. M. Weppler, R. J. Diefenbach, S. J. Dawson, R. F. Kefford, M. J. Millward, Z. Al-Ogaili, T. Tra, E. S. Gray, S. Q. Wong, R. A. Scolyer, G. V. Long, and H. RizoS. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res 26, no. 15 (2020): 4064–71. https://dx.doi.org/10.1158/1078-0432.CCR-19-3926.

Lee, J. H., E. Shklovskaya, S. Y. Lim, M. S. Carlino, A. M. Menzies, A. Stewart, B. Pedersen, M. Irvine, S. Alavi, J. Y. H. Yang, D. Strbenac, R. P. M. Saw, J. F. Thompson, J. S. Wilmott, R. A. Scolyer, G. V. Long, R. F. Kefford, and H. Rizos. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nat Commun 11, no. 1 (2020): 1897. https://dx.doi.org/10.1038/s41467-020-15726-7.

Barnhill, R., P. J. van Dam, P. Vermeulen, G. Champenois, A. Nicolas, R. V. Rawson, J. S. Wilmott, J. F. Thompson, G. V. Long, N. Cassoux, S. Roman-Roman, K. J. Busam, R. A. Scolyer, A. J. Lazar, and C. Lugassy. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: Frequency, characteristics, and robust prognostic value. J Pathol Clin Res 6, no. 3 (2020): 195–206. https://dx.doi.org/10.1002/cjp2.161.

Versluis, J. M., G. V. Long, and C. U. Blank. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 26, no. 4 (2020): 475–84. https://dx.doi.org/10.1038/s41591-020-0829-0.

Menzies, S. W., S. Liyanarachchi, E. Coates, A. Smith, C. Cooke-Yarborough, S. N. Lo, B. Armstrong, R. A. Scolyer, and P. Guitera. Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Res 30, no. 2 (2020): 193–97. https://dx.doi.org/10.1097/cmr.0000000000000619.

Ugurel, S., J. Rohmel, P. A. Ascierto, J. C. Becker, K. T. Flaherty, J. J. Grob, A. Hauschild, J. Larkin, E. Livingstone, G. V. Long, P. Lorigan, G. A. McArthur, A. Ribas, C. Robert, L. Zimmer, D. Schadendorf, and C. Garbe. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition – update 2019. Eur J Cancer 130 (2020): 126–38. https://dx.doi.org/10.1016/j.ejca.2020.02.021.

Pirozyan, M. R., H. M. McGuire, A. A. Emran, H. Y. Tseng, J. C. Tiffen, J. H. Lee, M. S. Carlino, A. M. Menzies, G. V. Long, R. A. Scolyer, B. Fazekas de St Groth, and P. Hersey. Pretreatment innate cell populations and CD4 T cells in blood are associated with response to immune checkpoint blockade in melanoma patients. Front Immunol 11 (2020): 372. https://dx.doi.org/10.3389/fimmu.2020.00372.

Jackett, L. A., A. J. Colebatch, R. V. Rawson, P. M. Ferguson, J. F. Thompson, S. W. McCarthy, J. S. Wilmott, and R. A. Scolyer. Molecular profiling of noncoding mutations distinguishes nevoid melanomas from mitotically active nevi in pregnancy. Am J Surg Pathol 44, no. 3 (2020): 357–67. https://dx.doi.org/10.1097/pas.0000000000001406.

Rapport, F., A. L. Smith, A. E. Cust, G. J. Mann, C. G. Watts, D. E. Gyorki, M. Henderson, A. M. Hong, J. W. Kelly, G. V. Long, V. J. Mar, R. L. Morton, R. P. Saw, R. A. Scolyer, A. J. Spillane, J. F. Thompson, and J. Braithwaite. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: Protocol paper for a mixed methods study. BMJ Open 10, no. 2 (2020): e032636. https://dx.doi.org/10.1136/bmjopen-2019-032636.

Malesu, R., A. J. Martin, J. G. Lyons, R. A. Scolyer, A. C. Chen, C. A. McKenzie, J. Madore, G. M. Halliday, and D. L. Damian. Nicotinamide for skin cancer chemoprevention: Effects of nicotinamide on melanoma in vitro and in vivo. Photochem Photobiol Sci 19, no. 2 (2020): 171–79. https://dx.doi.org/10.1039/c9pp00388f.

Elder, D. E., B. C. Bastian, I. A. Cree, D. Massi, and R. A. Scolyer. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144, no. 4 (2020): 500–22. https://dx.doi.org/10.5858/arpa.2019-0561-RA.

Niebling, M. G., L. E. Haydu, S. N. Lo, R. V. Rawson, L. G. E. Lamboo, J. T. Stollman, R. Z. Karim, J. F. Thompson, and R. A. Scolyer. The prognostic significance of microsatellites in cutaneous melanoma. Mod Pathol 33, no. 7 (2020): 1369–79. https://dx.doi.org/10.1038/s41379-020-0500-9.

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, no. 7793 (2020): 82–93. https://dx.doi.org/10.1038/s41586-020-1969-6.

Dummer, R., J. C. Brase, J. Garrett, C. D. Campbell, E. Gasal, M. Squires, D. Gusenleitner, M. Santinami, V. Atkinson, M. Mandala, V. Chiarion-Sileni, K. Flaherty, J. Larkin, C. Robert, R. Kefford, J. M. Kirkwood, A. Hauschild, D. Schadendorf, and G. V. Long. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): Exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol 21, no. 3 (2020): 358–72. https://dx.doi.org/10.1016/S1470-2045(20)30062-0.

Haydu, L. E., S. N. Lo, J. L. McQuade, R. N. Amaria, J. Wargo, M. I. Ross, J. N. Cormier, A. Lucci, J. E. Lee, S. D. Ferguson, R. P. M. Saw, A. J. Spillane, K. F. Shannon, J. R. Stretch, P. Hwu, S. P. Patel, A. Diab, M. K. K. Wong, I. C. Glitza Oliva, H. Tawbi, M. S. Carlino, A. M. Menzies, G. V. Long, A. J. Lazar, M. T. Tetzlaff, R. A. Scolyer, J. E. Gershenwald, J. F. Thompson, and M. A. Davies. Cumulative incidence and predictors of CNS metastasis for patients with American Joint Committee on Cancer 8th Edition stage III melanoma. J Clin Oncol 38, no. 13 (2020): 1429–41. https://dx.doi.org/10.1200/JCO.19.01508.

Pruessmann, W., J. Rytlewski, J. S. Wilmott, M. C. Mihm, Jr., G. H. Attrill, B. Dyring-Andersen, P. Fields, Q. Zhan, A. J. Colebatch, P. M. Ferguson, J. F. Thompson, K. Kallenbach, E. Yusko, R. A. Clark, H. Robins, R. A. Scolyer, and T. S. Kupper. Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nat Cancer 1, no. 2 (2020): 197–209. https://dx.doi.org/10.1038/s43018-019-0019-5.

da Silva, I. P., S. Lo, C. Quek, M. Gonzalez, M. S. Carlino, G. V. Long, and A. M. Menzies. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer 126, no. 1 (2020): 86–97. https://dx.doi.org/10.1002/cncr.32522.

House, I. G., P. Savas, J. Lai, A. X. Y. Chen, A. J. Oliver, Z. L. Teo, K. L. Todd, M. A. Henderson, L. Giuffrida, E. V. Petley, K. Sek, S. Mardiana, T. N. Gide, C. Quek, R. A. Scolyer, G. V. Long, J. S. Wilmott, S. Loi, P. K. Darcy, and P. A. Beavis. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res 26, no. 2 (2020): 487–504. https://dx.doi.org/10.1158/1078-0432.CCR-19-1868.

Luke, J. J., P. A. Ascierto, M. S. Carlino, J. E. Gershenwald, J. J. Grob, A. Hauschild, J. M. Kirkwood, G. V. Long, P. Mohr, C. Robert, M. Ross, R. A. Scolyer, C. H. Yoon, A. Poklepovic, P. Rutkowski, J. R. Anderson, S. Ahsan, N. Ibrahim, and M. Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol 16, no. 3 (2020): 4429–38. https://dx.doi.org/10.2217/fon-2019-0666.

2019

Lee, H., C. Quek, I. P. da Silva, A. Tasker, M. Batten, H. Rizos, S. Y. Lim, T. Nur Gide, P. Shang, G. H. Attrill, J. Madore, J. Edwards, M. S. Carlino, A. Guminski, R. P. M. Saw, J. F. Thompson, P. M. Ferguson, U. Palendira, A. M. Menzies, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients." Oncoimmunology 8, no. 2 (Oct 2019): e1537581. https://dx.doi.org/10.1080/2162402X.2018.1537581.

Colebatch, A. J., P. Ferguson, F. Newell, S. H. Kazakoff, T. Witkowski, A. Dobrovic, P. A. Johansson, R. P. M. Saw, J. R. Stretch, G. A. McArthur, G. V. Long, J. F. Thompson, J. V. Pearson, G. J. Mann, N. K. Hayward, N. Waddell, R. A. Scolyer, and J. S. Wilmott. "Molecular genomic profiling of melanocytic nevi." J Invest Dermatol 139, no. 8 (Aug 2019): 1762–68. https://dx.doi.org/10.1016/j.jid.2018.12.033.

Rozeman, E. A., A. M. Menzies, A. C. J. van Akkooi, C. Adhikari, C. Bierman, B. A. van de Wiel, R. A. Scolyer, O. Krijgsman, K. Sikorska, H. Eriksson, A. Broeks, J. V. van Thienen, A. D. Guminski, A. T. Acosta, S. Ter Meulen, A. M. Koenen, L. J. W. Bosch, K. Shannon, L. M. Pronk, M. Gonzalez, S. Ch'ng, L. G. Grijpink-Ongering, J. Stretch, S. Heijmink, H. van Tinteren, J. B. A. G. Haanen, O. E. Nieweg, W. M. C. Klop, C. L. Zuur, R. P. M. Saw, W. J. van Houdt, D. S. Peeper, A. J. Spillane, J. Hansson, T. N. Schumacher, G. V. Long, and C. U. Blank. "Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial." Lancet Oncol 20, no. 7 (Jul 2019): 948–60. https://dx.doi.org/10.1016/S1470-2045(19)30151-2.

da Silva, I. P., I. C. Glitza, L. E. Haydu, R. Johnpulle, P. D. Banks, G. D. Grass, S. M. A. Goldinger, J. L. Smith, A. S. Everett, P. Koelblinger, R. Roberts-Thomson, M. Millward, V. G. Atkinson, A. Guminski, R. Kapoor, R. M. Conry, M. S. Carlino, W. Wang, M. J. Shackleton, Z. Eroglu, S. N. Lo, A. M. Hong, G. V. Long, D. B. Johnson, and A. M. Menzies. "Incidence, features, and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies." Pigment Cell Melanoma Res 32, no. 4 (Jul 2019): 553–63. https://dx.doi.org/10.1111/pcmr.12775.

Edwards, J., A. Tasker, I. P. da Silva, C. Quek, M. Batten, A. Ferguson, R. Allen, B. Allanson, R. P. M. Saw, J. F. Thompson, A. M. Menzies, U. Palendira, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma patients: Implications for clinical trials." Clin Cancer Res 25, no. 11 (Jun 2019): 3247–58. https://dx.doi.org/10.1158/1078-0432.CCR-18-4011.

Gide, T. N., B. M. Allanson, A. M. Menzies, P. M. Ferguson, J. Madore, R. P. M. Saw, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment." Histopathology 74, no. 6 (May 2019): 817–28. https://dx.doi.org/10.1111/his.13814.

Wilmott, J. S., P. A. Johansson, F. Newell, N. Waddell, P. Ferguson, C. Quek, A. M. Patch, K. Nones, P. Shang, A. L. Pritchard, S. Kazakoff, O. Holmes, C. Leonard, S. Wood, Q. Xu, R. P. M. Saw, A. J. Spillane, J. R. Stretch, K. F. Shannon, R. F. Kefford, A. M. Menzies, G. V. Long, J. F. Thompson, J. V. Pearson, G. J. Mann, N. K. Hayward, and R. A. Scolyer. "Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility." Int J Cancer 144, no. 5 (Mar 2019): 1049–60. https://dx.doi.org/10.1002/ijc.31791.

Lim, S. Y., J. H. Lee, T. N. Gide, A. M. Menzies, A. Guminski, M. S. Carlino, E. J. Breen, J. Y. H. Yang, S. Ghazanfar, R. F. Kefford, R. A. Scolyer, G. V. Long, and H. Rizos. "Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy." Clin Cancer Res 25, no. 5 (Mar 2019): 1557–63. https://dx.doi.org/10.1158/1078-0432.CCR-18-2795.

Gide, T. N., C. Quek, A. M. Menzies, A. T. Tasker, P. Shang, J. Holst, J. Madore, S. Y. Lim, R. Velickovic, M. Wongchenko, Y. Yan, S. N. Lo, M. S. Carlino, A. Guminski, R. P. M. Saw, A. Pang, H. M. McGuire, U. Palendira, J. F. Thompson, H. Rizos, I. P. da Silva, M. Batten, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy." Cancer Cell 35, no. 2 (Feb 2019): 238–55. https://dx.doi.org/10.1016/j.ccell.2019.01.003.

da Silva, I. P., K. Y. X. Wang, J. S. Wilmott, J. Holst, M. S. Carlino, J. J. Park, C. Quek, M. Wongchenko, Y. Yan, G. Mann, D. B. Johnson, J. L. McQuade, R. Rai, R. F. Kefford, H. Rizos, R. A. Scolyer, J. Y. H. Yang, G. V. Long, and A. M. Menzies. "Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma." Clin Cancer Res 25, no. 4 (Feb 2019): 1272–79. https://dx.doi.org/10.1158/1078-0432.CCR-18-1680.

Quek, C., R. V. Rawson, P. M. Ferguson, P. Shang, I. P. da Silva, R. P. M. Saw, K. Shannon, J. F. Thompson, N. K. Hayward, G. V. Long, G. J. Mann, R. A. Scolyer, and J. S. Wilmott. "Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas." Oncotarget 10, no. 9 (Jan 2019): 930–41. https://dx.doi.org/10.18632/oncotarget.26584.

2018

Korkut, A., S. Zaidi, R. S. Kanchi, S. Rao, N. R. Gough, A. Schultz, X. Li, P. L. Lorenzi, A. C. Berger, G. Robertson, L. N. Kwong, M. Datto, J. Roszik, S. Ling, V. Ravikumar, G. Manyam, A. Rao, S. Shelley, Y. Liu, Z. Ju, D. Hansel, G. de Velasco, A. Pennathur, J. B. Andersen, C. J. O'Rourke, K. Ohshiro, W. Jogunoori, B. N. Nguyen, S. Li, H. U. Osmanbeyoglu, J. A. Ajani, S. A. Mani, A. Houseman, M. Wiznerowicz, J. Chen, S. Gu, W. Ma, J. Zhang, P. Tong, A. D. Cherniack, C. Deng, L. Resar, Cancer Genome Atlas Research Network, J. N. Weinstein, L. Mishra, and R. Akbani. "A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-beta superfamily." Cell Syst 7, no. 4 (Oct 2018): 422–37. https://dx.doi.org/10.1016/j.cels.2018.08.010.

Edwards, J., J. S. Wilmott, J. Madore, T. N. Gide, C. Quek, A. Tasker, A. Ferguson, J. Chen, R. Hewavisenti, P. Hersey, T. Gebhardt, W. Weninger, W. J. Britton, R. P. M. Saw, J. F. Thompson, A. M. Menzies, G. V. Long, R. A. Scolyer, and U. Palendira. "CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment." Clin Cancer Res 24, no. 13 (Jul 2018): 3036–45. https://dx.doi.org/10.1158/1078-0432.CCR-17-2257.

Long, G. V., V. Atkinson, S. Lo, S. Sandhu, A. D. Guminski, M. P. Brown, J. S. Wilmott, J. Edwards, M. Gonzalez, R. A. Scolyer, A. M. Menzies, and G. A. McArthur. "Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study." Lancet Oncol 19, no. 5 (May 2018): 672–81. https://dx.doi.org/10.1016/S1470-2045(18)30139-6.

Bailey, M. H., C. Tokheim, E. Porta-Pardo, S. Sengupta, D. Bertrand, A. Weerasinghe, A. Colaprico, M. C. Wendl, J. Kim, B. Reardon, P. K. Ng, K. J. Jeong, S. Cao, Z. Wang, J. Gao, Q. Gao, F. Wang, E. M. Liu, L. Mularoni, C. Rubio-Perez, N. Nagarajan, I. Cortes-Ciriano, D. C. Zhou, W. W. Liang, J. M. Hess, V. D. Yellapantula, D. Tamborero, A. Gonzalez-Perez, C. Suphavilai, J. Y. Ko, E. Khurana, P. J. Park, E. M. van Allen, H. Liang, The MC3 Working Group, Cancer Genome Atlas Research Network, M. S. Lawrence, A. Godzik, N. Lopez-Bigas, J. Stuart, D. Wheeler, G. Getz, K. Chen, A. J. Lazar, G. B. Mills, R. Karchin, and L. Ding. "Comprehensive characterization of cancer driver genes and mutations." Cell 173, no. 2 (Apr 2018): 371–85. https://dx.doi.org/10.1016/j.cell.2018.02.060.

Ding, L., M. H. Bailey, E. Porta-Pardo, V. Thorsson, A. Colaprico, D. Bertrand, D. L. Gibbs, A. Weerasinghe, K. L. Huang, C. Tokheim, I. Cortes-Ciriano, R. Jayasinghe, F. Chen, L. Yu, S. Sun, C. Olsen, J. Kim, A. M. Taylor, A. D. Cherniack, R. Akbani, C. Suphavilai, N. Nagarajan, J. M. Stuart, G. B. Mills, M. A. Wyczalkowski, B. G. Vincent, C. M. Hutter, J. C. Zenklusen, K. A. Hoadley, M. C. Wendl, L. Shmulevich, A. J. Lazar, D. A. Wheeler, G. Getz, and Cancer Genome Atlas Research Network. "Perspective on oncogenic processes at the end of the beginning of cancer genomics." Cell 173, no. 2 (Apr 2018): 305–20. https://dx.doi.org/10.1016/j.cell.2018.03.033.

Ge, Z., J. S. Leighton, Y. Wang, X. Peng, Z. Chen, H. Chen, Y. Sun, F. Yao, J. Li, H. Zhang, J. Liu, C. D. Shriver, H. Hu, Cancer Genome Atlas Research Network, H. Piwnica-Worms, L. Ma, and H. Liang. "Integrated genomic analysis of the ubiquitin pathway across cancer types." Cell Rep 23, no. 1 (Apr 2018): 213–26. https://dx.doi.org/10.1016/j.celrep.2018.03.047.

Liu, J., T. Lichtenberg, K. A. Hoadley, L. M. Poisson, A. J. Lazar, A. D. Cherniack, A. J. Kovatich, C. C. Benz, D. A. Levine, A. V. Lee, L. Omberg, D. M. Wolf, C. D. Shriver, V. Thorsson, Cancer Genome Atlas Research Network, and H. Hu. "An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics." Cell 173, no. 2 (Apr 2018): 400–16. https://dx.doi.org/10.1016/j.cell.2018.02.052.

Sanchez-Vega, F., M. Mina, J. Armenia, W. K. Chatila, A. Luna, K. C. La, S. Dimitriadoy, D. L. Liu, H. S. Kantheti, S. Saghafinia, D. Chakravarty, F. Daian, Q. Gao, M. H. Bailey, W. W. Liang, S. M. Foltz, I. Shmulevich, L. Ding, Z. Heins, A. Ochoa, B. Gross, J. Gao, H. Zhang, R. Kundra, C. Kandoth, I. Bahceci, L. Dervishi, U. Dogrusoz, W. Zhou, H. Shen, P. W. Laird, G. P. Way, C. S. Greene, H. Liang, Y. Xiao, C. Wang, A. Iavarone, A. H. Berger, T. G. Bivona, A. J. Lazar, G. D. Hammer, T. Giordano, L. N. Kwong, G. McArthur, C. Huang, A. D. Tward, M. J. Frederick, F. McCormick, M. Meyerson, Cancer Genome Atlas Research Network, E. M. Van Allen, A. D. Cherniack, G. Ciriello, C. Sander, and N. Schultz. "Oncogenic signaling pathways in the cancer genome atlas." Cell 173, no. 2 (Apr 2018): 321–37. https://dx.doi.org/10.1016/j.cell.2018.03.035.

Thorsson, V., D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T. H. Ou Yang, E. Porta-Pardo, G. F. Gao, C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra, F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M. Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M. Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Pedamallu, S. Bullman, A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt, C. S. Rabkin, Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L. Disis, B. G. Vincent, and I. Shmulevich. "The immune landscape of cancer." Immunity 48, no. 4 (Apr 2018): 812–30. https://dx.doi.org/10.1016/j.immuni.2018.03.023.

Gide, T. N., J. S. Wilmott, R. A. Scolyer, and G. V. Long. "Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma." Clin Cancer Res 24, no. 6 (Mar 2018): 1260–70. https://dx.doi.org/10.1158/1078-0432.CCR-17-2267.

Pre-2018

Kakavand, H., L. A. Jackett, A. M. Menzies, T. N. Gide, M. S. Carlino, R. P. M. Saw, J. F. Thompson, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Negative immune checkpoint regulation by vista: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients." Mod Pathol 30, no. 12 (Dec 2017): 1666–76. https://dx.doi.org/10.1038/modpathol.2017.89.

Hayward, N. K., J. S. Wilmott, N. Waddell, P. A. Johansson, M. A. Field, K. Nones, A. M. Patch, H. Kakavand, L. B. Alexandrov, H. Burke, V. Jakrot, S. Kazakoff, O. Holmes, C. Leonard, R. Sabarinathan, L. Mularoni, S. Wood, Q. Xu, N. Waddell, V. Tembe, G. M. Pupo, R. De Paoli-Iseppi, R. E. Vilain, P. Shang, L. M. S. Lau, R. A. Dagg, S. J. Schramm, A. Pritchard, K. Dutton-Regester, F. Newell, A. Fitzgerald, C. A. Shang, S. M. Grimmond, H. A. Pickett, J. Y. Yang, J. R. Stretch, A. Behren, R. F. Kefford, P. Hersey, G. V. Long, J. Cebon, M. Shackleton, A. J. Spillane, R. P. M. Saw, N. Lopez-Bigas, J. V. Pearson, J. F. Thompson, R. A. Scolyer, and G. J. Mann. "Whole-genome landscapes of major melanoma subtypes." Nature 545, no. 7653 (May 2017): 175–80. https://dx.doi.org/10.1038/nature22071.

Cancer Genome Atlas Network. "Genomic classification of cutaneous melanoma." Cell 161, no. 7 (Jun 2015): 1681–96. https://dx.doi.org/10.1016/j.cell.2015.05.044.